INTERNATIONAL GLAUCOMA ASSOCIATION LIMITED

England & Wales · Charity number 274681

Details

Other names	GLAUCOMA ASSOCIATION IGA, Glaucoma UK, I G A
Status	Registered
Legal form	Charitable company
Company number	01293286
Registered	1977-12-20
Register	View on the Charity Commission register

Contact

Address	Kent House 81 Station Road Ashford Kent TN24 1PP
Phone	01233648164
Email	info@glaucoma.uk
Website	www.glaucoma.uk

Activities

Objects: THE OBJECTS OF THE CHARITY ARE, FOR THE PUBLIC BENEFIT, TO:HELP PRESERVE THE SIGHT OF PEOPLE AFFECTED BY GLAUCOMA AND ALLIED CONDITIONS;ADVANCE EDUCATION AND RESEARCH INTO THE CAUSES, DIAGNOSIS, CARE AND TREATMENT OF GLAUCOMA AND ALLIED CONDITIONS;RAISE AWARENESS AND UNDERSTANDING OF GLAUCOMA; ANDPROVIDE ADVICE AND SUPPORT TO PEOPLE LIVING WITH GLAUCOMA AND THE PROFESSIONALS WHO SUPPORT THEM.

Activities: Our objectives are to help prevent glaucoma blindness and support people living with glaucoma. We:Provide information, advice and support through a telephone helpline and online forum.Publish a wide range of booklets and leaflets and distribute regular newsletters.Fund glaucoma researchRun support groups, conferences & awareness raising activities for patients and professionals.

Downloaded from opencharities.uk/ew/274681

Classification

- **How:** Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** Children/young People, Elderly/old People, People With Disabilities, Other Charities Or Voluntary Bodies, The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-07-31	£2,541,707	£2,709,519	£8,832,445	24
2024-07-31	£2,358,050	£2,077,745	£8,767,960	22
2023-07-31	£1,773,879	£1,753,224	£8,047,747	18
2022-07-31	£1,841,823	£1,479,106	£8,159,171	17
2021-07-31	£1,795,826	£1,042,652	£8,292,061	16

Downloaded from opencharities.uk/ew/274681

Trustees

Name	Role	Appointed
Christopher John Hunton		2022-03-11
Dr Cecilia Helen Fenerty		2022-03-11
Dr James Francis Kirwan		2026-03-12
Dr Roshini Sanders		2022-03-11
Dr Roxanne Crosby-Nwaobi		2019-03-15
Dr Susan Parkins		2018-03-23
Dr Winifred Nolan		2021-02-24
Prabhakar Sundaresan		2022-06-22
Raymond Spendiff		2016-03-04
Stephen Jay Epstein		2015-03-13
Teresa Borsuk		2020-09-16
Trevor William Jones		2026-03-12

Downloaded from opencharities.uk/ew/274681

INTERNATIONAL GLAUCOMA ASSOCIATION LIMITED

England & Wales - Charity number 274681

Accounts

Trustees' Annual Report & Financial Statements

for the year ending

31 July 2025

The International Glaucoma Association Limited operating as **Glaucoma UK**

Kent House,
81 Station Road
Ashford,
Kent,
TN23 1PP

Phone: 01233 648 164, Email: info@glaucoma.uk, Website: glaucoma.uk

Welcome From the Chair of Trustees

It is my privilege to present this year's Annual Report on behalf of Glaucoma UK. The period from August 2024 to July 2025 has been one of both challenge and opportunity, shaped by wider pressures in the economy and in the health system that directly affect the people we serve.

Across the charity sector, fewer people are donating regularly and many households remain under significant financial strain. This has made fundraising more difficult, and yet we are deeply grateful for the generosity and commitment shown by our supporters in such circumstances. Every gift, no matter its size, helps us continue our work and reach people who need us most.

In parallel, the eye care sector is under immense pressure. Ophthalmology remains one of the largest areas of NHS backlog, with hundreds of thousands waiting for hospital eye care, while workforce shortages continue to affect timely access to diagnosis and treatment. For those living with glaucoma, the need for reliable support, clear information and strong advocacy has never been greater.

Despite these challenges, there are also reasons for optimism. Constantly evolving treatments and service innovations like technician-led or virtual clinics, are beginning to reshape how care is delivered. Glaucoma UK is committed to ensuring that people understand these changes and can make informed choices about their care, while continuing to campaign for fair and equitable access for all.

Looking back on the year, I am proud of what has been achieved. Our helpline, patient information and other support services have reached more people than ever before. We have spoken up for those whose voices are not always heard, and we have worked in partnership with clinicians, researchers and policy makers to help influence the future of glaucoma care.

On behalf of the Board, I want to thank our dedicated staff, volunteers, members and supporters. Your passion and commitment enable Glaucoma UK to stand alongside everyone affected by glaucoma. Together, we will continue to fight sight loss and ensure that no one faces glaucoma alone.

Professor Anthony King, Consultant Ophthalmologist and Glaucoma UK Chair of Trustees

A Message From the CEO

This year has been one of remarkable growth and momentum for Glaucoma UK. Building on the energy of our 50th anniversary, we have seen expansion in almost every area of our work, culminating in nearly one million instances of contact and support for people affected by glaucoma. Maintaining this upward trajectory, especially after last year's spike in activity, has been both encouraging and inspiring.

Our community has grown stronger, with a 40% increase in membership sign-ups on the previous year and a significant rise in people sharing their experiences on our online forum. The dedication of our supporters, members, and partners has enabled us to extend our reach and deepen our impact, even as economic pressures continue to affect households and charitable giving.

This year, Glaucoma UK's influence in the glaucoma care pathway has been recognised nationally, with our inclusion in the draft 'Getting it Right First Time' Best Practice Operational Strategy for Glaucoma in England. We have also stepped up our political activity, contributing to the NHS 10-year plan consultation, co-hosting a parliamentary event during Glaucoma Awareness Week, and submitting evidence to a Westminster Hall Debate on Glaucoma Awareness.

Our commitment to supporting those most at risk has been demonstrated through the delivery of our "Eye Health for All" pilot project, engaging African Caribbean communities across the UK, and through the launch of our ambitious Glaucoma Patient Voice Study. These initiatives ensure that the voices and needs of people living with glaucoma are at the heart of everything we do.

Financially, we have made significant progress towards our three-year plan of achieving operating growth whilst increasing our research funding. We awarded over £800,000 in research grants in 2025 - the highest in our 50-year history. The introduction of our first Pitts Crick Career Fellowship marks a major investment in the future of glaucoma research.

Our team has grown to 31 colleagues, with new roles focused on patient information and support, ensuring we can meet the increasing demand for our services. Looking ahead, we remain committed to diversifying our income, expanding our support for those navigating stretched eye services, and investing in research, information, and advocacy that can change lives.

Glaucoma UK exists because glaucoma changes lives. We are here to ensure that support is available when and how it is needed.

Joanne Creighton, Chief Executive Officer

Our Vision and Priorities

Glaucoma UK is dedicated to ending avoidable sight loss caused by glaucoma—a group of eye conditions that can damage the optic nerve and result in permanent vision loss or blindness. We estimate that over 1 million people in the UK are living with glaucoma, yet almost half are unaware, due to the lack of symptoms in the early stages of the disease.

The most reliable way to detect glaucoma is through a thorough routine eye examination, but more than one in three adults in the UK do not attend regular check-ups. This challenge is even greater among high-risk groups, such as people facing economic hardship and those of African-Caribbean heritage, where attendance rates are lower still. That's why we are committed to increasing awareness about the importance of early detection in every community.

Early diagnosis, prompt treatment, and ongoing monitoring are all vital to helping people with glaucoma protect their sight. However, with growing demand and long waiting times, there is still much to do to ensure everyone can access consistent and effective care across the UK. We are passionate about making sure the experiences and needs of people with glaucoma are heard by clinicians, policymakers, and those who commission services.

Research is at the heart of our mission to prevent sight loss. We invest in studies to better understand what causes glaucoma, how it can be prevented, which treatments work best, and—ultimately—how it might be cured. Through our annual grants programme, we support innovative research into new medical and surgical approaches, as well as improved models of care. We also add value to other research programmes through the provision of expert advice and help researchers to recruit patients, who have an essential role to play by contributing their lived experience to research studies.

Our Theory of Change

Our Theory of Change describes the lasting difference we want to make for people affected by glaucoma. Through our work, we aim to:

1. Boost awareness and promote earlier diagnosis, especially among those at greatest risk.
2. Enable more people to live well and maintain their vision by ensuring fair and timely access to high-quality clinical care and emotional support.

To achieve these goals, we focus on four main priorities:

- **Raising awareness:** Sharing clear, accessible information about glaucoma risk and making sure professionals know about Glaucoma UK's role in supporting care.
- **Providing support:** Offering practical advice, emotional support, and information to people with glaucoma and their carers, and building a strong, supportive community.
- **Supporting research and development:** Funding high-quality research into prevention, diagnosis, treatment, and potential cures, and working with partners to improve outcomes.
- **Influencing policy and professional practice:** Championing the patient perspective in the design and delivery of glaucoma services, and providing trusted information and support to healthcare professionals.



Strategic Report

What we achieved in 2024-25

Priority 1 - Raising Awareness

Glaucoma UK's Theory of Change sets out the following core objectives for our awareness raising work:

- More people understand why they may be at risk of glaucoma and that it could impact their vision, even without symptoms.
- More people who are at highest risk of glaucoma seek an eye examination.

How did we do?

Through a series of national campaigns, targeted outreach, and innovative digital tools, Glaucoma UK reached millions of people across the UK with messages about glaucoma risk, the importance of regular eye tests, and the support available from the charity. Our work also engaged high-risk communities and strengthened professional awareness of our services.

More people understand why they may be at risk of glaucoma and that it could impact their vision, even without symptoms

Key Activities:

- **National Eye Health Week (September 2024):** Our campaign, themed *'Your essentials: Put your eye health on the list'*, used relatable graphics like fridge magnets to encourage regular eye tests. The campaign reached 471,390 people on social media and a further 480,000 via Kent & Medway TV (KMTV) and trade media.

- **Glaucoma Awareness Week (June 2025):** Focused on the symptomless nature of glaucoma, with calls to action encouraging people to check their risk and book an eye test. Activities included a trustee-led radio day, which secured over 21 hours of radio airtime across stations with a potential listenership of 55 million. Print coverage was secured in national publications (including The Mail on Sunday and the Sunday Times) with a combined readership of 21 million, and online campaign messaging reached 321,742 social media users.

- **Motorway Poster Campaign:** Branded awareness posters in both printed and digital format were displayed across 12 motorway service stations, with a potential cumulative footfall of 1.8 million people.

- **Online Risk Quiz**: Our brand new 'Know Your Risk' tool was developed to help individuals assess their individual glaucoma risk, find out more about the disease and

access further support and advice. Over 3,000 individuals completed the quiz during its launch in Glaucoma Awareness Week.

- **Family Storytelling Campaign:** This initiative encouraged people to share their family history of glaucoma to raise awareness and promote conversations about eye health.

Impact
People living with undiagnosed glaucoma: Glaucoma messaging conveyed to millions of people across broadcast, print, digital, and in-person channels. Increased public understanding of glaucoma and its symptomless nature. Thousands of individuals prompted to assess their risk and seek eye tests.

More people who are at highest risk of glaucoma seek an eye examination.

Key Activities:

- **Ramadan Campaign:** Delivered in partnership with the British Islamic Medical Association and the Muslim Council of Britain, this campaign used targeted audience-specific TV, radio, and print media to encourage people to maintain their eye drop routine during Ramadan, and seek regular eye checks. The campaign aired on 171 subscriber radio stations, with a combined potential reach of over 17 million listeners. A video was featured on the Islam TV channel and website, with a potential audience of 8 million viewers, as well as a live interview with a member of Glaucoma UK staff.

- **Spreading the Word**: Via 45 talks to community groups across the UK, we helped to raise awareness of glaucoma and the importance of regular eye examinations amongst over 1,000 individuals.

Impact
People living with, or at risk of, glaucoma: Targeted activities across national media and local community outreach raised awareness, encouraged adherence to treatment and prompted individuals to seek eye examinations.

Priority 2 - Providing Support

Glaucoma UK's Theory of Change sets out three core objectives for our work to provide support:

- More people understand their condition and feel able to adhere to their treatment regime.
- More people at increased risk of sight loss are able to access support from Glaucoma UK when and how they need it.
- People feel more confident and positive about their condition by being part of a supportive glaucoma community.

How did we do?

During the year, the charity provided 932,851 instances of support, information, or guidance for people living with glaucoma. The impact of our work in this area is evident not only in the numbers, but in the stories, understanding and increased confidence we see in the feedback we receive.

More people understand their condition and feel able to adhere to their treatment regime

Key Activities

- **Digital Glaucoma Support Groups (DGSGs):** Twelve online webinars were delivered, with 1,199 real-time attendees and over 17,000 views of the recordings on demand via the Glaucoma UK YouTube channel. 79% of participants reported a better understanding of their glaucoma, and 98% would recommend the sessions to others. The most popular topics included glaucoma and cataracts, eye drops, treatment options and glaucoma research.

- **Health Information:** We received 108,718 orders for our information booklets and a further 6,057 electronic versions were downloaded from our website. Two of our most popular booklets ("All About Glaucoma" and "Trabeculectomy") were updated to further improve accessibility and readability, in line with Patient Information Forum (PiF) standards. Our online guidance received over 720,000 views.

- **Helpline:** Glaucoma UK's helpline advisors responded to 5,106 enquiries – up 44% from the previous year. This represented over 570 hours of guidance in support of time-strapped eye care professionals. The most common topics included eye drops, driving, surgery, and support for the newly diagnosed.

- **Free Drop-aids:** We supported people who were struggling to administer their eye drops with the provision of 2952 free drop aids – a 22% increase on 2023-24.

Impact:

- **People living with glaucoma:** Improved understanding and confidence in managing their condition, reduced anxiety, and better adherence to treatment. The high engagement with webinars and booklets, and positive feedback, show that people feel more empowered to manage their health.

"This lecture was so clear and informative, describing all the many different treatments and answering some interesting questions. I feel I could have gone on listening . Luckily the webinar is usually available afterwards on the Glaucoma UK website on You Tube. Thank you to Glaucoma UK and the consultant for such a helpful talk. (DGSG attendee)"

- **Treatment providers:** Clinicians able to refer patients to trusted, accessible resources, knowing that Glaucoma UK's information is PIF TICK accredited and up to

date. Our helpline complements clinical care, providing essential reassurance and support when time at appointments is limited.

More people at increased risk of sight loss are able to access support from Glaucoma UK when and how they need it

Key Activities:

- **Helpline Expansion:** The recruitment of additional staff increased the capacity and responsiveness of our helpline service. Around 70% of helpline contacts were by phone and 30% by email, demonstrating flexibility across communication channels.

- **Targeted Outreach:** Our new "Eye Health for All" outreach project (due to run until March 2026) with African Caribbean communities reached 1642 attendees during 46 events across Manchester, Croydon, Belfast, Cardiff and Glasgow. Free eye test vouchers were distributed at some of these events in partnership with Specsavers.

- **Online Forum:** A total of 5,780 peer-to-peer conversations took place on the Glaucoma UK 'HealthUnlocked' forum, a 44% increase on the previous year. The forum is a valuable space for people to share their experiences, provide practical tips and give emotional reassurance, all overseen and moderated by our knowledgeable helpline advisors.

Impact:

- **People living with glaucoma:** Easier access to support, especially for those in high-risk or underserved groups. Increased options for seeking advice and guidance outside normal working hours. Outreach and digital channels reduce barriers related to geography, mobility, or the stigma of seeking health advice.
- **Treatment providers:** Enhanced referral options and confidence that patients can access ongoing support between appointments, reducing risk of disengagement or non-adherence to their treatment plan.

People feel more confident and positive about their condition by being part of a supportive glaucoma community

Key Activities:

- **Membership Growth:** 425 new members joined Glaucoma UK, a 40% increase in sign-ups on the previous year.

- **Insight Magazine:** Over 12,000 copies of our membership magazine 'Insight' were distributed during the year, with a further 5,000 digital copies accessed online. Filled with latest news, research information and advice from people living with glaucoma, this popular publication remains the cornerstone of our membership support.

- **Buddy Scheme:** We facilitated 91 buddy pairings during the year (a 47% increase on the previous year). The scheme provides invaluable peer support for those considering or recovering from glaucoma surgery.

- **Case Studies:** Our bank of lived-experience case studies rose to 100 (an 11% increase on 2023-24). The willingness of these individuals to share their stories and personal insights via our membership magazine and during our webinars is a vital source of support and encouragement for our glaucoma community.

- **Face-to-Face Support Groups:** Our Training & Engagement Officers welcomed 400 attendees at 34 support group sessions– a valuable option for those who prefer to connect in person or are unable to engage online.

- **Volunteers:** The charity benefited from the invaluable effort and commitment of 79 volunteers during the course of the year who offered their advice as buddies or served on our consultation and readers' panels.

Impact:

- **People living with glaucoma:** Increased sense of belonging, reduced isolation, and greater optimism about managing their condition. Feedback highlights the comfort and reassurance provided by Glaucoma UK's community

"I am a Life Member and was so impressed with the Autumn Insight. The full information about support for research projects confirmed for me the importance of Glaucoma UK"

- **Treatment providers:** Patients who feel supported are more likely to engage positively with treatment and follow-up, leading to better clinical outcomes.

Priority 3 – Supporting Research and Development

As the only UK charity solely dedicated to funding research into glaucoma, our work in this area is of vital importance. Desired outcomes of our research and development programme include:

- More of our research projects demonstrably transform glaucoma prevention, diagnosis and treatment.
- Research we fund is more widely disseminated to inform and improve glaucoma care.
- We achieve more leverage from our research support and sector relationships.

How did we do?

We have been investing in the administration and governance of our research work, to provide more robust data around the research we fund and its impact. We've also been building links with partners, to help encourage participation in research and ensure the voices of people with glaucoma are heard in the planning, delivery and dissemination of research. We disbursed the greatest sum of annual research grants in the history of the charity.

More of our research projects demonstrably transform glaucoma prevention, diagnosis and treatment.

Key activities:

- **Pitts Crick Research Fellow:** We awarded the first ever Pitts Crick Career Development Fellowship to Dr Giovanni Montesano, for his project "A digital twin for glaucoma". This three-year grant, worth £424,644, will support Giovanni in developing a framework for digital models of patients, another step forward in personalised medicine. Giovanni presented his plans at the AGM and Annual Lectures event in March 2025.

- **Glaucoma UK Grant Awards:** Having amalgamated our smaller funding streams in 2024-25, we awarded three projects grants during the year. These were to:

    - Associate Professor Kuang Hu, at UCL Institute of Ophthalmology for his project 'Clarifying the Prognosis: Identifying Glaucoma Progression Patterns with Artificial Intelligence'. The project will look at an AI tool called SuStaIn to identify subtypes of glaucoma from OCT scans. It has previously been successfully used in Alzheimer's dementia, and could help risk stratify patients with more confidence. The grant is worth just under £90,000 and his project will last 18 months.

    - Dr Lucy Bosworth and her team at the University of Liverpool for her project 'LIVTM: A Regenerative Cell-Based Implant to Restore Natural Eye Drainage in Glaucoma'. The project will involve looking at a bioengineered scaffold which is implanted into the trabecular meshwork drainage channels of the eye. Lucy and her colleagues are hoping that, as well as improving drainage of fluid out of the eye, the scaffold might restore the health of the meshwork. The grant is worth just under £100,000 and the project will last a year.

    - Dr Colin Chu and collaborators, also at UCL Institute of Ophthalmology for a project entitled 'Characterising the 3D Spatial Biology of the Human Optic Nerve Head in Glaucoma'. By imaging and mapping the optic nerve head (where the nerve cells leave the eye and head towards the brain), Dr Chu is hoping that scientists and clinicians will have a better understanding of

what's happening at a cellular level in this crucial part of the eye. This could help identify changes that occur in glaucoma which affect the health of the nerve cells. The grant is worth just under £50,000 and the project will last a year.

- **Joint UKEGS and Glaucoma UK Grant:** The grant was awarded to Dr Bledi Petriti, for his project 'Mitochondrial metabolism in glaucoma: Effects of the Optineurin E50K mutation and the reversal of dysfunction through pharmacological intervention'. The grant is worth just under £50,000 and his project is due to last 12 months. This is a follow-on project from work we previously funded looking at normal tension glaucoma, which was published in Nature Medicine in 2024.

- **The 2024 Open Call Grant:** This grant was awarded during the financial year 2024-25 due to delays signing the contract. The recipient was Professor David Crabb at City St George's University, London, for his project 'Visual field loss in primary angle closure glaucoma'. This project revisits visual field test results from a previous landmark trial to help us understand the patterns of sight loss in this less common form of glaucoma.

- **Co-Funded Projects:** We also co-funded two projects in partnership with other organisations:

    - Dr Keir Yong, at University College London, received £5,000 to support a project investing cortical visual dementia, a form of dementia which can be confused with glaucoma due to the impact it has on visual fields. The project aims to improve identification and diagnosis of people with cortical visual dementia, so they can receive the treatment they need, and free up space in glaucoma clinics. The project is also funded by Vivensa Foundation and the National Brain Appeal.

    - Dr Ngan Pan Bennett Au, at the University of Surrey, received £7,500 as part of our joint small grant programme with Fight for Sight. His project, 'Targeting members of the IgLON family as a novel and translatable approach to promote neuroprotection and nerve repair', is looking at a novel family of proteins which may be implicated in the death of critical nerve cells in glaucoma.

Impact:

- **People living with glaucoma:** The research funded this year offers the potential for earlier diagnosis, more personalised care, and new treatment options. Projects exploring regenerative implants and AI-driven risk profiling could lead to safer surgeries, better monitoring, and improved long-term outcomes—helping people preserve their sight and manage their condition with greater confidence.

- **Treatment providers:** Clinicians will benefit from tools that support more accurate risk stratification, deeper understanding of disease mechanisms, and improved trial

design. These advances will help target resources more effectively, inform clinical decisions, and support innovation in glaucoma care.

Research we fund is more widely disseminated to inform and improve glaucoma care.

Key activities:

- **Monitoring Impact:** For the first time, we subscribed to Researchfish, a tool widely used in research to monitor the impact of funding. Of the responses submitted for grants funded between 2016 and 2023, we found that research we supported resulted in:
    - 25 papers being published
    - 21 examples of awards or recognition
    - 15 examples of dissemination to non-academic audiences
    - 15 collaborations and partnerships

- **Website Improvements:** We relaunched the "Research We've Funded" page of our website, with more information about the grants we've provided, and the impact projects have had. This improved transparency and publicity around our research helps to increase engagement from clinicians, people with glaucoma and other researchers.

- **Better Research Communications:** We have also increased the communications around our research activity to our different audiences. For example,
    - A digital glaucoma support group in April 2025, titled "Glaucoma Research: an overview" was attended 117 people.

    - The recipients of the 2024 research grants were invited to our inaugural research showcase at the AGM and Annual Lectures in March 2025. This enables researchers and Glaucoma UK members to meet and share ideas.

- **Presentation of Research Findings Overseas:** Research we funded, and carried out by Dr Giovanni Montesano, won the prize of Best Paper at the American Academy of Ophthalmology meeting and garnered significant media interest. The work showed that visual field loss is 30% slower for people receiving laser treatment than eye drops, based on data from the landmark LiGHT trial.

Impact:

- **People living with glaucoma:** Improved communication of research findings has helped people affected by glaucoma better understand the condition and the progress being made to treat it. Updates to our website and digital support groups have made research more accessible, while showcasing projects at public events has helped build trust and engagement with the research process.

- **Treatment providers:** The use of Researchfish has enabled us to track and share the real-world impact of our funded research, including published papers, collaborations, and clinical recognition. Dissemination of findings—such as evidence supporting laser treatment over eye drops—has attracted media attention and may influence clinical practice, helping providers deliver more effective care.

We achieve more leverage from our research support and sector relationships.

Key activities:

- **Partnership Working with Other Research Funders:** The new CERT partnership (Charities for Eye Research Transformation), between Glaucoma UK, Fight for Sight, Macular Society and Retina UK, is starting to bear fruit. Glaucoma UK's Head of Research was invited to speak at a new event for early career researchers, on the importance of engaging the public and patients in research.

- **Visionary Conference Workshop**: Our Head of Research co-hosted a workshop at the Visionary conference, with the Macular Society. The focus was on increasing participation in research, understanding the barriers to engagement and identifying new ways to overcome them. These talks are critical in building the framework for growth in engagement in research.

- **Presentations at Key Sector Events:** Talks were also given to a range of professional audiences including UKEGS conference delegates, the Moorfields International Glaucoma Symposium and international representatives of industry partner Santen.

- **The 'Future of Glaucoma' Steering Group:** We were invited by pharmaceutical company Santen to join a steering group - along with other leading members of the glaucoma community from across the UK and Ireland - to discuss and debate the trends that are going to impact how patients with glaucoma are diagnosed, treated and managed in the future. The main output will be a series of articles in autumn 2025 and a range of sector 'asks' for those devising policy and making decisions about glaucoma care.

Impact:

- **People living with glaucoma:** By strengthening partnerships and increasing our visibility across the research and eye health sectors, Glaucoma UK is helping to ensure that the needs and experiences of people with glaucoma are embedded in future research. Our involvement in public engagement events and steering groups means that patient voices are shaping the direction of research and influencing how care is delivered.

- **Treatment providers:** Our growing presence in sector-wide collaborations and industry-led initiatives is helping to drive innovation and influence policy. By contributing to strategic discussions and sharing insights at national and

international events, we are supporting the development of more responsive, evidence-based approaches to glaucoma diagnosis, treatment and service design.

Glaucoma UK Academic Chair of Ophthalmology

In partnership with University College London the charity once again supported the role of the Glaucoma UK Academic Chair of Ophthalmology for Glaucoma and Allied Studies – Professor David (Ted) Garway-Heath.

Professor Garway-Heath's achievements for the year include:

- **Six new scientific publications and an editorial** – publications included the topics of metabolic changes in glaucoma and potential therapeutic compounds, laser treatment for eye pressure lowering after medical treatment, the impact of laser treatment on visual field preservation, the effect of blood pressure medication on visual field worsening, visual field improvement after eye pressure lowering, and the relationship between progression measures in structure and function.
- **A cumulative total of over 22,600 citations** (with 8,500 of those in just the last 5 years). Ted has had 236 papers cited at least 10 times and eight papers cited over 500 times.
- **Ten lectures at national and international conferences during 2024-25** - including for the European Glaucoma Society, Italian Glaucoma Society, Korean Glaucoma Society, (UK) Association of Optometrists, (international) Imaging and Perimetry Society, UK & Eire Glaucoma Society and the (international) Glaucoma Research Society.
- **Reviewing editor of the European Glaucoma Society (EGS) Guidelines for Laser Surgery –** Ted also contributed the Foreword to the 6th Edition of the EGS Terminology and Guidelines for Glaucoma.
- **Publication of the 'EGS research priorities for glaucoma care' in the British Journal of Ophthalmology in July 2024** – Ted continues to further the EGS patient advocacy project, the aims of which are to engage patients in the works of the EGS and to determine how the organisation can support patients across Europe and beyond.
- **EGS Ambassador to the American Glaucoma Society** - with the aim of strengthening the links and collaborations between the two societies in relation to the education and training of ophthalmologists.
- **Leadership of Project Oriel: the new Moorfields and Institute of Ophthalmology -** Ted leads the 'Innovation Hub' and 'Social Value' workstreams of this ambitious building project. The Innovation Hub is a showcase department of the new centre for advancing eye health bringing together innovators in digital medicine and aiming to accelerate bringing new diagnostics and treatments to patients. The Social Value workstream aims to optimise the building's contribution to the wellbeing of its users (patients, staff, students and the public) through a Creative Strategy encompassing Arts, Heritage and Science-on-show.

Professor Garway-Heath's research activities for the year also included work as Chief Investigator on the following ongoing projects:

- **'Identifying the genetic basis for heritable normal tension glaucoma, with a focus on mitochondrial function'**. Further joint Glaucoma UK and UKEGS funding for this work was secured by Dr Bledi Petriti "Mitochondrial metabolism in glaucoma: Effects of the Optineurin E50K mutation and the reversal of dysfunction through pharmacological intervention" with Prof Garway-Heath as a co-applicant. The outcome of this research is in draft paper form, with the aim to submit to a high impact journal by the end of 2025.

- **'NicotinAMide in Glaucoma (NAMinG): A randomised, placebo-controlled, multi-centre, Phase III trial'** - to test the effectiveness of vitamin B3 as a treatment for glaucoma. So far, 274 participants have been recruited, with a further 21 screened and eligible, representing almost 60% of the target of 496. The recruitment period has been extended, additional trial sites added and a costed extension will be submitted to the NIHR by mid-November.

- **REVAMP** – this Medical Research Council funded project (lead by Dr Redmond in Cardiff, a former post-doctoral student of Professor Garway-Heath's) aims to develop a more accurate and precise visual field test. This project is nearing completion and the study team has been invited to submit a renewal of the grant, following a successful outline application.

Priority 4 – Influencing Policy & Professional Practice

By working to influence policy and professional practice, we seek to achieve the following objectives:

- More people at increased risk of glaucoma have equitable and timely access to eyecare services.
- Those making decisions on policy and commissioning take greater account of glaucoma patient perspectives.
- More professionals feel better informed and equipped to support people to live well with glaucoma.

How did we do?

We continued our efforts to influence glaucoma care policy and professional practice by contributing to national consultations, engaging with decision-makers, and supporting professionals through training and events. While challenges remain, our work helped raise awareness and brought patient perspectives into important conversations about service design and delivery.

More people at increased risk of glaucoma have equitable and timely access to eyecare services

Key Activities:

- **NHS 10-year Plan Consultation:** Glaucoma UK contributed to the NHS England 10-Year Plan consultation, advocating for measures to ensure equitable access to eye care, especially for high-risk and underserved groups. We called for targeted screening, education, and tailored care pathways for populations with the highest risk and lowest engagement with health services, such as people of African, Caribbean, or Asian descent, and those in rural or socioeconomically disadvantaged areas. We also called for reduced waiting times, especially for follow-up appointments, and improved communication about treatment delays.

- **Promoting Timely Eye Care:** Glaucoma UK's new "Know Your Risk" online tool was launched during Glaucoma Awareness Week 2025 to help people understand their risk and seek timely eye health checks.

Impact:

Policy and Decision Makers: Our work helped raise awareness, promote early diagnosis, and push for fairer access to eye care—especially for high-risk and underserved groups. These efforts support timely treatment and reduce the risk of avoidable sight loss.

Those making decisions on policy and commissioning take greater account of glaucoma patient perspectives

Key Activities:

- **Representing Patients:** The Glaucoma UK team represented patient interests at key sector forums during the year, including the Clinical Council for Eye Health Commissioning, the Ophthalmology National Steering Group, and the UK Ophthalmology Alliance. Glaucoma UK also contributed to NICE consultations and took part in DVLA stakeholder sessions.

- **Capturing the Patient Voice:** UK launched a new and ambitious Glaucoma Patient Voice Study in June 2025. In preparation for an ambitious national survey in 2026 that collects more glaucoma patient perspectives than ever before, we sought early feedback on the topics our members and supporters would like to see featured. We received over 1,400 responses, giving us invaluable insight into the priorities of the people we serve. Early feedback has highlighted that appointment timeliness and experience at diagnosis are key areas of concern. The national survey will inform a national report for NHS leaders and policymakers.

- **Glaucoma in Parliament:** During Glaucoma Awareness Week 2025, we co-hosted a parliamentary drop-in event with the medtech company Glaukos. It was an

invaluable opportunity to raise awareness of the disease and advocate for more consistent and effective eye care provision across the UK. We also provided a briefing for a 'Glaucoma Awareness' Westminster Hall debate, which explored the importance of routine eye tests, the role of community optometry, and the need for a national glaucoma care pathway.

Impact:

- **Policy and Decision Makers:** These activities ensured that the lived experiences and priorities of people with glaucoma were understood and directly communicated to policymakers and commissioners.

More professionals feel better informed and equipped to support people to live well with glaucoma

Key Activities:

- **United Kingdom and Éire Glaucoma Society Conference:** The annual UKEGS conference brings together top glaucoma experts and researchers to explore latest developments in treatment and professional practice. The 2024 event, hosted at the National Oceanography Centre in Southampton, welcomed 430 attendees across the two days. The conference programme included a 'Patients First' session which showcased the importance of more effective communication and the benefits of patient involvement in treatment planning.

- **Training for Professionals:** Our Training and Engagement Officers delivered 19 General Optical Council accredited glaucoma training sessions for 223 professionals across social care, occupational therapy, optometry, vision rehabilitation and pharmacy to help raise awareness of Glaucoma UK's services and encourage patient referrals. Whilst the training receives excellent feedback, we are currently reviewing the content to ensure it remains up to date and to add more interactivity.

Impact:

- **Treatment Providers:** Our work in this area helped to enhance the knowledge and confidence of professionals, equipping them with up-to-date information and practical tools to support people living with glaucoma.

Fundraising Review 2024–25

Overview

The 2024–25 financial year was marked by both challenge and resilience for Glaucoma UK's fundraising efforts. Against a backdrop of economic uncertainty and increased competition for charitable giving, our community of supporters once again demonstrated remarkable commitment, with total voluntary income of £2,058,718 (2023–24: £1,787,919) – a very encouraging 15% increase on the previous year.

Legacy Income

Legacy gifts continued to be the cornerstone of our fundraising, with £1,777,367 in legacy donations received during the year (2023–24: £1,528,917). Accounting for 86% of our total voluntary income, legacy gifts are essential to Glaucoma UK. They enable us to plan confidently for the future, expand our reach, and invest in sight-saving research. We are deeply grateful to all those who remembered us in their wills and who placed their trust in our mission end preventable sight loss from glaucoma.

Despite this strong performance, the number of new legacy notifications fluctuated throughout the year, highlighting the need for continued investment in legacy marketing and stewardship. Initiatives to raise the profile of legacy giving included a redesign of our legacy web pages and the sharing of case studies in our Insight magazine.

Donations, Appeals, and Events

Other fundraising income, including general donations, appeals and events, was up by just under 10% on the previous year (£281,351 versus £259,002 in 2023-24). This was a pleasing continuation of the momentum created during our 50th anniversary year, with funds still coming in to support the Pitts Crick Research Fellowship during the current financial year.

Event fundraising continued to engage supporters through challenge events such as the London Marathon and the Ultra MMA Challenge. Our new "Run for Charity" platform began to match fundraisers to events nationwide.

Trusts, Foundations, and Corporate Support

Income from trusts and foundations totalled £15,450 (2023–24: £11,083), with significant contributions from the Orr Mackintosh Foundation and the Wyseliot Rose Charitable Trust. However, recruitment challenges in the fundraising team meant that anticipated growth was not realised in this area. Corporate support also fell below expectations, with £21,075 received, largely due to third-party delays in renewing sponsorship agreements and work to refresh our professional engagement strategy.

We were grateful to Specsavers for their contribution of £20,000 in respect of our annual licencing agreement which – along with considerable in-kind support – helps to amplify our messaging and expand the reach of our awareness raising work.

Membership

Membership income was £60,794 (2023–24: £51,460), with 425 new joiners during the year. Retention will be a key focus going forward, particularly for those approaching the end of their first year. Planned actions include exit surveys, enhanced stewardship, and a review of benefits to better further improve the experience of our membership community.

Fundraising Controls

At Glaucoma UK, maintaining the trust of our donors and the wider public is fundamental to the success of our fundraising. We are committed to ensuring that all our fundraising activity is transparent, ethical, and fully compliant with current regulations.

Oversight is provided at the highest level through a designated Fundraising Trustee Advocate on our Board of Trustees. In addition, our Finance and Governance Committee conducts quarterly reviews to monitor fundraising performance, regulatory compliance, and internal controls.

We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice. We uphold the principles of the Fundraising Promise and clearly outline our complaints policy on our website. We received no complaints about our fundraising activities during the year, and no requests were made through the Fundraising Preference Service to opt out of communications.

To safeguard vulnerable individuals, we follow the Institute of Fundraising's guidance on supporting people in vulnerable circumstances. Our Ethical Fundraising Policy and Supporter Promise guide all our fundraising practices.

We also monitor any third parties working on our behalf to ensure they meet the highest standards of data protection and supporter care. In 2024–25, we worked with one third-party provider—Bequeathed Limited—to deliver our free wills service. We did not engage any external professional fundraising agencies during the year.

Our lottery activities continue to be managed under our Gambling Commission licence, ensuring we meet all legal obligations and provide appropriate protections for participants.

Thank You to Our Donors and Fundraisers

Once again, Glaucoma UK's work has been made possible by the extraordinary generosity and commitment of our donors, fundraisers, members, and supporters. In a period marked by economic uncertainty and increased pressures on household finances, your willingness to stand with us has enabled the charity to maintain and expand vital services for people living with glaucoma.

Every gift—no matter its size—has helped us reach further, support more people, and invest in research and advocacy that can change lives. We are deeply grateful to those who have remembered Glaucoma UK in their wills, to everyone who has made a donation, taken on a fundraising challenge, or supported our appeals and campaigns. Your passion and commitment have taken us closer to our goal of an end to preventable sight loss from glaucoma.

We also want to thank our dedicated volunteers and partners, whose efforts and enthusiasm have been the foundation of our achievements this year. Whether you have amplified our messages, mentioned us in your own press campaign, organised an event, shared your personal story, or simply encouraged others to get involved, you have made a real difference to the lives of people affected by glaucoma.

Among the many inspiring stories this year:

- Debbie Page, a GP practice nurse living with chronic angle-closure glaucoma, took to the skies in a wing walk at Duxford. After losing four stone to meet the weight requirement, Debbie completed the challenge and raised over £1,500 for Glaucoma UK. Her courage and determination—despite ongoing treatment and vision loss—are a powerful reminder of the strength within our community.

- Professor Dan Lindfield, consultant ophthalmologist at the Royal Surrey County Hospital, ran the 2025 London Marathon for Glaucoma UK, raising over £8,000. His dedication to both his patients and the charity exemplifies the powerful connection between clinical care and community support.

- Jill Chapman, a long-standing member and volunteer telephone buddy, donated her winnings from a local Scrabble tournament. Her thoughtful gesture reminds us that fundraising can be personal, meaningful, and rooted in everyday passions.

- Linsey and fellow walkers took part in the Glasgow Kiltwalk, raising funds while enjoying the sights of the city. Their efforts helped us continue providing support and information to those navigating glaucoma treatment and diagnosis.

- UKEGS conference delegates contributed over £1,000 through a raffle in support of Dan Lindfield's marathon appeal, and an additional £1,292 towards our 50th Anniversary Research Fellowship.

These are but a few examples of the extraordinary effort and generosity shown by our many fundraisers and supporters during the year. On behalf of the Board, staff, and everyone we serve, thank you for your support.

Organisations Who Helped Us

We would also like to take this opportunity to thank the following organisations for their support during the year:

Direct Line Group
Inner Wheel Club of Workington
I-Star Medical
McPherson Optometry Ltd
National Tool Hire Ltd
Saint Laurence The Parish Church of Upminster
Seaton and District Club for the Visually Impaired
ShareGift, The Orr Mackintosh Foundation
Specsavers Optical Group HQ
The Dandy Charitable Trust
The Emily Weircroft Charitable Trust
The Wyndham Charitable Trust
Thea Pharmaceuticals Ltd
Topcon Healthcare
Trade Gear Limited
United Reformed Church Eastern Synod Office
VISUFarma
Wyseliot Rose Charitable Trust
Younger Lives Ltd

Looking Ahead

With our milestone 50th anniversary now behind us, and major changes to the eye health system afoot, we are more motivated than ever to ramp up our efforts to support those living and working with glaucoma. To that end, we have a busy year ahead. Across the UK, the Glaucoma UK team will be working hard to deliver the following projects:

National Patient Voice Study
Using insights gained from our member and supporter community during the 2025 Glaucoma Awareness Week, we will be working with the Picker Institute to undertake an ambitious UK-wide survey in early 2026. We want to gather more glaucoma patient perspectives than ever before to help us influence policy makers, commissioners and those delivering glaucoma care.

Review and Development of Our New Community Outreach Programme
Following the success of our pilot projects in Belfast, Croydon, Manchester and Glasgow, we will be evaluating outcomes and further refining our 'Eye Health for All' outreach programme. Designed to raise awareness in communities at highest risk of sight loss from glaucoma, rolling out this programme across the UK will be a key priority for the foreseeable future.

Patient and Public Involvement and Engagement in Research
Increasing opportunities for patient engagement in research will be a key area of focus in the coming year. We are developing plans for database of people interested in participating in and supporting research. In addition, we plan to collaborate with our charity partners at Macular Society, Retina UK and Fight for Sight on the creation of guidance resources and training modules for researchers. We will be focusing particularly on support for early career researchers, to help them understand the importance of working with patients at all stages of research.

Website Update and Review
With over 720,000 visits to the support pages of our website last year, it is vital that our material remains up to date and accessible for those who seek our help online. We will be undertaking a thorough review and refresh of our website content during 2025-26.

Financial Review

In the context of ongoing economic uncertainty and sector-wide fundraising challenges, Glaucoma UK ended the financial year 2024–25 in a robust position, with total funds of £8,832,445 (2024: £8,767,960).

Net income for the year showed a surplus of £64,485 (2024: £720,213). This was despite a significant planned increase in charitable expenditure of £2,709,519 (2024: £2,077,745), in line with our strategic objective of drawing down reserves to maximise reach and impact.

Incoming Resources

Total income for the year increased to £2,541,707, an 8% increase on the previous year (2024: £2,358,050). Our main sources of income included:

Voluntary income (made up of donations, legacies, and subscriptions), which remained the cornerstone of our funding, accounting for £2,058,718 (2024: £1,787,919). Legacies continued to be the largest single source, representing 86% of voluntary income. The year saw a particularly strong performance in legacy gifts, with £1,777,367 received, exceeding both budget and prior year figures. This was supported by several high-value bequests, including a significant legacy from a long-term supporter, which provided vital stability and enabled us to invest further in our charitable objectives.

Other fundraising streams - such as general donations, in memoriam gifts, trust and foundation grants, corporate support, and events—which delivered mixed results. General donations and Christmas card sales performed well, while income from trusts, foundations, and corporate partners fell short of targets, largely due to recruitment delays and a challenging external environment. The lottery and events income also underperformed against budget, though both remain important areas for future growth.

Membership income, which totalled £60,794(2024: £51,460), reflecting successful acquisition of over 400 new members. While recruitment of new members was encouraging, retention—particularly among first-year members—remains a key focus for improvement.

Investment income, which contributed £189,522 (2024: £198,496), with the charity's portfolio managed in line with a medium-risk, total return strategy. The year saw unrealised gains of £225,467 (2024: £439,908) on investments, reflecting continued market volatility. Realised gains totalled £6,830 (2024: 0).

We benefitted from the Google Ads grant scheme during the year, with free advertising to the value of US$71,748 (£54,332 as at 31 July 2025). Google Ads enabled us to serve advertisements to people searching online for particular keywords and encourage traffic to the charity's website.

Resources Expended

Total expenditure rose to £2,709,519 (2024: £2,077,745), reflecting our commitment to delivering on our Theory of Change and expanding our services. Key areas of increased spend included:

- **Staff costs**, which rose to £1,166,415 (2024: £975,235), as we invested in an additional helpline advisor, a new Digital Communications Assistant role and extra hours for our graphic designer and finance officer. This investment not only helps to address the current growth in service demand but will also position us well for greater impact and income growth in due course.
- **Research grants**, with £814,470 awarded (2024: £363,222), supporting a wide range of innovative projects and the launch of the new Pitts Crick Research Fellowship.
- **Support services and outreach**, with an increase of £52,936 on the previous year including delivery of the new Eye Health for All project and increased expenditure on our helpline service.
- **Raising awareness and influencing policy**, with increased investment of £17,509 in national campaigns, parliamentary engagement, and the development of new digital tools.

Restricted and Designated Funds

At year-end, restricted funds stood at £1,671,357 (2024: £1,629,944), including the Academic Chair Fund for the Professor of Ophthalmology at UCL (£1,509,186), a series of smaller project-specific funds (£23,739) and funds to support the work of the UK & Eire Glaucoma Society (£138,431). The overall increase was largely the result of strong delegate income for the November 2024 UKEGS conference in Southampton, without the elevated costs of the previous year's London venue.

A new Patient Voice Restricted Fund was created during the year to support the delivery of our national survey in 2026. The London Fund was wound up, with all restricted funds having been spent on delivering projects to support underserved audiences.

Designated funds totalled £3,800,322, a £540,469 reduction on the previous year (2024: £4,340,791). This drawdown – £ 424,445 of which related to the Pitts Crick Research Fellowship – reflects our financial objective to invest designated funds into growing the charity and expanding our services and research funding.

A total of £4,922 was undesignated during the year relating to the West Yorkshire Support Fund. This fund was originally set up by the trustees for activities in West Yorkshire but an initiative to fund volunteer-led support groups in the area did not result in any applications. The released funds will now be used to support the delivery of the 'Eye Health for All' outreach project.

Reserves Policy

The Trustees remain committed to maintaining a prudent reserves policy that ensures Glaucoma UK can meet its ongoing commitments, respond to unforeseen challenges, and invest in future growth. Our approach is to hold sufficient cash reserves and working capital

to cover both the charity's day-to-day operational needs and our planned development activities.

This strategy provides a stable foundation for delivering sustainable support to our beneficiaries and enables us to pursue ambitious, long-term objectives to prevent sight loss from glaucoma.

Recognising the inherent risks associated with a heavy reliance on legacy income—as well as broader economic uncertainties and fluctuations in investment markets—the Board has reaffirmed its policy of holding cash reserves equivalent to at least 12 months' operating costs.

At 31 July 2025, Glaucoma UK's general funds stood at £3,360,766 (2024: £2,797,225), comfortably exceeding the minimum cash reserves requirement for the year of £2,051,635. This surplus will be used to underpin the continued delivery of our Theory of Change and to support the expansion of our services and research activities over the coming years.

In addition to general funds, the charity held £3,800,322 (2024: £4,340,791) in designated funds at year-end. Of this, £3,413,634 is earmarked for research investment, supporting our ongoing commitment to funding innovative glaucoma research, including the Pitts Crick Research Fellowship, new PhD studentships, and collaborative projects with other sight sector charities. A further £363,782 is set aside for infrastructure development, ensuring we have the resources to maintain and enhance our operational capacity as we grow.

The Trustees regularly review the reserves policy to ensure it remains appropriate in light of the charity's financial position, strategic priorities, and the external environment.

Going Concern

The Board has reviewed the charity's financial position and is satisfied that Glaucoma UK remains a going concern, with adequate resources to meet its obligations and deliver its mission in the years ahead.

Investment Policy

Glaucoma UK's investment portfolio is managed by Rathbones Group Plc, under a balanced mandate with the objective of maximising total return over the long term, subject to a medium risk profile. The portfolio is managed with a 6-to-10 year time horizon and adopts a total return approach, with income arising within the portfolio transferred to the capital account for reinvestment.

The Trustees maintain a clear ethical policy, excluding direct investment in companies manufacturing tobacco or tobacco products, as well as companies deriving more than 10% of their revenues from alcoholic beverages, armaments, gambling, high-interest rate lending, or pornography. The portfolio is managed in accordance with the ethical policy of the Rathbone Core Investment Fund for Charities.

Oversight of the investment portfolio is delegated to the Finance and Governance Committee, which reviews performance benchmarks with the fund managers on an annual basis.

Portfolio Performance

As at 31 July 2025, the value of Glaucoma UK's investment portfolio stood at £7,665,582 (2024: £7,448,765), and dividend income received totalled £189,522 for the year. A drawdown of £225,000 was made during the year to help manage cash flow while awaiting a delayed legacy payment. This comprised £179,000 from the portfolio and £46,000 from the quarterly dividend. Over the 12 months to 31 July 2025, the portfolio delivered a total return of +5.8% (net of fees).

Trustees, Advisors and Staff

Serving trustees (who are also directors under company law) were:

Professor Anthony King	Chair of Trustees
Mr Stephen Epstein	Vice Chair (Chair, Finance & Governance Committee)
Mr Prabhakar Sundaresan	Hon Treasurer (Finance & Governance Committee)
Miss Winifred Nolan	Chair, Clinical Advisory Panel
Dr Susan Blakeney	(Finance & Governance Committee)
Ms Teresa Borsuk	(Finance & Governance Committee)
Professor Roxanne Crosby-Nwaobi	
Professor Cecilia Fenerty	
Mr Christopher Hunton	Academic Chair Fund Advocate (Finance & Governance Committee)
Mrs Yolanda Laybourne	Fundraising Advocate (Finance & Governance Committee)
Professor Roshini Saunders	
Mr Raymond Spendiff	(Finance & Governance Committee)
CEO & Company Secretary	Joanne Creighton
Company Number	1293286
Charity Number	274681
OSCR Number	SC041550
Registered office & operational address	Kent House, 81 Station Road Ashford, Kent, TN23 1PP www.glaucoma.uk
Bankers	Barclays Bank plc, 1 Churchill Place, London, E14 5HP CAF Bank Ltd, 25 Kings Hill Avenue, Kings Hill, Kent, ME19 4JQ HSBC Bank plc, Camberwell Green, 23 Denmark Hill, London, SE5 8RP
Auditors	Xeinadin Audit Limited, 12 Conqueror Court, Sittingbourne ME10 5BH
Investment Managers	Rathbones Investment Management Ltd, 30 Gresham Street, London EC2V 7QN

Structure and Management

Glaucoma UK is the operating name of the International Glaucoma Association Ltd, which was incorporated on 15 July 1976 and registered as a charity on 20 December 1977. As Glaucoma UK is both a charity and a company limited by guarantee, all board members are directors for the purposes of company law and trustees for the purposes of charity law. The objects of the charity are defined by its Articles of Association (last updated in 2025), which also set out trustees' powers and the permitted activities of the charity.

Following the review and refresh of the Articles of Association undertaken during our 50th Anniversary year in 2024, two further updates were agreed by the membership at the AGM on 13 March 2025:

- Membership criteria changes must be ratified by the Membership at a General Meeting.
- If fewer than 12 Trustees are elected or appointed in any year, the Board must explain the rationale at the Annual General Meeting.

The Board and Committees

The Board comprises not fewer than 8 and no more than 15 persons elected by the Members (or appointed by the Board to fill a temporary vacancy); and not more than three persons co-opted by the Board.

The current Board comprises people living with glaucoma, those with close family connections with the condition and others with backgrounds in ophthalmology, nursing, optometry, finance, public relations and business. At least three trustee positions are held each year by Fellows of The Royal College of Ophthalmologists or medically qualified equivalents.

Trustees retire after serving a three-year term but are eligible for re-election to a maximum of nine years' service. Those serving prior to the 2023 AGM are entitled to serve for a maximum of 12 years. Board meetings take place four times a year on either a face-to-face, virtual or hybrid basis.

There are two sub-committees:

- The Finance and Governance Committee, which has delegated responsibility for overseeing finance, investments, risk management and policy. Consisting of 7 trustees, the committee meets quarterly in advance of each Board meeting and on an ad-hoc basis, should the need arise.
- The UKEGS Committee, which has delegated responsibility for promoting the exchange of knowledge between glaucoma specialists and stimulating glaucoma research by bringing together scientists and clinicians at an open educational scientific meeting every year (the UKEGS annual conference). The Committee comprises 3 independent glaucoma professionals – the current President of UKEGS (who chairs the Committee and hosts the annual conference), immediate Past President and President Elect. The Chair of Glaucoma UK is also a member of the sub-committee, which meets on a regular basis throughout the year and monthly in the run-up to the annual conference.

The charity also has a Clinical Advisory Panel (CAP) to advise on clinical matters. The chair of the CAP oversees the award of research grants.

Trustee Recruitment and Training

When seeking new Board members, trustees have regard to any existing skills or knowledge gaps or any new disciplines that would be helpful in delivering the charity's future plans. Due consideration is also given to diversity and the need to ensure that the Board appropriately represents the communities served by the charity. New trustees are sought using existing networks, advertising or professional recruitment agencies, as required. Candidates are interviewed by a sub-committee of trustees, followed by a meeting with the Chair of Trustees. Suitable individuals are invited to meet the remaining trustees at a Board meeting and are then put forward to the membership as the Board's preferred candidates at the Annual General Meeting. Voting members are also eligible to nominate themselves or others for election.

A secure area is available for trustees on the charity's SharePoint system, featuring key resources and information, including Charity Commission guidance on trustee roles and responsibilities. A personalised induction is provided for all new trustees, including a charity overview and briefings on finance, fundraising, support services and communication. Trustees are required to undertake 'Understanding Governance' training within six months of joining the Board. Ongoing training is provided as required, including attendance on external courses or participation in internal workshops and briefings.

Operating Responsibility

Day-to-day responsibility for delivering services and achieving strategic and financial aims within organisational policies and the law is delegated to the Chief Executive, supported by the Senior Management Team.

Statement of Public Benefit

Glaucoma UK exists to raise awareness of the risks of glaucoma, support people to live well with the condition and fund research into the causes, prevention and treatment of the disease.

When reviewing the charity's objectives and planning future activities, the trustees refer to Charity Commission guidance on public benefit and can confirm that all Glaucoma UK's activities are undertaken to further our charitable purposes for public benefit, in accordance with Section 17 of the Charities Act 2011.

Related Parties and Connected Charities

Glaucoma UK acted as an agent for the unincorporated organisation the United Kingdom Paediatric Glaucoma Society (UKPGS) during the year, providing infrastructure and administrative support. UKPGS exists to promote the exchange of knowledge between glaucoma specialists, stimulate research, establish a scientific community and promote interest in glaucoma as an ophthalmological sub-specialty. One trustee of Glaucoma UK also sits on the trustee board of UKPGS. In July 2025 UKPGS established themselves as a

Charitable Incorporated Organisation and withdrew funds totalling £29,124 previously held by Glaucoma UK, bringing the agency arrangement to a close.

In 2022 Glaucoma UK awarded a research grant of £57,300.56 to Nottingham University Hospital in respect of a project for which Professor Anthony King, Chair of Glaucoma UK, is the lead researcher. This was duly disclosed and recorded. The project finished during 2025, with the final report signed off by Glaucoma UK. The outstanding balance (£31,515.56) will be paid upon receipt of invoices from Nottingham University Hospital.

Risk Management and Internal Control

The Board of Trustees retains overall responsibility for risk management at Glaucoma UK, with formal assessment and review delegated to the Finance and Governance Committee. The Chief Executive submits a comprehensive risk register on a quarterly basis, identifying current and emerging risks, rating each by likelihood, impact, and velocity, and detailing the controls and mitigations in place.

During 2024–25, the trustees have reviewed and assessed the principal risks facing Glaucoma UK as follows:

1. Lack of Income Diversity

Despite ongoing efforts to diversify income streams, Glaucoma UK remains heavily reliant on legacy gifts. For the year, legacy income accounted for approximately **70% of total income** (legacy income: £1,777,367; total income: £2,541,707058,718). The following measures are in place to mitigate this risk:

- **Regular monitoring**: Monthly management accounts and quarterly reports are reviewed by the Finance & Governance Committee.
- **Cash flow and pipeline oversight**: Cash flow forecasts and legacy gift pipeline reports are presented at each quarterly committee meeting.
- **Reserves and investment**: The charity maintains cash reserves and a diversified investment portfolio to cover medium and long-term income shortfalls.
- **Theory of Change and impact reporting**: The new Theory of Change framework and outcome reporting mechanisms are in place to better demonstrate impact and secure higher levels of corporate, major donor, and charitable trust support.

2. Investment Failure

All investments are subject to the risk of sustained or long-term decline in value. The Board seeks to offset these risks through:

- **Professional management**: Investments are held in a professionally managed portfolio, with access to live online reports.
- **Regular review**: Quarterly reporting to the Finance & Governance Committee and annual meetings with investment managers.
- **Policy oversight**: The Investment Policy is reviewed annually.
- **Liquidity**: A minimum of two months' operating costs is held in cash accounts to ensure operational resilience.

3. Compromised IT Systems and Cyber Security Failure

With the increasing prevalence of cybercrime and a stringent data protection environment, Glaucoma UK has implemented robust mitigations:

- **Professional support**: External agency retained to provide helpdesk support, ongoing staff training and regular system security monitoring.
- **Cyber Essentials**: Accreditation maintained (achieved June 2025), confirming compliance with best practice.
- **Staff training**: Cyber security training is mandatory for all staff.
- **Technical controls**: Multi-factor authentication, strict access controls, regular software updates, patch management, and daily offsite backups.
- **System protections**: Firewall, antivirus, anti-malware, and Intrusion Detection and Prevention Systems (IDPS) are in place.
- **Data protection**: Encryption of sensitive data and annual review of Information Governance, ICT, and Data Protection policies.
- **Cyber insurance**: Comprehensive cover, including post-incident support.
- **Website security**: 'reCAPTCHA' technology is installed on the online shop to prevent automated transactions.

4. Other Key Risks

- **Operational change**: The charity is managing risks associated with the transition to a new accounting system, with a detailed project plan and specialist third-party support to ensure continuity and compliance.
- **Compliance and data protection**: Anticipated changes to data protection regulations are being monitored, with new procedures under development to ensure ongoing compliance.

Remuneration Policy

The trustees consider the Board of Trustees and the Chief Executive as comprising the key management personnel, in charge of directing, controlling and operating the charity on a day-to-day basis.

All trustees give of their time freely and no trustee remuneration was paid in the year. Trustees are required to disclose all relevant interests and withdraw from decisions where a conflict of interest arises.

The pay of the charity's Chief Executive is reviewed annually by the Chair of Trustees and Finance and Governance Committee. The Chief Executive reviews all other staff salaries annually and makes recommendations to the Board as part of the annual budget setting process.

When setting salaries, trustees are guided by a remuneration policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public and private sector pay increase estimates), affordability, sustainability, and appropriateness.

Glaucoma UK aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2025 these ratios were 3.5:1 and 2.5:1 respectively.

Statement of Trustee Responsibilities

The trustees are responsible for preparing the Trustees' Annual Report including the strategic report and financial statements in accordance with applicable law and United Kingdom accounting standards (UK generally accepted accounting practice).

Company law requires the trustees to prepare financial statements which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees' Annual Report is approved by order of the Board of Trustees, and the Strategic Report (included therein) is approved by the Board of Trustees in their capacity as directors, in their meeting on 25 November 2025, and signed on its behalf by



Professor Anthony King Chair of Trustees

Independent Auditors' Report

We have audited the financial statements of The International Glaucoma Association Limited for the year ended 31 July 2025 on pages 39 to 53. The financial reporting framework that has been applied in their preparation is applicable law and FRS 102 (effective January 2015), as well as the Statement of Recommended Practice for Charities (effective January 2015).

This report is made solely to The International Glaucoma Association's members and Board of Trustees, as a body, in accordance with Section 144 of the Charities Act 2011, and regulations made under Section 154 of that Act, as well as Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Council of Management those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective Responsibilities of Trustees and Auditors

As explained more fully in the Trustees' Responsibilities set out on page 35, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditors under Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 and report in accordance with regulations made under those Acts.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the Audit of the Financial Statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees' Annual Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies, we consider the implications for our report.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities. The extent to which our procedures can detect irregularities, including fraud, is detailed below:

- Gaining a full and extensive knowledge of the entity, environment and the regulatory framework to which it must abide by.
- Evaluating and assessing the extent to which the entity's internal systems are adhering to these as well as gaining a full and comprehensive understanding of the entity's activities and effectiveness of its control environment (including those in place to identify and prevent fraud).

We achieved this by carrying out the following:

- Enquiry of the detailed communication with management and those charged with governance.
- Reviewing internal systems and controls.
- Reviewing financial statement disclosures and compliance with applicable laws and regulations.

Opinion on the Financial Statements

In auditing the financial statements, we have concluded that the trustees/directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the entity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees/directors with respect to going concern are described in the relevant sections of this report.

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 July 2025 and of its incoming resources and application of resources, including its result, for the year then ended;
- have been properly prepared in accordance with the Financial Reporting Standards 102 (effective January 2015);
- have been prepared in accordance with the requirements of the Companies Act 2006, and Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006.

Matters on Which We Are Required to Report by Exception

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- the information given in the Report of the Board of Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Rosanna Turner ACA DChA
For and on behalf of Xeinadin Audit Limited,
Registered Auditors
12 Conqueror Court, Sittingbourne ME10 5BH
Eligible to act as an auditor in terms of Section 1212 of the Companies Act

Glaucoma UK (the operating name of the International Glaucoma Association Limited)

Statement of financial activities *(incorporating an income and expenditure account)*
For the year ended 31 July 2025

	Note	Restricted £	Unrestricted £	**2025 Total £**	2024 Total £
Income					
Donations, legacies and subscriptions	2	76,650	1,982,068	**2,058,718**	1,787,919
Investment income	3	38,113	152,911	**191,024**	199,934
Charitable activities					
Professor of Ophthalmology for Glaucoma and Allied Studies at UCL	4	-	-	**-**	9,130
Influencing policy & practice	4	244,357	-	**244,357**	254,950
Corporate support	4	200	20,875	**21,075**	81,950
Lottery	4	-	19,794	**19,794**	18,256
Christmas cards	4	-	5,753	**5,753**	4,721
Other income	4	-	986	**986**	1,190
Total income		**359,320**	**2,182,387**	**2,541,707**	**2,358,050**
Expenditure on:					
Raising funds					
Cost of generating funds		-	231,732	**231,732**	293,181
		-	231,732	**231,732**	293,181
Expenditure on charitable activities					
Raising awareness		-	277,901	**277,901**	244,342
Providing support		12,149	875,636	**887,786**	615,290
Supporting research and development		171,729	782,081	**953,810**	457,490
Influencing policy and practice		181,149	177,141	**358,290**	465,154
Total expenditure	5	**365,027**	**2,344,492**	**2,709,519**	**2,077,745**
Realised gains on investment assets	11	1,374	5,456	**6,830**	-
Net Income		(4,333)	(162,105)	**(160,982)**	280,305
Unrealised gains on investment assets	11	45,746	179,721	**225,467**	439,908
Net incoming resources before transfers	6	41,413	23,072	**64,485**	720,213
Gross transfer between funds		-	-	**-**	-
Net movement in funds		41,413	23,072	**64,485**	720,213
Reconciliation of funds					
Total funds brought forward		1,629,944	7,138,016	**8,767,960**	8,047,747
Total funds carried forward		**1,671,357**	**7,161,088**	**8,832,445**	**8,767,960**

All of the results above are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 16 to the financial statements.

Glaucoma UK (the operating name of the International Glaucoma Association Limited)

Charity No 274681

Balance sheet

Scotland No SC041550

Company No. 1293286

As at 31 July 2025

	Note		2025 £	2024 £
Fixed assets				
Tangible fixed assets	10		**715**	806
Investments	11		**7,665,583**	7,481,765
Total fixed assets			**7,666,298**	7,482,571
Current assets				
Debtors	12	19	**1,595,210**	1,692,539
Cash at bank and in hand			**1,046,423**	554,254
			2,641,633	2,246,793
Liabilities				
Creditors: amounts due within one year	13	18, 19	**1,002,536**	798,304
Net current assets			**1,639,097**	1,448,489
Total assets less current liabilities			**9,305,395**	8,931,060
Creditors: amounts due after more than one year	14, 19		**472,950**	163,100
Net assets	15		**8,832,445**	8,767,960
Funds	16			
Restricted funds			**1,671,357**	1,629,944
Unrestricted funds				
Designated funds			**3,800,322**	4,340,791
General funds			**3,360,766**	2,797,225
Total funds			**8,832,445**	8,767,960

Approved by the board of trustees of the International Glaucoma Association Limited and signed on its behalf by Mr Stephen Epstein, Trustee

Stephen Epstein

Stephen Epstein (Jan 29, 2026 18:01:06 GMT)

Glaucoma UK (the operating name of the International Glaucoma Association Limited)

Statement of cash flow

For the year ended July 2025

Cashflows from operating activities:	**2025**	2024
Net cash provided by (used in) operating activities	**253,739**	**(95,529)**
Cashflows from investing activities		
Dividends and interest from investments	**191,024**	199,934
Purchase of property, plant and equipment	**(1,074)**	(1,208)
Proceeds from sale of property, plant and equipment	**-**	452
Proceeds from sale of investments	**179,111**	-
Purchase of investments	**(130,166)**	(181,719)
Net cash provided by (used in) investing activities	**238,895**	17,459
Change in cash and cash equivalents in the reporting period	**492,634**	(78,070)
Cash and cash equivalents at the beginning of the reporting period	**554,403**	**632,473**
Cash and cash equivalents at the end of the reporting period	**1,047,037**	554,403
Increase/Decrease in cash balances	**492,634**	**(78,070)**

Reconciliation of net movement in funds to net cash flow from operating activities

Net movements in funds for the reporting period (as per the statement of financial activities)	**64,485**	720,213
Adjustments for:		
Depreciation	**1,164**	3,160
Dividends & interest from investments	**(191,024)**	(199,934)
Loss/(Profit) on sale of investments	**(232,297)**	(439,908)
(Increase)/Decrease in stock	**-**	3,656
(Increase)/Decrease in debtors	**97,329**	(242,032)
Increase/(Decrease) in creditors	**514,082**	59,316
Net cash provided by (used in) operating activities	**253,739**	**(95,529)**

Analysis of cash and cash equivalents

Cash in hand	**1,046,423**	**554,254**
Investments Capital account	**614**	**149**
	1,047,037	**554,403**

1. Accounting policies

a) The financial statements have been prepared under the historical cost convention, as modified by the revaluation of fixed asset investments, and in accordance with applicable accounting standards and the Companies Act 2006. They follow the recommendations in the Statement of Recommended Practice, Accounting and Reporting by Charities. The accounting standards policies have been prepared under Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice) and SORP 2019.The Trustees confirm that the charitable company is a public benefit entity. The accounts are prepared in sterling pound and rounded to the nearest £1. The charity is a company limited by guarantee from 627 voting members incorporated on 15 July 1976 and registered as a charity on 20 December 1977. The objects of the charity are defined by its Articles of Association (last updated in 2024). The International Glaucoma Association Ltd (IGA) is constituted both as a charity and as a company limited by guarantee and as such the members of its Board are directors for the purposes of company law and trustees of the charity for the purposes of charity law. The powers of the Board and the permitted activities of the association are described in its governing document, which is the Articles of Association. The International Glaucoma Association Ltd registered office is Kent House, 81 Station Road, Ashford, Kent, TN23 1PP. The International Glaucoma Association Ltd is registered as a company in the United Kingdom.

In assessing the charity's status as a going concern, the trustees have considered a range of information in relation to the financial year ahead, including the current status of the UK economy, the charity's cash resources and known liabilities. The charity's 3-year financial plan for the period 2024-2027 shows the charity to have adequate resources to continue operating an effective service for at least 36 months and to meet its obligations as they fall due. The financial

b) statements have therefore been prepared on a going concern basis.

Voluntary income received by way of subscriptions, donations and gifts are included in full in the statement of financial activities when receivable.

c) Income from legacies is accounted for on a receivable basis, recognised when entitlement to the income has been established and it is probable that Glaucoma UK will receive the amounts ascertained. This treatment is within SORP 2019 and Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Sales income represents sale of goods excluding VAT where appropriate.

Investment income is accounted for on an accruals basis.

d) Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

e) Unrestricted funds are donations and other incoming resources received or generated for general charitable purposes. Designated funds are unrestricted funds earmarked by the Board of trustees for particular purposes. Within these

f) funds is money awarded as grants, funding a range of research projects to develop more effective methods of glaucoma diagnosis and treatment.

g) Costs of generating funds relates to the costs incurred in fundraising activities.

h) Critical accounting judgements are used within these accounts as follows:

Residual legacy income debtors are valued at 85% of the expected value of the legacy when certain criteria are met and receipt is probable. Residual legacies that are over the material amount set by Glaucoma UK at £300,000 are recorded in the accounts at 100% once criteria is met and receipt is probable.

The support and governance costs are re-apportioned by staff time as explained in note (i). The staff costs attributed to each activity are reviewed each year when the new budget is set.

Resources expended are recognised in the period in which they are incurred. Resources expended include attributable VAT which cannot be recovered.

i) Resources expended are allocated to a particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function which includes finance and support and governance is apportioned on the following basis which is an estimate based on staff time of the amount attributable to each activity.

Support costs	
Cost of generating funds	13%
Expenditure on charitable activities	78%
Research	8%

j) Grants awarded are charged to the Statement of Financial Activities in the year in which they are awarded and are subject to receipt of progress reports.

k) Governance costs are the costs associated with the governance of the charity, including constitutional and statutory requirements and costs associated with the strategic management of the charity's activities.

l) Monetary assets and liabilities in foreign currencies are translated into sterling at the Bank of England exchange rate for that day.

m) Investments held as fixed assets are revalued at market value at the balance sheet date. The Trustees consider that market value is a reasonably accurate representation of the fair value. The gain or loss for the period is taken to the statement of financial activities.

n) The fixed assets are held at cost less depreciation and any impairment. Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures, fittings and equipment	20%
Computers	33%

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

o) Stocks are stated at the lower of cost and net realisable value. In general, cost is determined on a first in first out basis. Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation. Provision is made where necessary for obsolete, slow moving and defective stock. During the year the charity received donated items that have been stated at fair value.

p) The charity contributes to a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. Contributions payable are charged as an expense in the SOFA (Statement of financial activities) within staff costs then shared between the SOFA categories by staff time within these activities.

q) Financial instruments assets and liabilities are valued in the accounts at fair value and are subsequently carried at amortised cost shown in Note 19.

r) Debtors are stated at their net realisable value after allowing for bad and doubtful debts. The recoverability of debtors is reviewed at year end and provision is made, either general or specific, based on value, age and composition of our year end debtor balance.

s) Trade creditors are recognised in the accounts at its settlement amount when there is a present obligation to the entity arising from past events.

2. Voluntary income

	2025 Restricted £	2024 Restricted £	**2025 Unrestricted £**	2024 Unrestricted £	**2025 Total £**	2024 Total £
Donations and subscriptions	**23,937**	41,139	**256,064**	215,620	**280,001**	256,759
Corporate donations	**-**	-	**1,350**	2,243	**1,350**	2,243
Legacies	**52,713**	6,432	**1,724,654**	1,522,485	**1,777,367**	1,528,917
Total	**76,650**	47,571	**1,982,068**	1,740,348	**2,058,718**	1,787,919

3. Investment income

	2025 Restricted £	2024 Restricted £	**2025 Unrestricted £**	2024 Unrestricted £	**2025 Total £**	2024 Total £
Interest	**21**	-	**1,481**	1,438	**1,502**	1,438
Dividends	**38,092**	41,605	**151,430**	156,891	**189,522**	198,496
Total	**38,113**	41,605	**152,911**	158,329	**191,024**	199,934

4. Incoming resources from charitable activities

	2025 Restricted £	2024 Restricted £	**2025 Unrestricted £**	2024 Unrestricted £	**2025 Total £**	2024 Total £
Professor of Ophthalmology for Glaucoma and Allied Studies at UCL	**-**	9,130	**-**	-	**-**	9,130
Influencing policy & practice	**244,357**	254,950	**-**	-	**244,357**	254,950
Corporate support	**200**	2,500	**20,875**	79,450	**21,075**	81,950
Lottery	**-**	-	**19,794**	18,256	**19,794**	18,256
Christmas cards	**-**	-	**5,753**	4,721	**5,753**	4,721
Other income	**-**	-	**986**	1,190	**986**	1,190
	244,557	**266,580**	**47,408**	**103,617**	**291,965**	**370,197**

5. Total Expenditure

	Charitable activities	Raising funds	Staff costs (Note 7)	Finance & Governance	2025 Total	2024 Total
Cost of generating funds	-	47,976	123,926	-	**171,902**	225,904
Raising awareness	93,724	-	124,210	-	**217,934**	200,425
Providing support	144,745	-	501,111	-	**645,856**	474,461
Supporting research and development (Note 8)	814,470	-	79,057	22,115	**915,642**	431,080
Influencing policy and practice	150,586	-	140,077	-	**290,663**	389,193
Finance and administration	-	-	163,645	264,165	**427,810**	318,736
Governance	-	-	34,389	5,323	**39,712**	37,946
Total	**1,203,525**	**47,976**	**1,166,415**	**291,603**	**2,709,519**	2,077,745

Expenditure note 5 continued

Finance, administration and governance costs reallocated

	Cost of generating funds	Raising awareness	Providing support	Supporting research and development	Influencing policy and practice	2025 Total	2024 Total
Finance, admin & governance costs	59,830	59,967	241,930	38,168	67,627	467,522	356,682
Direct costs	171,902	217,934	645,856	915,642	290,663	2,241,997	1,721,063
Total SOFA	**231,732**	**277,901**	**887,786**	**953,810**	**358,290**	**2,709,519**	2,077,745

6. Net (outgoing)/incoming resources

This is stated after charging/crediting:

	2025	2024
	£	£
Depreciation charge for the year - owned assets	**1,164**	3,160
Auditors' remuneration:		
audit	**6,930**	6,300
other services	**1,650**	4,319
Trustees' expenses	**1,262**	2,161
Investment managers fee	**15,898**	12,006

Trustees' expenses represent the travel and subsistence costs of 6 trustees for 8 meetings £1,262 (2024:£2,161). Within 2025 most of the Trustees meetings were held virtually.
Donations totalling £501 were received from Trustees, (2024: £664).

No Trustees received remuneration for their services during the financial year.

7. Staff costs and numbers

Staff costs were as follows:

	2025	2024
	£	£
Salaries and wages	**1,015,290**	846,577
Social security costs	**101,682**	87,068
Pension contributions	**49,443**	41,590
	1,166,415	975,235

Only one member of key management personnel earned £80,000 or more in the year.

	2025	2024
	No.	No.
£70,000- £80,000	**0**	0
£80,000- £90,000	**0**	1
£90,000- £100,000	**1**	0

Pension contributions in respect of the above £90,000 - £100,000 full-time employee totalled £4,475 (2024: £4,134).

NI contributions in respect of the above £90,000-£100,000 employee totalled £11,622 (2024: £10,155)

The calculated unspent staff holiday entitlement at year end was £905 (2024: £2,907).

The charity contributes to a Royal London defined contribution pension scheme for employees.

The Key Management Personnel having authority and responsibility for planning, directing and controlling the activities of Glaucoma UK are the Senior Management Team. The total of Key Management personnel, employee benefits and remuneration were £491,353, (2024: £381,319)

When setting salaries, trustees are guided by a remuneration policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public and private sector pay increase estimates), affordability, sustainability, and appropriateness. Glaucoma UK aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2025 these ratios were 3.5:1 and 2.5:1 respectively.

7. Staff costs and numbers (continued)

The average weekly number of employees (full-time equivalent) during the year was:

	2025 **No.**	2024 No.
Cost of generating funds	**2.16**	3.95
Patient information and support	**11.12**	7.44
Professional information and support	**3.17**	5.35
Campaigning and awareness	**2.78**	1.49
Research	**1.36**	1.27
Governance	**0.57**	0.52
Finance and Support costs	**3.26**	2.86
	24.42	22.88

The actual number of staff (including part time and full time) at July 2025 was 31 (2024: 27) at year end.

8. Grants Awarded

	2025	2024
University College London's Institute of Ophthalmology - Glaucoma UK Chair Fund	**79,114**	74,673
Fight for Sight	**7,500**	-
City University London	**42,512**	-
University College London	**144,237**	-
Moorfields Eye Hospital NHS Foundation Trust	**474,637**	-
Ulster University	**-**	99,919
Manchester University NHS Foundation Trust	**-**	49,791
Liverpool University	**99,782**	50,000
University of Birmingham	**-**	99,652
Grants underspent by researchers	**(33,312)**	(10,813)
	814,470	363,222

These grants were awarded in accordance with the Glaucoma UK grants policy, and were awarded to fund research into the diagnosis and treatment of glaucoma.

Glaucoma UK awards its funding through open competition and uses a panel of independent experts to support in decision making. The host institution is considered as part of this process, to ensure the support and infrastructure are available for a successful project. Glaucoma UK is not affiliated with any particular research institution

The negative figure represents underspend by researchers on grants awarded in previous years.

9. Taxation

The charity is exempt from corporation tax and income tax as all its income is charitable and is applied for charitable purposes.

10. Tangible fixed assets

	Computer equipment £	**Total £**
Cost		
At the start of the year	37,941	**37,941**
Additions in year	1,074	**1,074**
Disposals in year	-	**-**
At the end of the year	39,015	**39,015**
Depreciation		
At the start of the year	37,135	**37,135**
Charge for the year	1,165	**1,165**
Disposals in year	-	**-**
At the end of the year	38,300	**38,300**
Net book value		
At the end of the year	715	**715**

11. Investments

	2025 £	2024 £
Rathbones Core Investments fund for charities		
At 1st August 2024	**7,481,616**	6,859,989
Additions at historic cost	**130,166**	181,719
Disposal proceeds	**(179,111)**	0
Realised gains	**6,830**	0
Unrealised gains/losses	**225,467**	439,908
Market value at the end of the year	**7,664,968**	7,481,616
Cash held as part of portfolio	**614**	149
Total	**7,665,582**	7,481,765

11. Investments continued

Investment management costs were £15,898 (£12,006 - 2024)

Glaucoma UK Ltd, Glaucoma International Ltd, Glaucoma Europe Ltd, and Glaucoma Association Ltd are dormant companies historically held by Glaucoma UK (the operating name of the International Glaucoma Association Limited) in order to protect the company identity and to give future flexibility in terms of the charity name. International Glaucoma Association hold 100% of all the dormant companies.

Glaucoma UK Limited number 04323894 total shareholder funds £1. Glaucoma Europe Limited number 04591043 total shareholders funds £1. Glaucoma International Limited number 04323990 total shareholders funds £1. Glaucoma Association Ltd number 05316092 shareholders funds £1.

12. Debtors

	2025	2024
	£	£
Trade debtors	**6,205**	**47,102**
Legacy debtors	**1,510,764**	**1,619,363**
Prepayments and accrued income	**77,986**	**26,074**
Vat Liability	**255**	**-**
	1,595,210	**1,692,539**

13. Creditors: amounts due within one year

	2025 £	2024 £
Trade creditors	**117,482**	166,396
Obligations under grant agreemer	**629,067**	403,061
Funds held as agent	**-**	28,214
Accruals & Deferred income	**255,987**	196,789
Vat liability	**-**	3,844
	1,002,536	798,304

Funds held as agent represent those held for UKPGS, for which Glaucoma UK provided administration and infrastructure support during the year, as shown in note 18. In July 2025 UKPGS was established as a Charitable Incorporated Organisation in its own right and closing funds were duly transferred.

14. Creditors: amounts due after one year

	2025 £	2024 £
Obligations under grant agreements	**472,950**	163,100
	472,950	163,100

15. Analysis of net assets between funds

	Restricted funds £	Designated funds £	General funds £	**Total funds £**
Tangible fixed assets	-	-	715	**715**
Investments	1,671,357	3,800,322	2,193,904	**7,665,583**
Net current assets	-	-	1,639,097	**1,639,097**
Creditors: amounts falling due after more than one year	-	-	(472,950)	**(472,950)**
Net assets at the end of the year	**1,671,357**	**3,800,322**	**3,360,766**	**8,832,445**

16. Movements in funds

	At the start of the year £	Incoming resources £	Outgoing resources £	Other gains and losses £	Transfers £	**At the end of the year £**
Restricted funds:						
Academic Chair fund	1,504,578	40,313	(82,825)	47,120	-	**1,509,186**
North East fund	6,150	-	(2,759)	-	-	**3,391**
Research fund	-	54,590	(54,590)	-	-	**-**
Folkestone fund	3,293	-	(71)	-	-	**3,222**
Children and Young People's Support fund	8,662	-	(2,700)	-	-	**5,962**
London fund	1,587	-	(1,587)	-	-	**-**
Scottish Optom fund	5,918	-	(5,032)	-	-	**886**
UK & Eire Glaucoma Society fund	75,223	244,357	(181,149)	-	-	**138,431**
50th Anniversary fund	24,533	9,781	(34,314)	-	-	**-**
Patient Voice Study fund	-	10,279	-	-	-	**10,279**
Total restricted funds	**1,629,944**	**359,320**	**(365,027)**	**47,120**	**-**	**1,671,357**
Unrestricted funds:						
Designated funds:						
Income Endowment	22,906	-	-	-	-	**22,906**
Equipment Replacement and Infrastructure fund	434,745	-	(70,963)	-	-	**363,782**
Research Investment fund	3,878,078	-	(464,444)	-	-	**3,413,634**
West Yorkshire Support fund	5,062	-	(140)	-	(4,922)	**-**
Total designated funds	4,340,791	-	(535,547)	-	(4,922)	**3,800,322**
General funds	2,797,225	2,182,387	(1,808,945)	185,177	4,922	**3,360,766**
Total unrestricted funds	**7,138,016**	**2,182,387**	**(2,344,491)**	**185,177**	**-**	**7,161,088**
Total funds	**8,767,960**	**2,541,707**	**(2,709,519)**	**232,297**	**-**	**8,832,445**

16. Movements in Funds (continued)

Purposes of restricted funds

The Academic Chair fund is used to fund the post of Professor of Ophthalmology for Glaucoma and Allied Studies at University College London.

The North East fund was established following receipt of a legacy and is restricted to supporting our work in the North East of England.

The Research fund represents donations, charitable trust and legacies income received specifically to fund glaucoma research. The fund was drawn on throughout the year as detailed on Note 8.

The Folkestone fund comprises legacy income restricted to work in Folkestone.

The Children and Young People's Support fund comprises income donated for services for young people affected by glaucoma and their families and carers. It aims to help us better understand their particular support needs and deliver appropriate services in response.

The London fund is restricted to the London area and has been used mainly for awareness raising and support work with BAME communities at greatest risk of glaucoma sight loss.

The Scottish Optom training fund is charitable trust income earmarked for eye drop adherence training for optometrists across Scotland. Following delays due to Covid-19 and changes to the professional training landscape in the intervening period, we have now developed new training courses for optometrists and other staff in optical practices. We are hoping to get this accredited by the GOC and roll out the training over the next two years.

The UKEGS fund comprises money for the work of the United Kingdom and Eire Society (UKEGS), a national scientific society that operates under the aegis of Glaucoma UK.

The 50th anniversary research fund comprises income donated as part of our 50th anniversary appeal. It is to be used towards the Pitts Crick Research Fellowship award to support research into glaucoma to improve the lives of people affected by glaucoma.

The Patient Voice Study restricted fund supports our work to gather insights from people living with glaucoma. Donations will directly support the collection of these voices during 2026 which will be compiled into a comprehensive report to share with policymakers and healthcare professionals, helping to drive improvements in glaucoma care.

The designated income endowment fund represents the donation of shares which form the basis of a stock market portfolio, with the eventual goal of providing for the running costs of the association.

The designated Equipment Replacement and Infrastructure fund is held to cover the cost of equipment replacement, infrastructure development, premises costs and dilapidations.

The designated Research Investment fund aims to produce a reliable income stream specifically to fund the charity's research priorities in the years ahead.

The West Yorkshire Support fund was undesignated during the year. This fund was originally set up by the trustees for activities in West Yorkshire but an initiative to fund volunteer-led support groups in the area did not result in any applications. The released funds will now be used to support the delivery of the Eye Health for All community outreach project.

17. Operating lease commitments

The charity had annual commitments at the year end under operating leases expiring as follows:

	Property	
	2025	2024
	£	£
Within one year	**12,858**	**19,834**
Within 1 -2 Years	**-**	**-**

We have given notice on the lease office building and are renting a small room in an office building. The lease finishes December 2025.

18. Related Parties

In 2022 Glaucoma UK awarded a grant of £57,300.56 to Nottingham University Hospital for which the lead researcher was Glaucoma UK Chair, Professor Anthony King. This was duly disclosed and recorded. The research project finished during 2025, with the final report signed off by Glaucoma UK and the outstanding balance of £31,515.56 to be paid upon receipt of invoices from Nottingham University Hospital.
Included in Note 13 are funds due to related parties held for the UK Paediatric Glaucoma Society (UKPGS) for which Glaucoma UK provided administration and infrastructure support. One Glaucoma UK Trustee was also a UKPGS committee member during the financial year.

Financial Statement of UKPGS	**2025**	2024
	£	£
Income	**22,450**	15,720
Expenditure	**(21,539)**	(19,710)
Closing balance	**911**	(3,990)
Balance brought forward	**28,213**	32,204
Total funds transferred to UKPGS	**29,124**	28,213

19. Financial Instruments

Financial Debt instruments measured at amortised cost	**2025**	2024
	£	£
Trade debtors	**6,205**	47,102
Legacy debtors	**1,510,764**	1,619,363
Prepayments, accrued income and Vat liability	**78,241**	26,074
	1,595,210	1,692,539

Financial instruments measured at amortised cost		
Trade creditors	**117,482**	166,396
Obligations under grant agreements	**1,102,017**	566,161
Funds held as agent	**-**	28,214
Accruals & Deferred income	**255,987**	196,789
Vat & National Insurance liability	**-**	3,844
	1,475,486	961,404

INTERNATIONAL GLAUCOMA ASSOCIATION LIMITED

England & Wales - Charity number 274681

Accounts

The International Glaucoma Association Limited **operating as** Glaucoma UK

Trustees' **Annual Report** and **Financial Statements**

for the year ending **31 July 2024**



Glaucoma UK

Celebrating **50 years** 1974 - 2024


will...

Contents

04 Welcome from the Chair

06 A message from the CEO

08 Our vision and priorities

10 Our Theory of Change

12 Strategic report: what we achieved in 2023-24
- 12 Priority 1: Raising awareness
- 16 Priority 2: Providing support
- 22 Priority 3: Funding research
- 30 Priority 4: Influencing policy and practice

34 Fundraising review

40 Looking forward

42 Financial review

46 Trustees, advisors and staff

48 Structure and management

54 Statement of trustee responsibilities

56 Independent auditors' report

60 Financial statements

Welcome from the Chair

I'm delighted to be sharing our Trustees' Annual Report for 2023-24 with you. It has certainly been a memorable 12 months as we have celebrated our 50th anniversary.

I feel very fortunate to be the incumbent Chair as Glaucoma UK reaches this highly significant milestone, and I want to take a moment to extend my thanks to all those who have preceded me. The charity, as it stands today, owes a debt of gratitude to the commitment and vision of the previous chairpersons, trustees and staff members who worked so hard to improve the lives of people living with glaucoma.

Principal actor among that cast is, of course, our founder Ronald Pitts-Crick, who established the charity in 1974 and dedicated 30 years of his life to leading its work. Although much has changed since that time – including the charity's name - the passion to bring an end to preventable sight loss from glaucoma remains unabated.

To honour our founder in this anniversary year, it has been a great pleasure to introduce the new Pitts-Crick Research Fellowship. This initiative offers an excellent opportunity to support an ambitious researcher over three years as they work to further our understanding of the disease.

Another key feature of our anniversary celebrations has been a deepened focus on what it means to be a member of Glaucoma UK. The team have been working harder than ever to ensure that our members feel part of a dynamic and mutually supportive community. We hope everyone who enjoyed our regular Insight magazine, called our helpline, attended our webinars or lectures, took part in a support group, received training or sought advice from one of our Buddy volunteers will agree that we achieved that goal.

The country has seen considerable change during the year, with a new government and an ever more varied range of diagnostic and treatment options for glaucoma patients to navigate. Against that backdrop, it's essential that we offer continuity, advocacy and trusted advice for our members and supporters. So, as we enter our second half-century, we will continue working to raise awareness, provide support, fund sight-saving research and influence glaucoma policy and practice.

As we tackle this ambitious 'To Do' list, we will be mindful that none of it would be possible without the extraordinary people who fundraise for our charity and those who make voluntary gifts to support our essential work. Your generosity and kindness underpin every achievement you will read about in this report. As such, it is dedicated to you, with our heartfelt thanks.

Professor Anthony King,
Consultant Ophthalmologist
and Glaucoma UK Chair

A message from the CEO

I echo the Chair's comments about what a privilege it is to find oneself at the helm during Glaucoma UK's special anniversary year. It is also a huge responsibility.

While it is a joy to look back on 50 years of progress, we are keenly aware that we must achieve even more in the future. We must make more people aware of the risk of glaucoma; we must provide even more support in more accessible ways to more people; we must spend more on sight saving research. And – most importantly of all – we must share the voice of our members even more loudly with those responsible for developing and delivering glaucoma care.

To make all this happen, we are excited to be embarking on a period of growth. As this report highlights, we have already begun to reap the benefits of a new Head of Research, additional helpline resource and a new team of Training and Engagement Officers who took up permanent roles in all four nations of the UK during the year.

Among those benefits was our highest ever number of helpline enquiries, the best-attended UK and Eire Glaucoma Society (UKEGS) Conference in the event's history, the highest ever attendance at our online webinars, the introduction of a new research fellowship and just under 1 million instances of support for people living with glaucoma.

We have made a promising start to our ambitious three-year financial plan, which will see us seeking new income streams and drawing on our reserves to maximise the reach and impact of our vital sight saving work. Our progress to date is thanks to the wise counsel of our Board of Trustees and the hard work and dedication of my extraordinary colleagues; I hope you enjoy reading about their achievements in this report.

Joanne Creighton,
Chief Executive Officer

> "We are excited to be embarking on a period of **growth**



Our **vision** and **priorities**

Glaucoma is a complex group of eye diseases that damage the optic nerve and, if left untreated, can lead to irreversible vision loss and even blindness.

At Glaucoma UK, our goal is to eliminate preventable glaucoma-related sight loss. Currently, we believe that well over 700,000 people in the UK are affected by glaucoma, yet nearly half are unaware of it due to the frequent lack of early symptoms.

The only reliable way to detect glaucoma is through a comprehensive eye examination, but more than a third of UK adults don't attend regular check-ups.

The issue is even more pressing in high-risk groups, including individuals facing socio-economic challenges and those of African-Caribbean descent, where attendance rates are even lower. Therefore, we are dedicated to raising awareness about the importance of early diagnosis across all communities. Alongside early detection, timely treatment and ongoing monitoring are also essential in helping people with glaucoma preserve their vision for life. However, with rising demand and lengthy wait times, much remains to be done to establish a reliable and consistent treatment pathway across the UK. We strive to amplify the voices of those living with glaucoma, so they are heard by healthcare providers, policymakers, and service commissioners.

Perhaps our greatest tool in preventing sight loss from glaucoma is research. We aim to understand the causes of glaucoma, how to prevent it, which treatments are most effective, and—ultimately—how to cure it. Through our annual funding program, we support research that explores new medical and surgical approaches and innovative treatment models in the hope of finding these answers.

Our **Theory of Change**

Our Theory of Change sets out the long-term, sustained impact we want our work to have for people living with glaucoma. As a result of our efforts, we want to change the glaucoma care landscape in the following ways:

1 **Increased awareness and earlier diagnosis of glaucoma** among those who are most at risk.

2 **More people are able to live well and maintain sight** through equitable and timely access to effective clinical care and pastoral support.

We focus on four priority areas in pursuit of these sustained impact goals:

Priority 1: Raising awareness

- Disseminating clear, accessible, impactful messaging about the risk to individuals.
- Ensuring professionals are aware of Glaucoma UK's role in supporting glaucoma care.

Priority 2: Providing support

- Giving accessible and effective advice and information to individuals and their carers.
- Offering practical and emotional support to help individuals adhere to their treatment regime.
- Creating and promoting an active and mutually supportive glaucoma community.

Priority 3: Supporting research and development

- Providing funding for high-quality research into glaucoma prevention, diagnosis, treatment and cure.
- Liaising with corporate bodies to improve glaucoma treatments and patient outcomes.

Priority 4: Influencing policy and professional practice

- Advocating for the patient perspective in the design, development and delivery of glaucoma care pathways.
- Providing relevant and credible information and support for medical professionals.

Strategic report: what we achieved in 2023-24

Priority 1: Raising awareness

The first step in bringing about an end to glaucoma sight loss is to raise awareness about the disease and the risk to individuals. Our awareness raising campaigns encourage people to have their eyes examined every two years, unless advised otherwise by their healthcare professional.

We also want to ensure that people know about our work and the many services we provide to help them manage their glaucoma.

We work to raise awareness among eyecare professionals, too. They have an essential role to play in signposting their patients to our charity, so that we can provide the pastoral support that simply cannot happen in the time-strapped clinic environment.

Desired outcomes of our efforts to raise awareness include:

- More people understand why they may be at risk of glaucoma and that it could impact their vision, even without symptoms.
- More people who are at highest risk of glaucoma seek an eye examination.
- More professionals are aware of Glaucoma UK and refer people to us for advice and support.

How did we do?

Understanding the risk

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Our National Eye Health Week Campaign in September delivered essential bite-sized information via seven short videos, designed to be easily shared on social media.	Over 1.1 million people reached on social media and an estimated 1.5 million readers via an article in The Guardian newspaper.
In November, we shared our Road Safety Week message via social media and adverts on petrol nozzles in cities with a lower uptake of eye tests. A range of eye sector publications also featured the campaign.	Our social media posts were seen 14,297 times and an estimated 432,000 people saw the petrol nozzle ads.
For Father's Day in June, we ran a digital billboard campaign to highlight the hereditary nature of glaucoma, alongside a social media advertising campaign.	The billboards were seen by an estimated 39 million people across the UK, with a further 242,219 people reached via social media.
During Glaucoma Awareness Week in June, we invited people to share their family stories to help raise awareness of glaucoma in families, encourage people to talk about their eye health history and highlight the importance of regular eye tests.	The campaign secured over 21 hours of airtime across a wide network of radio stations and reached 321,742 social media users.
An epic challenge by one of our members to run from Land's End to John o' Groats in June this year helped to raise awareness of glaucoma across the UK.	Over 27 million people reached via regional and national press coverage and 438 items of radio coverage secured.

Reaching those at highest risk

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Our Ramadan Campaign, in partnership with the British Islamic Medical Association and the Muslim Council of Britain, was featured in print media, on the regional news network and on posters in opticians' practices throughout the UK.	Individuals received our message via the British Muslim Magazine (45,000 readers) and the magazine's website (74,000 monthly views).
Via 27 talks to community groups and other charities across the UK, we helped to raise awareness of glaucoma amongst groups at highest risk.	Sessions attended by 460 individuals from varied backgrounds and ethnicities.
We ran targeted social media advertising campaigns throughout the year for communities known to be at a greater risk of glaucoma. These included people of African-Caribbean and East Asian ethnicity, the over 60s and those experiencing social deprivation.	A total of 1,097 searches for free NHS eye tests were made on our website by those who viewed the advertisements.

Raising awareness of Glaucoma UK among health care professionals

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Glaucoma UK was invited to present at the Glaucoma Risk Prediction event at City University in November 2023 and the Moorfields International Glaucoma Symposium (MIGS) in January 2024.	Patient-focused advocacy with over 300 glaucoma professionals.
Our Training and Engagement Officers delivered 15 presentations to professionals during the year to raise awareness of the charity, detail the services we provide and encourage patient referrals.	Over 200 professionals in attendance from social care, occupational therapy, sensory support, vision rehabilitation, optometry and pharmacy.

Priority 2: Providing support

Supporting people with glaucoma and their loved ones is a vital element of our work. Glaucoma treatment can be complex and challenging, with some individuals finding the treatment worse than the early effects of the disease itself.

Understanding glaucoma and its allied conditions and making choices about the many different treatment options can be overwhelming. With clinic appointments generally infrequent and brief, it is hard for individuals to have the time and space they need to ask questions and fully digest the replies.

At Glaucoma UK, we want to empower people by offering the right help and advice, delivered in the right way, at the right time. We want to be at the heart of a vibrant, supportive glaucoma community, where people can share their experiences with others facing the same challenges and choices.

Our various services provided just under 1 million instances of support, information and guidance during the year.

Desired outcomes of our support services include:

» More people understand their condition and feel able to adhere to their treatment regime.
» More people at increased risk of sight loss are able to access support from Glaucoma UK when and how they need it.
» People feel more confident and positive about their condition by being part of a supportive glaucoma community.

How did we do?

Improving understanding and adherence

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Our interactive Digital Glaucoma Support Groups, featuring expert guest speakers, covered topics including 'What do you want to know about glaucoma?' 'Vitamin B3 research', 'Preserflo and trabeculectomy', 'Glaucoma and cataracts' 'Glaucoma jargon busting', 'All about glaucoma', 'Eye drops', and 'Dry eye'.	Over 800 people joined the live sessions, with a further 25,199 accessing the recordings on demand. 99% of survey respondents said they would recommend the sessions and 72% gained a better understanding of the disease.
PIF TICK accreditation was achieved during the year, confirming the charity's status as a trusted information creator. The PIF TICK is the UK's only assessed quality mark for health information.	PIF TICK accreditation helped to ensure that the information we provided was evidence-based, understandable, jargon-free and up to date.
In August 2023 we launched a new, more accessible, version of our popular booklet 'Driving and glaucoma', with updated information covering all four nations of the UK.	Over 9,500 copies of the new booklet have since been distributed to individuals and healthcare settings.

Supporting those at highest risk

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
The recruitment of an additional helpline advisor increased our capacity to respond to calls and emails. Once again, the most popular topics were eye drops, driving with glaucoma, advice about surgery and support with appointments.	A total of 3,544 calls and emails were answered, representing over 560 hours of support. This was a 30% increase on the previous year and our highest annual total to date.
Our HealthUnlocked forum continued to be a popular resource for those who prefer to take part in online discussions at a time convenient to them.	Over 4,000 posts and responses were shared, and 759 new members were welcomed to the community.
By hosting 26 face-to-face support groups, we enabled glaucoma patients to meet others, ask questions of professionals and learn more about the help we provide.	A total of 350 individuals received in-person support at our support groups.



Creating a supportive glaucoma community

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Our volunteer Buddy Scheme continued to be a source of invaluable peer-to-peer support for those considering glaucoma surgery. The introduction of virtual Buddy Coffee Mornings provided a welcome opportunity to more regularly thank our Buddies and discuss the successes and challenges of this vital volunteer role.	Over 60 buddy pairings were facilitated during the year and 44 new buddies agreed to join the scheme, bringing our total of buddy volunteers to 82.
Case study volunteers shared their experiences of living with glaucoma via radio and TV interviews, podcast recordings, billboard campaigns and media interviews. Case study stories were also featured in every edition of our Insight magazine.	Our community of over 90 case study volunteers helped us by sharing stories that were featured in all our major awareness raising campaigns during the year.
Growing our Glaucoma UK community has been a key priority for our 50th anniversary. In addition to further improving our member communications, we introduced a new 'Welcome webinar' in July, featuring key facts and statistics about glaucoma and information about the services we provide.	We welcomed 638 new members to our 4,849 strong community of glaucoma patients and professionals.
Sign-ups for our 'Focus' e-newsletter, grew significantly during 2023-24, driven largely by successful, targeted social media campaigns, helping us reach and engage a broader audience.	The Focus audience more than doubled during the year, with a total of 5,398 subscribers by July 2024.

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
We ran our first Digital Glaucoma Support Group led by glaucoma patients during the year. The session entitled, 'Lived experience of eye drops', featured speakers recruited via our online HealthUnlocked forum.	Over 20 people attended, with 85% stating that their knowledge of glaucoma increased and 99% willing to recommend the session to others.
A special-edition membership magazine called 'Inspire' showcased the inspirational fundraising efforts of our members and publicised a new campaign called 'I will...", inviting pledges of support for people living with glaucoma.	From urging family members to have an eye test, through to running a marathon, responses to our 'I Will...' campaign highlighted the loyalty and dedication of the Glaucoma UK community.
For World Glaucoma Week in March, we ran a series of webinars showcasing glaucoma care in different parts of the world and revealing how research findings are shared across the globe.	A total of 30 attendees enjoyed our 'Glaucoma care everywhere' series.
The annual Excellence in Glaucoma Care Award, which is presented at our Annual General Meeting, celebrates individuals or teams making remarkable contributions to the field of glaucoma care.	The winner for 2023-24 was Zainab Alrikabi, a PhD student at Glasgow Caledonian University, who gave first-class care to participants in her research study.

Inspire
Inspiration from our glaucoma community
Spring 2024
1000 miles. 5 weeks.
Former Red Arrow Martin Higgins' epic challenge during Glaucoma UK's 50th year
page 12
GCU
Vision Centre
Excellence in eye care and health

Priority 3: Supporting research and development

As the only UK charity solely funding research into glaucoma, our work to support the most promising studies, led by the most talented researchers, is a key aspect of our mission.

In addition to our annual awards for ophthalmologists, health and social care professionals and members of the UK and Éire Glaucoma Society (UKEGS), we also offer an 'Open Call' programme to attract novel research into new methods of diagnosis, care and treatment.

By helping to fund the Professor of Ophthalmology at University College London and working with partners including the Royal College of Ophthalmologists, we aim to deliver an ambitious research programme that will have a real impact for the people we serve - now and in the future.

In 2023-24, we awarded new grants to the value of £412,711 (but with one of £49,489 to be accounted for in next year's accounts, due to a contract delay at the financial year-end). The grants were awarded in open competition by an awards panel chaired by a Glaucoma UK trustee. Other panel members were drawn from our Clinical Advisory Panel and our lay member volunteers. All awards were subject to a peer review process.

Desired outcomes of our research programme include:

» More of our research projects demonstrably transform glaucoma prevention, diagnosis and treatment.
» Research we fund is more widely disseminated to inform and improve glaucoma care.
» We achieve more leverage from our research support and sector relationships.

How did we do?

Transforming glaucoma prevention, diagnosis and treatment.

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
We launched the brand-new Pitts-Crick Career Development Research Fellowship in March, in recognition of the charity's 50th anniversary. Through this three-year programme, we hope to support a rising star in glaucoma research who will go on to play a pivotal role in transforming glaucoma care.	Promising applications have been received from individuals across a range of specialisms including ophthalmology, optometry and research science. The Fellowship will be awarded in early 2025.
The £50,000 UKEGS research grant for 2023 was awarded to Patrick Gunn, Lead Optometrist at the Manchester Royal Eye Hospital, for his project entitled 'Minimising the implementation gap in management of narrow angle glaucoma suspects through education and technology'. The project commenced in December 2023 and will run for two years.	By supporting optometrists to manage low-risk patients more effectively in community settings, the project seeks to reduce unnecessary hospital referrals, free up time for more complex cases and reduce treatment delays.
We were delighted to award two grants for this year's joint award with the Royal College of Ophthalmologists: Dr Lisa Hill, Associate Professor at the University of Birmingham, was awarded just under £100,000 for her project to explore whether a new anti-scarring treatment can be delivered to the eye to improve drainage through the trabecular meshwork.	Both projects will explore innovative, novel therapies for glaucoma, particularly focussing on the causes of poor drainage of fluid from the eye. The studies offer real potential for the discovery of an alternative to pressure-lowering eye drops.

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Dr Victoria McGilligan at Ulster University was also awarded just under £100,000 for her investigation into an antibody which can harness the body's natural immune system and reduce inflammation in the drainage channels of the eye.	(*See previous page*)
The £50,000 Health and Social Care Professionals' grant for 2023 was awarded to Matt Roney at Liverpool Hospital Foundation Trust and the University of Liverpool. The project will investigate whether OCT can be used to identify early signs of surgical failure after surgery.	Earlier intervention after surgery could mean more successful surgeries, with fewer complications and - ultimately – the reduction of sight loss due to glaucoma in the longer term.
Glaucoma UK is now an introductory member of the Association of Medical Research Charities (AMRC). We are reviewing and improving our processes and procedures in order to achieve full membership status within the next two years.	By becoming an AMRC member we will benefit from opportunities to connect and collaborate with other research organisations and receive support to fund the best and most impactful research.

Glaucoma UK Chair of Ophthalmology

In partnership with University College London and the Moorfields Biomedical Research Centre, the charity provided continued financial support for the role of the Glaucoma UK Chair of Ophthalmology for Glaucoma and Allied Studies – Professor David (Ted) Garway-Heath.

Professor Garway-Heath's achievements for the year included:

- 9 new scientific publications
- 18 national and international lectures for a range of organisations including the Irish College of Ophthalmology (Mooney Lecture), European Glaucoma Society, Italian Glaucoma Society, Imaging and Perimetry Society and the Moorfields International Glaucoma Symposium.
- Provision of strategic input and guidance for the European Glaucoma Society (EGS) as member of the Executive Committee and immediate Past President
- Furtherance of the EGS patient advocacy project, including the first patient-initiated and organised plenary session at the European Glaucoma Society Congress in Dublin.
- Chief Investigator for the research projects:
  - » 'The association between mitochondrial function and glaucoma–identifying susceptible patients';
  - » 'Identifying the genetic basis for heritable normal tension glaucoma, with a focus on mitochondrial function' and,
  - » 'NicotinAMide in Glaucoma (NAMinG): A randomised, placebo-controlled, multi-centre, Phase III trial' to test the effectiveness of vitamin B3 as a treatment for glaucoma.

Disseminating research findings to inform glaucoma care

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Research jointly funded by Glaucoma UK and the UK & Eire Glaucoma Society (UKEGS) was published in the prestigious Nature Medicine magazine in June 2024. The project, which identified a new biomarker for glaucoma progression, was carried out by Bledi Petriti and Professor Garway-Heath, the Glaucoma UK Professor of Ophthalmology. Following publication of the article, Ted Garway-Heath was also interviewed on BBC Radio 4's 'In Touch' programme.	Nature Medicine has one of the highest impact factors of any journal (the measure of how frequently the articles have been cited in a particular year). The research findings will help to identify patients at risk of faster progression, informing personalised treatment strategies and targeted therapies.
Other projects we have funded have resulted in presentations at conferences such as the world-leading ARVO (the Association for Research and Vision in Ophthalmology) and UKEGS, as well as publications in journals including Cells and PLOS One.	Ensuring that the outcomes of our research funding are widely shared among glaucoma professionals will help improve the prospects for prevention and cure.
A new UK Clinical Eye Research Strategy, featuring consultation feedback from Glaucoma UK members, was featured on BBC Radio 4's In Touch programme in July. The strategy sets out new priorities for all aspects of eye research, but glaucoma was the topic receiving the highest consultation response.	The strategy will help channel precious resource in eye research towards the most important topics. It will encourage government, charity and industry funding into these areas.

Achieving leverage from our research and sight sector relationships

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Glaucoma UK continued to be an active member of the Vision Impairment Charity Sector Partnership (VICSP), which was rebranded as the 'Vision Partnership' during the year. This partnership of eight organisations, including RNIB and Guide Dogs UK, seeks to achieve alignment and added value for people living with – or at risk of – sight loss. A new strategic direction was set out for the group in January, aligning closely with Glaucoma UK's Theory of Change.	Involvement in the partnership offers the combined resources and collective influence of all key organisations in the sight sector. Priorities for the next three years include: • Influencing national policy. • Improving access to services for underserved communities. • Advocating for more medical research funding.
Glaucoma UK's Head of Research led a workshop for charity partners in June, exploring ways to increase research funding and get more patients involved in ground-breaking eye research.	Over 20 representatives from eight sight sector organisations shared ideas and identified joint working opportunities.
We became an affiliate charity of 'Our Future Health' during the year - a charitable health research project seeking 5 million volunteers to share their health data and thereby help develop new ways to prevent, detect and treat diseases.	Involvement in the project will enable us to learn from their expertise in reaching high-risk populations and securing engagement in health research.

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Glaucoma UK is taking part in a thought-leadership project, led by the pharmaceutical company Santen, to explore future trends in glaucoma diagnosis, treatment and management. Following research with glaucoma patients and professionals, a series of studies will be produced, focusing on artificial intelligence, genomics and biomarkers, service delivery, innovative treatments, health equity and patient education.	With an overarching theme of 'the glaucoma patient of the future', Glaucoma UK will be well placed to ensure that the interests of its beneficiaries are at the heart of this important piece of work.
In January, Glaucoma UK announced a one-year partnership with the care plan provider OcuPlan to improve awareness of eyecare options for glaucoma patients. The collaboration is a joint effort to enhance awareness and support for individuals living with the disease. As well as working together to improve understanding of glaucoma more generally, the partnership will also promote patient choice and informed decision-making about eyecare options.	Just under 100 people attended a Digital Glaucoma Support Group led by OcuPlan's CEO, and 14 Glaucoma UK members took part in a consultation to help OcuPlan understand the challenges faced by glaucoma patients. In support of the partnership, OcuPlan contributed £50,000 towards the delivery of Glaucoma UK's free support services.



The progress we made during the year

Our relationship with Specsavers continues to offer a valuable opportunity to showcase the work of Glaucoma UK and amplify our messaging.

Chairman Anthony King was a guest speaker at the Specsavers' Professional Advancement Conference in September 2023 and also the 100% Optical event in London's Excel in February 2024.

Joint messaging was agreed for World Glaucoma Week and Glaucoma Awareness Week. For the latter, Specsavers worked with artist Louisa Schmolke to create a piece of art that reflected the effects of glaucoma on eyesight. The artwork was kindly gifted to Glaucoma UK.

The impact on people with living with, or at risk of, glaucoma

All joint awareness raising in partnership with the UK's biggest high street optometry chain offered a valuable opportunity to highlight Glaucoma UK's key messages and showcase the ways in which those working in community optometry can help deliver our charitable objectives.

Priority 4: Influencing policy and professional practice

With the eyecare landscape changing at such a rapid pace, we must ensure that the voice of people living with glaucoma is heard by policy makers and those making decisions about care services. We also feel we have an important role to play in providing information, advice and support to health care professionals.

We want all those involved in delivering glaucoma care to have up-to-date information and access to effective professional networks for sharing best practice. Through the work of our Professional Engagement Team, we seek to make connections that can help to promote, protect and safeguard the interests of people living with - or at risk of - glaucoma.

Through our administration and support for the United Kingdom and Éire Glaucoma Society (UKEGS) – which became part of Glaucoma UK in 2019 – we play a key role in bringing together scientists and clinicians in a vibrant, aspirational scientific community.

Desired outcomes of our professional engagement work include:

- More people at increased risk of glaucoma have equitable access to eyecare services.
- Those making decisions on policy and commissioning take greater account of glaucoma patient perspectives.
- More people at increased risk receive timely access to eyecare services.
- More professionals feel better informed and equipped to support people to live well with glaucoma.

How did we do?

Promoting equitable and timely access to eyecare services

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
A Westminster Hall debate took place in April, focusing on the current state of glaucoma care. Glaucoma UK was referenced by the shadow minister for health, along with our message about the importance of regular eye tests.	Subsequent requests for media comment allowed us to highlight the benefits of a National Strategy for Eye Care to ensure equality for glaucoma patients across the UK.
In April, Glaucoma UK was represented at an All-Party Parliamentary Group (APPG) open meeting about innovation in Eye Health. Discussion topics included AI assisted diagnostic hubs and community monitoring.	Glaucoma UK supported the call for better connectivity between primary and secondary eyecare and the need for more consistency in provision across the UK.

Sharing glaucoma patient perspectives

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
Glaucoma UK represented glaucoma patients at a number of eyecare sector forums during the year, including The Clinical Council for Eye Health Commissioning (CCEHC), The Ophthalmology National Steering Group and The UK Ophthalmology Alliance (UKOA). The charity was also represented at a National Institute for Health and Care Excellence (NICE) committee meeting regarding approval of the new pressure-reducing eye drop, Roclanda. Glaucoma UK attended two stakeholder meetings with the DVLA during the year, to represent the views and experiences of drivers with glaucoma.	As members of the CCEHC, we supported the development of a Clinical Specification for Community Minor and Urgent Eye Care Services. We also shared patient insights with the National Clinical Director as she works on a plan to improve eyecare across the UK. Through the National Steering Group, we recommended suggested glaucoma research priorities to the National Institute of Health Research (NIHR). Following the NICE committee meeting, which featured a submission from a Glaucoma UK patient member, the drug Roclanda was approved.
Glaucoma UK staff and members took part in a consultation to help develop a new Eye Care Support Pathway to help transform eyecare services. With far greater emphasis on patient experience, the pathway focuses on the practical and emotional support that individuals need at various stages of their treatment.	Building upon the launch of the pathway, we are now working with sector partners to develop a glaucoma-specific strand, that will better reflect the particular needs and challenges faced by those living with glaucoma.
Glaucoma UK was delighted to take part in a nation-wide campaign by charities, passenger watchdogs and disability groups to speak out against the proposed mass closures of ticket offices during the year.	Proposals to close ticket offices were withdrawn by train operators in November 2023.

Ensuring professionals are informed and well equipped to support glaucoma patients

The progress we made during the year	The impact on people with living with, or at risk of, glaucoma
The 2023 UKEGS Conference in London was the biggest in the event's history, with over 500 delegates. The conference brought together top glaucoma experts, researchers, and professionals for a two-day programme to explore the theme of "Best Evidence for Best Practice".	The programme included a presentation from the Glaucoma UK CEO, highlighting the anxiety felt by those receiving a glaucoma diagnosis and current shortfalls in patient communication.
We were delighted that the General Optical Council approved our Eye Drop Support training for their CPD scheme during the year, allowing optometrists and dispensing opticians to claim career development points. Course attendees receive Eye Drop Support Boxes containing information on eye drop usage and samples of the aids available to help patients put them in. Over 200 boxes have been distributed across the UK since the scheme was launched in 2022.	100% of course attendees found the dispensing aids useful and 93% found it helpful learn more about the barriers people face in using eye drops. 95% stated that the course taught them something new about glaucoma.
Our team of Training and Engagement Officers delivered a new pilot project for pharmacy and optical practice front of house staff, to help them better support people with their eye drops.	We welcomed 61 attendees to 8 training sessions, with 100% of survey respondents agreeing they would recommend the course.

Fundraising review

Nearly three-quarters of our total income was made up of voluntary gifts from our generous members and supporters. This demonstrates the critical role our glaucoma community plays in funding our work and we are deeply grateful to each individual, family, company, trust and foundation that supported us throughout the year. Collectively, our donors helped us to raise just under £1.8 million in support of our efforts to make a difference to people living with glaucoma.

Legacy gifts

Legacy gifts are essential for us, and we are indebted to the members, supporters, and grateful patients who remember Glaucoma UK in their wills each year. In 2023-24, we recorded a total of £1,528,917 in legacy income and received 32 new legacy notifications. These gifts are vital not only for sustaining our current work but also for enabling us to plan confidently for the future. Legacy donations are a testament to the positive impact we have had on individuals' lives, and we are grateful to those who have chosen to support us in such a meaningful way. We are also grateful to their families and friends, many of whom choose to stay in touch and continue their loved one's support for our work. Legacy gifts ensure that we can continue our mission to prevent sight loss from glaucoma for future generations and allow us to dedicate more funding to essential glaucoma research.

We have, however, seen a decline in the number of new legacy notifications in recent years. With an average 12-month lag time between notification and receipt of the funds, this threatens to have a significant impact on our voluntary income in the medium-term. It is essential, therefore, that we continue to communicate the enormous importance of legacy gifts to our supporters and that we work ever harder to ensure membership of our charity proves to be an invaluable resource for those who need us during their lifetime.

Other income

To help ensure a sustainable future for the charity, we have been focusing on diversifying our income to reduce the current strong emphasis on legacy gifts. In 2023-24, we were delighted to receive support from our community via a range of income streams, including membership subscriptions, one-off gifts, responses to

appeals, regular giving, Christmas card sales, In Memoriam donations, corporate partnerships, challenge events, and our weekly lottery. Together, these contributions totalled £363,929, a 34% increase from the previous year (2023: £270,677).

We are always especially touched to receive In Memoriam donations from those who choose to honour their loved ones by directing funeral collections to Glaucoma UK. Income from this source showed a 25% increase year-on-year (2024: £21,185 versus 2023: £16,821).

Our corporate supporters also played a vital role, contributing £84,194 to our income—over five times higher than the previous year (2022-23: £14,649). This increase was largely thanks to our partnership with OcuPlan, who contributed £50,000 towards our community outreach work. We were also grateful to receive £20,000 from our licencing agreement with Specsavers, which steered our joint promotional efforts throughout the year. In addition, for Glaucoma Awareness Week 2024, Specsavers donated a piece of art that had been specially commissioned to show the effects of glaucoma on eyesight. The artwork will be used to help raise awareness of glaucoma and generate funds through auction or sale.

Challenge event fundraising

We are thankful for the extraordinary efforts of our challenge fundraisers, whose mental and physical determination raised an impressive



£80,022 for Glaucoma UK in the past financial year - exceeding our previous highest-ever year in 2022-23. It was especially heartening to see how the number of challenge fundraisers has increased from only three participants a few years ago to 18 people in 2023-24, highlighting the growing strength and commitment of our glaucoma community.

We were particularly grateful to Martin Higgins, a distinguished former member of the RAF Red Arrows, who took on a monumental challenge to run from Land's End to John o' Groats to raise awareness of glaucoma as part of our 50th anniversary celebrations. Martin's efforts raised a total of £18,625 – representing almost half of the £38,970 raised from our members and supporters towards the charity's new Pitts-Crick Research Fellowship.

Over 30 years since he last attempted the feat in aid of Glaucoma UK, former Chair and Consultant Ophthalmologist, Michael Miller ran the London Marathon in April. Thanks to his incredible efforts, Michael raised £21,238 for the charity.

Once again, Professor Keith Barton, Consultant Ophthalmic Surgeon at Moorfields Eye Hospital and former Chair of Glaucoma UK, undertook the gruelling London to Paris bike ride in aid of Glaucoma UK. Crossing the finishing line in under 24 hours, his achievement raised £30,329. This brings Keith's remarkable fundraising total to over £168,000 for Glaucoma UK in the last 11 years.

A special thanks also goes to James Broadbent, who took on the challenge of cycling a distance equivalent to the height of Everest—nearly 8,850 metres—raising £3,830 in the process. We are equally grateful to Connor Bice, who cycled an impressive 150 miles - the equivalent distance from his family home to Birmingham Children's Hospital and back - to raise awareness of primary congenital glaucoma following his daughter's diagnosis at just seven months old. Connor's incredible effort raised £3,025. Our thanks, also, to Tanika, Sally, Richard, Beth, Francesco, Grace, Katy and Kathryn who took part in various marathons, runs and walks across the UK to raise funds in support of our essential work.

MIKE
HIGGY

Organisations who helped us

We would like to take this opportunity to thank the following organisations for their support during the year:

ELIOS Vision
Envision Pharma Group
Glaukos
Harry and Gertrude Landy Charitable Trust
i-STAR Medical
KMS (UK) LTD
Medicom Healthcare
OcuPlan
Pinner Folk and Blues Club
Santen UK
Specsavers
Stranraer Folk Club
The Dandy Charitable Trust
The Emily Weircroft Charitable Trust
The Masonic Lodge of Equity No. 3692
The Monk Bretton Charitable Trust
The Wyndham Charitable Trust
Théa Pharma UK
Wyseliot Rose Charitable Trust

Fundraising controls

Securing and maintaining the trust of our donors and the public is vital to the success of our fundraising activity. We therefore have controls in place to ensure our fundraising is transparent, ethical and compliant with current regulations. We have the benefit of a designated Fundraising Trustee Advocate on our Board of Trustees, to ensure oversight at the highest level. In addition, our Finance and Governance Committee monitors fundraising performance, control and regulation through quarterly reviews.

Glaucoma UK is registered with the Fundraising Regulator and follows the Code of Fundraising Practice. We comply with the key principles embodied in the Code and are committed to the Fundraising Promise. Our website carries our complaints policy for the public and explains clearly how an individual may complain. We received no complaints from August 2023 - July 2024. We are also registered with the Fundraising Preference Service so that individuals can opt out from receiving fundraising communications, should they wish. We received no such requests during the year.

To ensure that all reasonable steps are taken to protect vulnerable adults, Glaucoma UK complies with the Institute of Fundraising guidance relating to the needs of people in vulnerable circumstances and our activities are governed by an Ethical Fundraising Policy and Supporter Promise.

Glaucoma UK monitors any third parties working with us to help raise funds, ensuring that they adhere to the Code of Fundraising Practice and are operating to the highest possible standards of respect for the personal data and wishes of our supporters and prospective supporters. We worked with one third party – Bequeathed Limited - in the delivery of a free wills service, but did not work with any external professional fundraising agencies during the year.

Our Lottery activities are managed under our Gambling Commission licence which ensures we can meet our legal obligations and provide the necessary protections for our players.

Looking **forward**

With 50 years of history to build upon, we now have an exciting opportunity to set out ambitious and inspiring plans for the future. Our ultimate goal is to ensure that the charity doesn't exist to celebrate its 100th anniversary. By finding that all-elusive cure for glaucoma, we can eliminate the need for our services. It's a tall order, but one that merely serves to sharpen our focus and determination.

In pursuit of this goal, we will be working towards a number of exciting outcomes in 2024-25:

Expanding our reach and impact

Our programme to maximise our impact across the UK will continue in the coming year, with investment in new colleagues to help grow and develop our fundraising, outreach, helpline and digital communications activities.

Engaging new audiences

Our team of training and engagement officers will be developing a series of pilot projects to engage those at highest risk of glaucoma sight loss in targeted communities across the four nations. This will help to identify exactly what effective community engagement for underserved audiences looks like and will enable us to collect valuable impact data to help seek funding to roll out this work across the UK in due course.

Representing the patient voice

We have welcomed lots of new members to the charity as a result of our anniversary year celebrations and so this is the perfect time to collect more comprehensive and up-to-date information on glaucoma patient perspectives. We will be collecting feedback from our members on a wide range of topics across the coming year in order to more accurately and effectively represent their views and concerns to those who develop policy, provide treatment and make decisions about glaucoma care.

Growing our support for research

The appointment of a Head of Research in early 2024 is already paying significant dividends for our work in this area and we will be further expanding our research funding in the coming year. In addition to the introduction of the charity's first-ever Career Development Research Fellowship, we will be offering a second PhD studentship and working with other sight sector charities to explore options for transformational partnership projects. Having the benefit of our £3.87 million Designated Research Fund offers an exciting opportunity to invest in more ambitious, larger scale projects that have the potential to transform current approaches to the diagnosis, treatment and monitoring of glaucoma.

Improving efficiency

We will be exploring the potential offered by artificial intelligence to assist our work in the coming year and will be increasing the use of automation within Glaucoma UK's administrative systems. This will free up the time available for engaging with audiences and developing new products and services for people living with glaucoma.

Enhancing quality standards

Following on from our achievement of PIF Tick accreditation for our health information, we will be signing up to the Helplines Partnership Quality Standard in 2024-25 to further improve the service we offer for those reaching out to us for help and advice.

Financial review

Against the backdrop of a mixed, but gradually improving economic environment, Glaucoma UK ended the Financial Year 2023-24 with a net increase in funds of £720,213. This takes the charity's total funds to £8,767,960 (2023: £8,047,747).

Net income showed a surplus of £280,305, largely due to the receipt of an unusually large legacy during the year. Expenditure increased to £2,077,745, up 18.5% on the previous year, in line with the strategic objective to maximise Glaucoma UK's reach and expand services in the coming three-to-five year period.

With recession avoided after the inflationary pressures of the previous year, movements in the stock market resulted in unrealised gains of £439,908 on our investment portfolio.

Incoming resources

At £2,358,050, total income was up 33% on the previous year (2023: £1,773,879). This was thanks to an exceptional legacy (the largest in the charity's history) which resulted in a growth in voluntary income of £303,273 year-on-year (2024: £1,787,919 versus 2023: £1,484,646)

Legacies remain a crucial revenue stream for Glaucoma UK, representing just under 70% of total income, on average, over the last five years. As in the previous year, we continued to receive more complicated bequests, often resulting in an extension in the time between being notified of a gift and receiving the funds. This is reflected in the legacy debtor figure, which remains high at £1,619,363. In recent years, we have invested in additional staff resource and worked to further improve our administrative systems in an ongoing drive to reduce that figure.

Income from our charitable activities was up by £245,161 on the previous year (2024: £370,197 versus 2023: £125,036). This was due in part to higher sponsorship and delegate income for our UK and Eire Glaucoma Society (UKEGS) Conference and also the receipt of £81,950 in relation to corporate support, including our partnership agreements with Specsavers (£20,000) and

OcuPlan (£50,000). In addition to the benefits these partnerships bring in helping to amplify our key messages and supporting the delivery of our strategic objectives, this is an increasingly important income stream for the charity as we seek to reduce the emphasis on legacy gifts. Work to develop this area will continue throughout the strategic plan period, but with due regard to the importance of independence and objectivity in the charity's activities and decision-making.

We benefitted from the Google Ads grant scheme during the year, with free advertising to the value of $64,861 (£50,449 as at 31 July 2024). Google Ads enabled us to serve advertisements to people searching online for particular keywords and encourage traffic to the charity's website.

Resources expended

Total expenditure in the year was £2,077,745, up by £324,521 on the previous year (2023: £1,753,224). As we continue to build capacity within our team and expand our activities to more effectively deliver our Theory of Change, staff costs accounted for 43% of this increase, rising to £975,235 from £835,770 in 2023.

During the year, we introduced the role of Head of Research, the charity's first ever designated resource in this important strategic area. To help address growing demand in both the number and nature of helpline calls, we also invested in a third helpline advisor. Total staff numbers at the year-end were 22.88 (full-time equivalent) compared to 18.53 at the end of 2023. Other areas of expenditure growth included the costs of a larger, more expensive London-based UKEGS conference and more expenditure on patient education, including our ongoing work to update and reprint our suite of information booklets.

We accounted for £363,222 in respect of new research grants awarded during the year. This was down by £45,438 on the previous year (2023: £408,660), due to a third-party contract delay that remained unresolved at the financial year end. Taking account of the £49,489 delayed award, we actually granted £412,711 in funding for new projects, which was the highest figure to date and maintains our strategic drive to increase the impact of our research support. In a move to address timing issues at the financial year end, we will be redesigning our grant awards programme in 2024-25. Total expenditure on research, including staff costs, premises, administration and professional fees was £431,080 during the year.

Restricted Funds

Of total funds at the year end, the sum of £1,629,943 was restricted. The

majority (£1,504,578) represents the Chair Fund, which will support the Chair of Ophthalmology for Glaucoma and Allied Studies until his term comes to an end in March 2028. Of the remainder, £75,223 is restricted to the delivery of the UK and Éire Glaucoma Society (UKEGS) conference, and the rest is allocated to a range of specific small projects at the request of the donors.

We introduced a new restricted fund during the year – the 50th Anniversary Fund - for donations towards our new Pitts-Crick Research Fellowship.

Reserves policy

The policy of the trustees is to maintain at least the minimum of cash reserves and working capital sufficient to meet known development plans, as well as the day-to-day needs of the charity. Funds are also held in reserve to provide secure, sustainable support for our beneficiaries and to ensure we can commit to ambitious, long-term plans to help bring an end to sight loss from glaucoma.

The Trustees recognise the risk to income posed by the reliance on legacy gifts and factors outside the organisation's control, such as economic uncertainty and investment volatility. Having considered these factors, the Board of Trustees agreed to maintain cash reserves of 12 months' operating costs during the year.

General funds totalled £2,797,225 (2023: £2,140,977) against a cash reserves requirement of £2,005,807 at the year-end. The surplus will support the delivery of the new Theory of Change framework and the expansion of our services in the period 2023-2026.
Other unrestricted funds at the year-end amounted to £4,340,791 (2023: £4,387,968). Of the total, £3,878,078 is designated to the funding of research, including a contribution to the new Pitts-Crick Research Fellowship, the recruitment of a new PhD Studentship in 2025 and new partnership initiatives currently in development with other research charities in the sight sector. A further £434,745 remains designated for equipment replacement and infrastructure development, which will include modernisation of the Head Office environment (scheduled for 2025) and the subsidy of two new posts to strengthen our staffing infrastructure as we work to grow additional income.

Going concern

In assessing the charity's status as a going concern, the trustees have considered a range of information in relation to the financial year ahead, including the current status of the UK economy, the charity's cash resources and known liabilities.

The charity's three-year financial plan for the period 2024 – 2027 shows the charity to have adequate resources to continue operating an effective service

for at least 36 months and to meet its obligations as they fall due. The financial statements have therefore been prepared on a going concern basis.

Investment policy and performance

The charity's assets are invested in the Rathbone Core Investment Fund for Charities, with management delegated to Rathbone Investment Management Ltd. A total return approach is adopted for the portfolio and withdrawals can be comprised of physical income and/or capital gain.

Our Investment Policy is:

- To maximise total return subject to a medium level of risk.
- To ensure that the charity's assets are invested widely and diversified by asset class and by security.
- To avoid direct investment in any companies manufacturing tobacco or tobacco products.
- To avoid investment in any companies that derive more than 10% of their revenues from the manufacture of alcoholic beverages, armaments, gambling, high interest rate lending or pornography.

Responsibility for monitoring the performance of the investment portfolio is delegated to the Finance and Governance Committee and performance benchmarks are reviewed with the fund managers on an annual basis.

The total value of our investment portfolio at the year-end was £7,481,616, an increase of £621,627 on the previous year (2023: £6,859,989). A total of £198,496 in dividends was reinvested into the portfolio and no funds were drawn down during the year. The fund benefited from unrealised gains totalling £439,908.

The investment portfolio underperformed against the composite index benchmark by 2% during the year but outperformed its peer group. In reviewing the Investment Policy for 2024-25, the trustees were mindful that the aim of the portfolio is to maximise total return subject to a medium level of risk over the long term. The decision to maintain the risk profile and retain the fund at its current level was taken after consideration of steady economic growth in the UK and Eurozone, continued reduction in inflation and the reasonable health of the US economy.

Trustees, advisors and staff

The trustees (who are also directors under company law) are:

Professor Anthony King	Chair
Mr Stephen Epstein	Vice Chair (Chair, Finance & Governance Committee)
Mr Prabhakar Sundaresan	Hon Treasurer (Finance & Governance Committee)
Miss Winifred Nolan	Chair, Clinical Advisory Panel
Dr Susan Blakeney	(Finance & Governance Committee)
Ms Teresa Borsuk	(Finance & Governance Committee)
Dr Roxanne Crosby-Nwaobi	
Mr Julian Exeter	(Retired, 14 March 2024)
Professor Cecilia Fenerty	
Mrs Yolanda Laybourne	Fundraising Advocate (Finance & Governance Committee)
Professor Roshini Sanders	
Mr Raymond Spendiff	(Finance & Governance Committee)
Mr Christopher Hunton	Chair Fund Advocate (Since 14 March 2024 - previously co-opted)

Chief Executive & Company Secretary	Joanne Creighton
Company Number	1293286
Charity Number	274681
OSCR Number	SC041550
Registered office & operational address	Woodcote House, 15 Highpoint Business Village, Henwood, Asford, Kent, TN24 8DH www.glaucoma.uk
Bankers	Barclays Bank plc, 1 Churchill Place, London, E14 5HP CAF Bank Ltd, 25 Kings Hill Avenue, Kings Hill, Kent, ME19 4JQ HSBC Bank plc, Camberwell Green, 23 Denmark Hill, London, SE5 8RP
Auditors	Xeinadin Audit Limited, 12 Conqueror Court, Sittingbourne ME10 5BH
Investment Managers	Rathbones Investment Management Ltd, 30 Gresham Street, London EC2V 7QN

Structure and **management**

Glaucoma UK is the operating name of the International Glaucoma Association Ltd, which was incorporated on 15 July 1976 and registered as a charity on 20 December 1977. As Glaucoma UK is both a charity and a company limited by guarantee, all board members are directors for the purposes of company law and trustees for the purposes of charity law. The objects of the charity are defined by its Articles of Association (last updated in 2024), which also set out trustees' powers and the permitted activities of the charity.

As we entered our 50th anniversary year, there was a useful and welcome opportunity to review and refresh the Articles of Association to ensure our governing document remains fit for purpose into the next half-century. Changes included:

- Simpler language to improve readability and transparency.
- Updated terminology, e.g. 'Charity' not 'Foundation'.
- Removal of obsolete clauses.
- Updated Objects to include a specific reference to providing advice and support, which is now such a vital aspect of our work.
- Modernisation of our activities, e.g. communication via electronic means and the holding of virtual meetings if required.
- Clarification of the Board's powers, e.g. explicit reference to employing staff and procuring consultancy advice as necessary.
- Increased flexibility, most notably the ability to award a research grant to a project led by a serving trustee, subject to the appropriate conflict of interest controls.
- Improved clarity around the role and powers of our members to help as we seek to recruit more members and encourage more people to exercise their right to vote.

The membership approved the revised Articles of Association at the AGM on 14 March 2024.

The Board and committees

The Board comprises not fewer than 8 and no more than 15 persons elected by the Members (or appointed by the Board to fill a temporary vacancy); and not more than three persons co-opted by the Board.

The current Board comprises people living with glaucoma, those with close family connections with the condition and others with backgrounds in ophthalmology, nursing, optometry, finance, public relations and business. At least three trustee positions are held each year by Fellows of The Royal College of Ophthalmologists or medically qualified equivalents. Trustees retire after serving a three-year term but are eligible for re-election to a maximum of nine years' service. Those serving prior to the 2023 AGM are entitled to serve for a maximum of 12 years. Board meetings take place four times a year on either a face-to-face, virtual or hybrid basis.
There is one sub-committee: the Finance and Governance Committee, which has delegated responsibility to oversee finance, investments, risk management and policy. Consisting of six trustees, the committee meets quarterly in advance of each Board meeting and on an ad-hoc basis, should the need arise.

The charity also has a Clinical Advisory Panel (CAP) to advise on clinical matters. The chair of the CAP oversees the award of research grants.

Trustee recruitment and training

When seeking new Board members, trustees have regard to any existing skills or knowledge gaps or any new disciplines that would be helpful in delivering the charity's future plans. Due consideration is also given to diversity and the need to ensure that the Board appropriately represents the communities served by the charity. New trustees are sought using existing networks, advertising or professional recruitment agencies, as required. Candidates are interviewed by a sub-committee of trustees, followed by a meeting with the Chair. Suitable individuals are invited to meet the remaining trustees at a Board meeting and are then put forward to the membership as the Board's preferred candidates at the Annual General Meeting. Voting members are also eligible to nominate themselves or others for election.

A Trustee Handbook sets out trustee roles and responsibilities. A personalised induction is provided for all new trustees, including a charity overview and briefings on finance, fundraising, support services and communication. Direction is also provided on the Charity Commission Guidance, 'The Essential Trustee' and

trustees are required to undertake 'Understanding Governance' training within six months of joining the Board. Ongoing training is provided as required, including attendance on external courses or participation in internal workshops and briefings.

Operating responsibility

Day-to-day responsibility for delivering services and achieving strategic and financial aims within organisational policies and the law is delegated to the Chief Executive, supported by the Senior Management Team.

Statement of Public Benefit

Glaucoma UK exists to raise awareness of the risks of glaucoma, support people to live well with the condition and fund research into the causes, prevention and treatment of the disease.

When reviewing the charity's objectives and planning future activities, the trustees refer to Charity Commission guidance on public benefit and can confirm that all Glaucoma UK's activities are undertaken to further our charitable purposes for public benefit, in accordance with Section 17 of the Charities Act 2011.

Related parties and connected charities

Glaucoma UK acted as an agent for the unincorporated organisation the United Kingdom Paediatric Glaucoma Society (UKPGS) during the year, providing infrastructure and administrative support. UKPGS exists to promote the exchange of knowledge between glaucoma specialists, stimulate research, establish a scientific community and promote interest in glaucoma as an ophthalmological sub-specialty. One trustee of Glaucoma UK also sits on the trustee board of UKPGS.

In 2022 Glaucoma UK awarded a research grant of £57,300.56 to Nottingham University Hospitals NHS Trust in respect of a project for which Glaucoma UK Chairman, Anthony King, is lead researcher. In this financial year, a payment of £25,785 was made in respect of the ongoing project.

Risk management and internal control

Overall responsibility for the charity's risk management lies with the Board of Trustees, with formal assessment and review delegated to the Finance and Governance Committee. A risk register is submitted by the Chief Executive on a quarterly basis which identifies current and new risks, rates each in terms of likelihood, probability and velocity and identifies appropriate controls and mitigations.

The trustees have assessed the major risks to which Glaucoma UK is exposed as follows:

Lack of income diversity
Although work to diversify income streams continues, the charity is still heavily dependent on gifts in wills, with legacy income representing 65% of total income in the year 2023-24. The following measures are in place to mitigate this risk:

Income position monitored via monthly management accounts and quarterly reports to the Finance & Governance Committee.

- Cash flow forecasts and legacy gift pipeline report presented at each quarterly Finance & Governance Committee meeting.
- Reserves holding and investment portfolio with diversified risk to cover medium and longer-term income shortfalls.
- Staff capacity increased in the fundraising department in 2023 to create additional resource for income diversification and speed up the administration of legacy gifts.
- New Theory of Change framework and outcome reporting mechanisms in place to better demonstrate the charity's impact and secure higher levels of corporate sponsorship, major donor funding and charitable trust support.

Investment failure
All investments are at risk of sustained and long-term fall in value of funds held in stock markets. The Board of Trustees seeks to offset risks to its investment holdings in the following ways:

- Investments held in a professionally managed portfolio.
- Access to live online investment reports.
- Quarterly reporting to Finance and Governance Committee and annual meeting with investment managers.
- Investment Policy reviewed annually.
- Minimum of three months' operating costs held in cash account.

Compromised IT systems and cyber security failure
In response to increasing levels of cybercrime in the UK and a tightly regulated data protection environment, the following mitigations are in place:

- Retained professional support for staff training and regular system security monitoring.
- Cyber Essentials accreditation achieved in June 2024.
- Cyber training programme in place for all staff.
- 'reCAPTCHA' technology installed on the Glaucoma UK website shop to prevent automated transactions.
- Daily offsite backup and office-hours support contract in place.
- Appropriate policies in place (Information Governance, ICT, Data Protection) and subject to annual review.

- Cyber insurance in place, with support for post-incident management.
- Multi Factor Authentication enforced on all available systems.
- Strict access controls to ensure that only authorised personnel can access sensitive information and systems.
- Regular software updates and patch management to protect against known vulnerabilities.
- Intrusion Detection and Prevention Systems (IDPS) to monitor network traffic for suspicious activity and prevent potential threats.
- Firewall, antivirus and anti-malware software in place.
- Encryption of sensitive data.

Remuneration policy

The trustees consider the Chief Executive and the Senior Management Team as comprising the key management personnel, in charge of directing, controlling and operating the charity on a day-to-day basis.

All trustees give of their time freely and no trustee remuneration was paid in the year. Trustees are required to disclose all relevant interests and withdraw from decisions where a conflict of interest arises.

The pay of the charity's Chief Executive is reviewed annually by the Board Chair and Finance and Governance Committee. The Chief Executive reviews all other staff salaries annually and makes recommendations to the Board as part of the annual budget setting process.

When setting salaries, trustees are guided by a remuneration policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public and private sector pay increase estimates), affordability, sustainability, and appropriateness. Glaucoma UK aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2024 these ratios were 3.6:1 and 2.7:1 respectively.

Glaucoma
UK

Statement of **trustee responsibilities**

The trustees are responsible for preparing the Trustees' Annual Report including the strategic report and financial statements in accordance with applicable law and United Kingdom accounting standards (UK generally accepted accounting practice).

Company law requires the trustees to prepare financial statements which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees' Annual Report is approved by order of the Board of Trustees, and the Strategic Report (included therein) is approved by the Board of Trustees in their capacity as directors on 20th February 2025 and signed on their behalf by



Professor Anthony King
Chair

Independent auditors' report

We have audited the financial statements of The International Glaucoma Association Limited for the year ended 31 July 2024 on pages 60 to 75. The financial reporting framework that has been applied in their preparation is applicable law and FRS 102 (effective January 2015), as well as the Statement of Recommended Practice for Charities (effective January 2015).

This report is made solely to The International Glaucoma Association's members and Board of Trustees, as a body, in accordance with Section 144 of the Charities Act 2011, and regulations made under Section 154 of that Act, as well as Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Council of Management those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditors

As explained more fully in the Trustees' Responsibilities set out on pages 54 and 55, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditors under Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 and report in accordance with regulations made under those Acts. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees' Annual Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies, we consider the implications for our report.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities. The extent to which our procedures can detect irregularities, including fraud, is detailed below:

- Gaining a full and extensive knowledge of the entity, environment and the regulatory framework to which it must abide by.
- Evaluating and assessing the extent to which the entity's internal systems are adhering to these as well as gaining a full and comprehensive understanding of the entity's activities and effectiveness of its control environment (including those in place to identify and prevent fraud).

We achieved this by carrying out the following:

- Enquiry of the detailed communication with management and those charged with governance.
- Reviewing internal systems and controls.
- Reviewing financial statement disclosures and compliance with applicable laws and regulations.

Opinion on financial statements

In auditing the financial statements, we have concluded that the trustees/directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the entity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees/directors with respect to going concern are described in the relevant sections of this report.

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 July 2024 and of its incoming resources and application of resources, including its result, for the year then ended;
- have been properly prepared in accordance with the Financial Reporting Standards 102 (effective January 2015);
- have been prepared in accordance with the requirements of the Companies Act 2006, and Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- the information given in the Report of the Board of Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Rosanna Turner (Feb 21, 2025 14:42 GMT)

Rosanna Turner

For and on behalf of Xeinadin Audit Limited,
Registered Auditors
12 Conqueror Court, Sittingbourne ME10 5BH
Eligible to act as an auditor in terms of Section 1212 of the Companies Act

Financial statements

for the year ended **31 July 2024**

Glaucoma UK (the operating name of the International Glaucoma Association Limited). Charity No. 274681, in Scotland No. SC041550. Company No. 1293286

Statement of financial activities

incorporating an income and expenditure account

For the year ended 31 July 2024

	Note	Restricted £	Unrestricted £	**2024 Total £**	2023 Total £
Income					
Donations, legacies and subscriptions	2	47,571	1,740,348	**1,787,919**	1,464,956
Investment income	3	41,605	158,329	**199,934**	181,738
Charitable activities					
Professor of Ophthalmology for Glaucoma and Allied Studies at UCL	4	9,130	-	**9,130**	10,484
Influencing policy & practice	4	254,950	-	**254,950**	87,975
Corporate support	4	2,500	79,450	**81,950**	2,149
Lottery	4	-	18,256	**18,256**	17,541
Christmas cards	4	-	4,721	**4,721**	6,858
Other income	4	-	1,190	**1,190**	2,178
Total income		**355,756**	**2,002,294**	**2,358,050**	**1,773,879**
Expenditure on:					
Raising funds					
Finance and support		3,848	18,211	**22,059**	22,614
Cost of generating funds		14,438	256,684	**271,122**	198,825
		18,286	274,895	**293,181**	221,439
Expenditure on charitable activities					
Raising awareness		-	244,342	**244,342**	119,780
Providing support		4,227	611,063	**615,290**	694,754
Supporting research and development		103,373	354,117	**457,490**	453,935
Influencing policy and practice		210,933	254,221	**465,154**	261,538
Christmas cards		-	2,288	**2,288**	1,778
Total expenditure	5	**336,819**	**1,740,926**	**2,077,745**	**1,753,224**
Realised losses on investment assets	11	-	-	**-**	(7,710)
Net Income		18,937	261,368	**280,305**	12,945
Unrealised losses on investment assets	11	92,205	347,703	**439,908**	(124,368)
Net incoming resources before transfers	6	111,142	609,071	**720,213**	(111,423)
Gross transfer between funds		-	-	**-**	-
Net movement in funds		111,142	609,071	**720,213**	(111,423)
Reconciliation of funds					
Total funds brought forward		1,518,802	6,528,945	**8,047,747**	8,159,170
Total funds carried forward		**1,629,944**	**7,138,016**	**8,767,960**	**8,047,747**

All of the results above are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 17 to the financial statements.

Glaucoma UK (the operating name of the International Glaucoma Association Limited)

Balance sheet

As at 31 July 2024

Charity No. **274681**
Scotland No. **SC041550**
Company No. **1293286**

	Note	2024 £	2023 £
Fixed assets			
Tangible fixed assets	10	**806**	3,210
Investments	11	**7,481,765**	6,860,720
Total fixed assets		**7,482,571**	6,863,930
Current assets			
Stock	12	**-**	3,656
Debtors	13 20	**1,692,539**	1,450,507
Cash at bank and in hand		**554,254**	631,742
		2,246,793	2,085,905
Liabilities			
Creditors: amounts due within one year	14 19, 20	**798,304**	647,532
Net current assets		**1,448,489**	1,438,373
Total assets less current liabilities		**8,931,060**	8,302,303
Creditors: amounts due after more than one year	15, 20	**163,100**	254,556
Net assets	16	**8,767,960**	8,047,747
Funds			
	17		
Restricted funds		**1,629,944**	1,518,802
Unrestricted funds			
Designated funds		**4,340,791**	4,387,968
General funds		**2,797,225**	2,140,977
Total funds		**8,767,960**	8,047,747

Approved by the board of trustees of the International Glaucoma Association Limited and signed on its behalf by Mr Raymond Spendiff, Trustee.

Raymond Spendiff (Feb 21, 2025 16:47 GMT)

Glaucoma UK (the operating name of the International Glaucoma Association Limited)

Statement of cash flow

For the year ended 31 July 2024

Cashflows from operating activities:	**2024**	2023
Net cash provided by (used in) operating activities	**(95,529)**	(48,332)
Cashflows from investing activities		
Dividends and interest from investments	**199,934**	181,738
Purchase of property, plant and equipment	**(1,208)**	-
Proceeds from sale of property, plant and equipment	**452**	-
Proceeds from sale of investments	**-**	225,476
Purchase of investments	**(181,719)**	(167,503)
Net cash provided by (used in) investing activities	**17,459**	239,711
Change in cash and cash equivalents in the reporting period	**(78,070)**	191,379
Cash and cash equivalents at the beginning of the reporting period	**632,473**	441,094
Cash and cash equivalents at the end of the reporting period	**554,403**	632,473
Increase/Decrease in cash balances	**(78,070)**	191,379
Reconciliation of net movement in funds to net cash flow from operating activities		
Net movements in funds for the reporting period (as per the statement of financial activities)	**720,213**	(111,423)
Adjustments for:		
Depreciation	**3,160**	12,931
Dividends & interest from investments	**(199,934)**	(181,738)
Loss/(Profit) on sale of investments	**(439,908)**	132,078
(Increase)/Decrease in stocks	**3,656**	111
(Increase)/Decrease in debtors	**(242,032)**	(335,432)
Increase/(Decrease) in creditors	**59,316**	435,141
Net cash provided by (used in) operating activities	**(95,529)**	(48,332)
Analysis of cash and cash equivalents		
Cash in hand	**554,254**	**631,742**
Investments Capital account	**149**	**731**
	554,403	**632,473**

Notes to the financial statements

For the year ended 31 July 2024

1. Accounting policies

a) The financial statements have been prepared under the historical cost convention, as modified by the revaluation of fixed asset investments, and in accordance with applicable accounting standards and the Companies Act 2006. They follow the recommendations in the Statement of Recommended Practice, Accounting and Reporting by Charities. The accounting standards policies have been prepared under Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice) and SORP 2019.The Trustees confirm that the charitable company is a public benefit entity. The accounts are prepared in sterling pound and rounded to the nearest £1. The charity is a company limited by guarantee from 627 voting members incorporated on 15 July 1976 and registered as a charity on 20 December 1977. The objects of the charity are defined by its Articles of Association updated in March 2012. The International Glaucoma Association (IGA) is constituted both as a charity and as a company limited by guarantee and as such the members of its council are directors for the purposes of company law and trustees of the charity for the purposes of charity law. The powers of the council and the permitted activities of the association are described in its governing document, which is the Articles of Association. The International Glaucoma Association registered office is Woodcote House, 15 Highpoint Business Village, Henwood, Ashford, Kent, TN24 8DH. The International Glaucoma Association is registered as a company in the United Kingdom.

In assessing the charity's status as a going concern, the trustees have considered a range of information in relation to the financial year ahead, including the current status of the UK economy, the charity's cash resources and known liabilities. The charity's 3-year financial plan for the period 2024-2027 shows the charity to have adequate resources to continue operating an effective service for at least 36 months and to meet its obligations as they fall due. The financial statements have therefore been prepared on a going concern basis.

b) Voluntary income received by way of subscriptions, donations and gifts are included in full in the statement of financial activities when receivable.

c) Income from legacies is accounted for on a receivable basis, recognised when entitlement to the income has been established and it is probable that Glaucoma UK will receive the amounts ascertained. This treatment is within SORP 2019 and Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Sales income represents sale of goods excluding VAT where appropriate.

Investment income is accounted for on an accruals basis.

d) Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

e) Unrestricted funds are donations and other incoming resources received or generated for general charitable purposes.

f) Designated funds are unrestricted funds earmarked by the Board of trustees for particular purposes. Within these funds is money awarded as grants, funding a range of research projects to develop more effective methods of glaucoma diagnosis and treatment.

g) Costs of generating funds relates to the costs incurred in fundraising activities.

h) Critical accounting judgements are used within these accounts as follows:
Residual legacy income debtors are valued at 85% of the expected value of the legacy when certain criteria are met and receipt is probable. Residual legacies that are over the material

1. Accounting policies (continued)

amount set by Glaucoma UK at £300,000 are recorded in the accounts at 100% once criteria is met and receipt is probable.

The support and governance costs are re-apportioned by staff time as explained in note (i). The staff costs attributed to each activity are reviewed each year when the new budget is set.

Resources expended are recognised in the period in which they are incurred. Resources expended include attributable VAT which cannot be recovered.

i) Resources expended are allocated to a particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function which includes finance and support and governance is apportioned on the following basis which is an estimate based on staff time of the amount attributable to each activity.

Support costs

Cost of generating funds	20%
Expenditure on charitable activities	73%
Research	7%

j) Grants awarded are charged to the Statement of Financial Activities in the year in which they are awarded and are subject to receipt of progress reports.

k) Governance costs are the costs associated with the governance of the charity, including constitutional and statutory requirements and costs associated with the strategic management of the charity's activities.

l) Monetary assets and liabilities in foreign currencies are translated into sterling at the Bank of England exchange rate for that day.

m) Investments held as fixed assets are revalued at market value at the balance sheet date. The Trustees consider that market value is a reasonably accurate representation of the fair value. The gain or loss for the period is taken to the statement of financial activities.

n) The fixed assets are held at cost less depreciation and any impairment. Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures, fittings and equipment	20%
Computers	33%

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

o) Stocks are stated at the lower of cost and net realisable value. In general, cost is determined on a first in first out basis. Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation. Provision is made where necessary for obsolete, slow moving and defective stock. During the year the charity received donated items that have been stated at fair value.

p) The charity contributes to a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. Contributions payable are charged as an expense in the SOFA (Statement of financial activities) within staff costs then shared between the SOFA categories by staff time within these activities.

q) Financial instruments assets and liabilities are valued in the accounts at fair value and are subsequently carried at amortised cost shown in Note 20.

r) Debtors are stated at their net realisable value after allowing for bad and doubtful debts. The recoverability of debtors is reviewed at year end and provision is made, either general or specific, based on value, age and composition of our year end debtor balance.

s) Trade creditors are recognised in the accounts at its settlement amount when there is a present obligation to the entity arising from past events.

2. Voluntary income

	2024 Restricted £	2023 Restricted	**2024 Unrestricted £**	2023 Unrestricted	**2024 Total £**	2023 Total £
Donations and subscriptions	**41,139**	2,567	**215,620**	235,920	**256,759**	256,028
Corporate donations	**-**	-	**2,243**	14,649	**2,243**	14,649
Legacies	**6,432**	35,449	**1,522,485**	1,178,520	**1,528,917**	1,213,969
Total	**47,571**	38,016	**1,740,348**	1,429,089	**1,787,919**	1,484,646

3. Investment income

	2024 Restricted £	2023 Restricted	**2024 Unrestricted £**	2023 Unrestricted	**2024 Total £**	2023 Total £
Interest	**-**	-	**1,438**	504	**1,438**	504
Dividends	**41,605**	38,024	**156,891**	143,210	**198,496**	181,234
Total	**41,605**	38,024	**158,329**	143,715	**199,934**	181,738

4. Incoming resources from charitable activities

	2024 Restricted £	2023 Restricted £	**2024 Unrestricted £**	2023 Unrestricted £	**2024 Total £**	2023 Total £
Professor of Ophthalmology for Glaucoma and Allied Studies at UCL	**9,130**	10,484	**-**	-	**9,130**	10,484
Influencing policy & practice *	**254,950**	87,975	**-**	-	**254,950**	87,975
Corporate support	**2,500**	-	**79,450**	-	**81,950**	-
Lottery	**-**	-	**18,256**	17,541	**18,256**	17,541
Christmas cards	**-**	-	**4,721**	6,858	**4,721**	6,858
Other income	**-**	-	**1,190**	2,178	**1,190**	2,178
	266,580	**98,459**	**103,617**	**26,577**	**370,197**	**125,036**

* Includes UK and Éire Glaucoma Society

5. Total Expenditure

	Cost of generating funds	Raising awareness	Providing support	Supporting research and development
	£	£	£	£
Staff costs (Note 7)	164,591	103,907	333,198	62,487
Research (Note 8)	-	-	-	363,222
Raising funds	36,966	-	-	-
Helpline service	-	-	21,801	-
Outreach services	-	-	11,108	-
Events, advertising and media	-	80,513	3,348	-
Patient education	-	-	105,006	-
Christmas cards	2,288	-	-	-
Premises & administration	-	16,005	-	2,726
Finance & professional	22,059	-	-	2,645
Expenditure	225,904	200,425	474,461	431,080
Finance & support reallocated	60,509	38,200	122,497	22,972
Expenditure including Finance & Support	286,413	238,625	596,958	454,052
Governance reallocated	9,056	5,717	18,332	3,438
Total Expenditure	**295,469**	**244,342**	**615,290**	**457,490**

Influencing policy and practice	Finance and support	Governance	2024 Total	2023 Total
£	£	£	£	£
179,725	108,246	23,081	**975,235**	**835,770**
-	-	-	**363,222**	**408,660**
-	-	-	**36,966**	**33,762**
-	-	-	**21,801**	**6,685**
14,419	-	-	**25,527**	**10,230**
195,049	-	5,989	**284,899**	**122,313**
-	-	-	**105,006**	**10,521**
-	-	-	**2,288**	**4,043**
-	146,905	4,088	**169,724**	**201,714**
-	63,585	4,788	**93,077**	**119,526**
389,193	318,736	37,946	**2,077,745**	1,753,224
66,073	(318,736)	8,485		
455,266	-	46,431	**2,077,745**	1,753,224
9,888	-	(46,431)		
465,154	**-**	**-**	**2,077,745**	1,753,224

6. Net (outgoing)/incoming resources

This is stated after charging/crediting:

	2024	2023
	£	£
Depreciation charge for the year - owned assets	3,160	12,931
Auditors' remuneration:		
audit	6,300	4,300
other services	4,319	1,348
Trustees expenses	2,161	3,143
Investment managers fee	12,006	18,139

Trustees expenses represent the travel and subsistence costs of 6 trustees for 9 meeting £2,161 (2023: £3,143). Within 2024 some Trustees meetings were still held virtually.

Donations totalling £664 were received from Trustees (2023: £597).

No trustees received remuneration for their services during the financial year

7. Staff costs and numbers

Staff costs were as follows:

	2024	2023
	£	£
Salaries and wages	846,577	726,053
Social security costs	87,068	73,727
Pension contributions	41,590	35,990
	975,235	835,770

Only one member of key management personnel earned £80,000 or more in the year.

	2024	2023
	No.	No.
£70,000 - £80,000	0	1
£80,000 - £90,000	1	0

Pension contributions in respect of the above £80,000 - £90,000 full-time employee totalled £4,134 (2023: £3,900). NI contributions in respect of the above £80,000-£90,000 employee totalled £10,155 (2023: £9,724)

The calculated unspent staff holiday entitlement at year end was £2,907 (2023: £14,430).

The charity contributes to a Royal London defined contribution pension scheme for employees.

The Key Management Personnel having authority and responsibility for planning, directing and controlling the activities of Glaucoma UK are the Senior Management Team. The total of Key Management personnel, employee benefits and remuneration were £381,319, (£315,439 23-24)

When setting salaries, trustees are guided by a remuneration policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public and private sector pay increase estimates), affordability, sustainability, and appropriateness. Glaucoma UK aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2024 these ratios were 3.6:1 and 2.7:1 respectively.

7. Staff costs and numbers (continued)

The average weekly number of employees (full-time equivalent) during the year was:

	2024	2023
	No.	No.
Cost of generating funds	**3.95**	2.46
Patient information and support	**7.44**	9.57
Professional information and support	**5.35**	2.52
Campaigning and awareness	**1.49**	1.16
Research	**1.27**	0.38
Governance	**0.52**	0.49
Finance and Support costs	**2.86**	1.95
	22.88	18.53

The actual number of staff (including part time and full time) at July 2024 was 27 (2023: 26) at year end.

8. Grants Awarded

	2024	2023
	£	£
University College London's Institute of Ophthalmology - Glaucoma UK Chair Fund	**74,673**	73,389
Fight for Sight		22,433
Cardiff University		49,293
London School of Hygiene and Tropical Medicine		24,760
Queens University Belfast		99,328
University of Plymouth		48,287
Moorfields Eye Hospital NHS Foundation Trust		96,082
Anglia Ruskin University		10,000
Ulster University	**99,919**	
Manchester University NHS Foundation Trust	**49,791**	
Liverpool University	**50,000**	
University of Birmingham	**99,652**	
Grants underspent by researchers	**(10,813)**	(14,912)
	363,222	408,660

These grants were awarded in accordance with the Glaucoma UK grants policy, and were awarded to fund research into the diagnosis and treatment of glaucoma.

The negative figure represents an underspend by researchers on grants awarded in previous years

9. Taxation

The charity is exempt from corporation tax and income tax as all its income is charitable and applied for charitable purposes

10. Tangible fixed assets

	Computer equipment £	**Total £**
Cost		
At the start of the year	37,185	**37,185**
Additions in the year	1,208	**1208**
Disposals in the year	452	**452**
At the end of the year	37,941	**37,941**
Depreciation		
At the start of the year	33,975	**33,975**
Charge for the year	3,613	**3,613**
Disposals in the year	453	**453**
At the end of the year	37,135	**37,135**
Net book value		
At the end of the year	**806**	**806**

11. Investments

	2024 £	2023 £
Rathbones Core Investments fund for charities		
At 1st August 2024	**6,859,989**	7,050,040
Additions at historic cost	**181,719**	167,503
Disposal proceeds	**-**	(225,476)
Realised losses	**-**	(7,710)
Unrealised gains/losses	**439,908**	(124,368)
Market value at the end of the year	**7,481,616**	6,859,989
Cash held as part of portfolio	**149**	731
Total	**7,481,765**	6,860,720

11. Investments (continued)

Investment management costs were £12,006 (£18,139 - 2023)

Glaucoma UK Ltd, Glaucoma International Ltd, Glaucoma Europe Ltd, and Glaucoma Association Ltd are dormant companies historically held by Glaucoma UK (the operating name of the International Glaucoma Association Limited) in order to protect the company identity and to give future flexibility in terms of the charity name. International Glaucoma Association hold 100% of all the dormant companies.

Glaucoma UK Limited number 04323894 total shareholder funds £1. Glaucoma Europe Limited number 04591043 total shareholders funds £1. Glaucoma International Limited number 04323990 total shareholders funds £1. Glaucoma Association Ltd number 05316092 shareholders funds £1.

12. Stock

	2024	2023
	£	£
Goods for resale	**-**	3,656

13. Debtors

	2024	2023
	£	£
Trade debtors	**47,102**	**18,956**
Legacy debtors	**1,619,363**	**1,315,702**
Prepayments and accrued income	**26,074**	**115,849**
	1,692,539	**1,450,507**

14. Creditors: amounts due within one year

	2024 £	2023 £
Trade creditors	**166,396**	65,276
Obligations under grant agreements	**403,061**	282,884
Funds held as agent	**28,214**	32,205
Accruals & Deferred income	**196,789**	264,469
Vat liability	**3,844**	2,698
	798,304	647,532

Funds held as agent represent those held for UKPGS, for which Glaucoma UK provides administration and infrastructure support as shown in note 19.

15. Creditors: amounts due after one year

	2024 £	2023 £
Obligations under grant agreements	**163,100**	254,556
	163,100	254,556

16. Analysis of net assets between funds

	Restricted funds £	Designated funds £	General funds £	**Total funds £**
Tangible fixed assets	-	-	806	**806**
Investments	1,629,944	4,340,791	1,511,030	**7,481,765**
Net current assets	-	-	1,448,489	**1,448,489**
Creditors: amounts falling due after more than one year	-	-	(163,100)	**(163,100)**
Net assets at the end of the year	**1,629,944**	**4,340,791**	**2,797,225**	**8,767,960**

17. Movements in funds

	At the start of the year £	Incoming resources £	Outgoing resources £	Other gains and losses £	Transfers £	**At the end of the year £**
Restricted funds:						
Chair fund	1,437,760	53,134	(78,521)	92,205	-	**1,504,578**
North East fund	9,815	-	(3,665)	-	-	**6,150**
Research fund	-	8,701	(8,701)	-	-	**-**
Folkestone fund	3,733	-	(440)	-	-	**3,293**
Children and Young people's Support fund	8,784	-	(122)	-	-	**8,662**
London fund	1,587	-	-	-	-	**1,587**
Scottish Optom fund	9,321	-	(3,403)	-	-	**5,918**
UK & Éire Glaucoma Society	47,802	254,951	(227,530)	-	-	**75,223**
50th Anniversary fund	-	38,970	(14,437)	-	-	**24,533**
Total restricted funds	**1,518,802**	**355,756**	**(336,819)**	**92,205**	**-**	**1,629,944**
Unrestricted funds:						
Designated funds:						
Income Endowment	22,906	-	-	-	-	**22,906**
Equipment Replacement and Infrastructure fund	460,000	-	(25,255)	-	-	**434,745**
Research Investment fund	3,900,000	-	(21,922)	-	-	**3,878,078**
West Yorkshire Support fund	5,062	-	-	-	-	**5,062**
Total designated funds	4,387,968	-	(47,177)	-	-	**4,340,791**
General funds	2,140,977	2,002,294	(1,693,749)	347,703	-	**2,797,225**
Total unrestricted funds	**6,528,945**	**2,002,294**	**(1,740,926)**	**347,703**	**-**	**7,138,016**
Total funds	**8,047,747**	**2,358,050**	**(2,077,745)**	**439,908**	**-**	**8,767,960**

17. Movements in Funds (continued)

Purposes of restricted funds

The Chair fund is used to fund the post of Professor of Ophthalmology for Glaucoma and Allied Studies at University College London.

The North East fund was established following receipt of a legacy and is restricted to supporting our work in the North East of England.

The Research fund represents donations, charitable trust and legacies income received specifically to fund glaucoma research. The fund was drawn on throughout the year as detailed on Note 8.

The Folkestone fund comprises legacy income restricted to work in Folkestone.

The Children and Young People's Support fund comprises income donated for services for young people affected by glaucoma and their families and carers. It aims to help us better understand their particular support needs and deliver appropriate services in response.

The London fund is restricted to the London area and has been used mainly for awareness raising and support work with BAME communities at greatest risk of glaucoma sight loss.

The Scottish Optom training fund is charitable trust income earmarked for eye drop adherence training for optometrists across Scotland. Following delays due to Covid-19 and changes to the professional training landscape in the intervening period, we have now developed new training courses for optometrists and other staff in optical practices. We are hoping to get this accredited by the GOC and roll out the training over the next two years.

The UKEGS fund comprises money for the work of the United Kingdom and Eire Society (UKEGS), a national scientific society that operates under the aegis of Glaucoma UK.

The 50th anniversary research fund comprises income donated as part of our 50th anniversary appeal. It is to be used towards the Research Fellowship award to support research into glaucoma to improve the lives of people affected by glaucoma.

The designated income endowment fund represents the donation of shares which form the basis of a stock market portfolio, which will eventually provide for the running costs of the association.

The designated Equipment Replacement and Infrastructure fund is held to cover the cost of equipment replacement, infrastructure development, premises costs and dilapidations.

The designated Research Investment fund aims to produce a reliable income stream specifically to fund the charity's research priorities in the years ahead.

The West Yorkshire Support fund was set up by the trustees from a legacy our charity received which the legator expressed interest in the funds being used towards any general activities we have in the West Yorkshire area. This aligned with Glaucoma UK setting a new project this year for funds to be awarded for establishing or developing Glaucoma support groups in areas of greatest need or with greatest potential for impact.

18. Operating lease commitments

The charity had annual commitments at the year end under operating leases expiring as follows:

	Property	
	2024	2023
	£	£
Within one year	**19,834**	**34,000**
Within 1 - 2 Years	**-**	**-**

19. Related parties

In 2022 Glaucoma UK awarded a grant of £57,300.56 to Nottingham University Hospital which the lead researcher is Professor King. This was duly disclosed and recorded. In this financial year, the research project has started, and an initial payment of £25,785 for this grant was paid to Nottingham University Hospital. This leaves an outstanding balance due to Nottingham University Hospital of £31,515.56.

Included in Note 14 are funds due to related parties held for the UK Paediatric Glaucoma Society (UKPGS) of which we provide administration and infrastructure support. One Glaucoma UK Trustee is also a UKPGS trustee during the financial year.

Financial Statement of UKPGS	**2024**	2023
	£	£
Income	**15,720**	26,385
Expenditure	**(19,710)**	(18,694)
Closing balance	**(3,990)**	7,691
Balance brought forward	**32,204**	24,514
Total funds held	**28,214**	32,204

20. Financial Instruments

Financial Debt instruments measure at amortised cost	**2024**	2023
	£	£
Trade debtors	**47,102**	18,956
Legacy debtors	**1,619,363**	1,315,702
Prepayments and accrued income	**26,074**	115,849
	1,692,539	1,450,507
Financial instruments measured at amortised cost		
Trade creditors	**166,396**	65,276
Obligations under grant agreements	**566,161**	537,440
Funds held as agent	**28,214**	32,205
Accruals & Deferred income	**196,789**	264,469
Vat & National Insurance liability	**3,844**	2,698
	961,404	902,088

Glaucoma UK

Celebrating **50 years** 1974 - 2024

Glaucoma UK
Woodcote House
15 Highpoint Business Village
Henwood
Ashford
Kent TN24 8DH

Phone: 01233 648 164
Email: info@glaucoma.uk
Website: glaucoma.uk

Glaucoma UK is the operating name of the International Glaucoma Association Limited.
Charity registered in England and Wales No. 274681 and Scotland No. SC041550

Company Registered in England & Wales no. 1293286

INTERNATIONAL GLAUCOMA ASSOCIATION LIMITED

England & Wales - Charity number 274681

Accounts

Trustees' Annual Report and Financial Statements

for the year ending
31 July 2023

Glaucoma UK

Contents

04 Welcome from the Chair

06 A message from the CEO

08 Our vision and priorities
- 10 Our Vision
- 12 Our Theory of Change

18 Strategic report: What we achieved in 2022-23
- 20 Priority 1: Raising awareness
- 28 Priority 2: Providing support
- 38 Priority 3: Funding research
- 44 Priority 4: Influencing policy and practice

50 Fundraising review

58 Looking forward

62 Our finances
- 64 Financial review
- 68 Reserves policy
- 69 Going concern
- 70 Investment policy and performance

72 Governance and leadership
- 74 Trustees, advisors and staff
- 76 Structure and management
- 77 The Board and committees
- 79 Statement of Public Benefit
- 80 Risk management and internal control
- 82 Remuneration policy
- 83 Statement of Trustee responsibilities

86 Independent auditors' report

92 Financial statements

Welcome from the Chair

Anthony King

Consultant Ophthalmologist and Glaucoma UK Chair

My first full year as Chair of Glaucoma UK has been busy but enormously enjoyable. Following a strategic review, we have a renewed sense of purpose and a stronger than ever focus on ending preventable sight loss from glaucoma.

And that sharpened focus is timely, because a backdrop of growing NHS pressures and rising demand for ophthalmology services means the work of our charity has never been more important. It is vital that we do all we can to not only support those who are living with glaucoma, but also to help influence policy makers and those delivering services.

Although changes during the COVID–19 pandemic helped to prioritise high-risk patients, hospital eye care services now desperately need increased capacity to address the 'hidden risk' of deterioration of lower priority cases. More experienced clinical decision-makers are required in primary and secondary care and a consistent, seamless, national pathway needs to be developed between community and hospital provision. There needs to be increased public awareness of glaucoma and much earlier engagement with individuals in the highest risk groups. Those priorities, and the ways we may be able to influence them, are certainly at the forefront of our minds as we develop our future plans. In delivering those plans, I am keenly aware of how dependent we are on the commitment, energy and kindness of a wide-ranging supporting cast.

It is vital that we do all we can to not only support those who are living with glaucoma, but also to help influence policy makers and those delivering services.

In recognition of that fact, I would like to take this opportunity to say a huge 'thank you' to the Glaucoma UK staff team who show such passion for their work and achieve so much. I would also like to thank our tireless volunteers, who give their time so generously in sharing their stories and providing invaluable peer-to-peer advice. I am most grateful to my fellow trustees, who dedicate their time and wisdom to helping steer the charity and ensuring the very best outcomes for our beneficiaries.

Finally — on behalf of everyone at Glaucoma UK — I sincerely thank our members and donors. Through your membership subscriptions, regular gifts, one-off donations, sponsorship events and legacy bequests, you are the very lifeblood of Glaucoma UK. Because of you, we can continue our mission to end preventable sight loss from glaucoma.

From us all - thank you so much.

A message from the CEO

Joanne Creighton

Glaucoma UK Chief Executive Officer

It has been a genuine privilege to work with my colleagues, trustees and a range of stakeholders to review and refresh Glaucoma UK's strategy this last year.

As the Chairman describes in his welcome to this report, the landscape in which we are operating holds many challenges and it is important we get ourselves into the best possible shape to tackle them head-on.

Our new 'Theory of Change' (more detail on page 12) is already proving to be an invaluable tool in setting out exactly how we want to change the lives of people living with glaucoma — today and into the longer term. Essentially a roadmap to help get from where you are to where you want to go, the Theory of Change framework has helped us to identify the activities we need to undertake and the impact we need to have in order to end preventable sight loss from glaucoma, whether that be slight loss of visual field or total loss of vision.

There is a strong emphasis on the measurement of tangible outcomes, which we hope will help to keep us on track throughout the journey.

"We need to challenge ourselves – and others – to think bigger, work smarter and achieve even more for people living with glaucoma

There was, of course, already much excellent work being done to raise awareness of glaucoma, to support individuals living with the disease and to fund vital research and this report showcases some of that activity. However, our review highlighted that there was still more we could be doing to reach the audiences most at risk and to ensure that our services are delivered in the most accessible and sustainable ways. With ophthalmology the busiest outpatient specialty in the NHS and only 64% of patients being seen within the NHS's maximum target 18-week timeframe[1], it is clear that we need to challenge ourselves – and others – to think bigger, work smarter and achieve even more for people living with glaucoma. So, with our roadmap in place, we are getting ourselves in shape, with the introduction of some additional roles, improved processes and the development of some new strategic partnerships.

There is lots to do and we are certainly not complacent, but it is an exciting time. And what makes it especially exciting is the wonderfully collaborative nature of the task. Staff, volunteers, trustees, researchers, eye–care professionals, corporate supporters, our members and donors alike all have their own unique but vital part to play. I would like to echo Professor King's thanks to each and every one who has Glaucoma UK in their hearts and minds. **This report is dedicated to you.**

1 NHS England (March 2023) Consultant-led referral to treatment waiting times data 2022-23. https://www.england.nhs.uk/statistics/statistical-work-areas/rtt-waiting-times/rtt-data-2022-23/

Our vision and priorities

Our vision

Glaucoma is a complicated group of eye diseases that damage the optic nerve. Left untreated, glaucoma will lead to irreversible sight loss and even blindness. At Glaucoma UK, our vision is an end to preventable glaucoma sight loss.

Over 700,000 people in the UK are affected by glaucoma.

However, because most people experience no symptoms in the early stages, it is estimated that **almost half of those people are unaware they are living with the disease**.

A full eye examination is the only guaranteed way of detecting glaucoma, but **more than a third of British people do not attend regular checks.**

In the highest risk groups – including those experiencing socio-economic deprivation and those of African-Caribbean ethnic origin – the levels of take-up are even lower. We therefore have a vital job to do in publicising the importance of early detection across all areas of society.

Of course, appropriate treatment and monitoring is also crucial in ensuring that those living with glaucoma are able to retain useful sight for life. But with demand increasing and excessive waiting times for many people, there is much to be done to create an effective and consistent treatment pathway throughout the UK. We need to ensure that the voice of people living with glaucoma is heard by those who provide treatment, design care pathways, devise policy and commission services.

Perhaps our most powerful weapon in the fight against preventable glaucoma sight loss is research.

We need to understand what causes the disease, how it can be prevented, what are the most effective treatments and – ultimately - how it could be cured. Through our annual funding programme, we support studies that seek answers to those questions by testing new medical and surgical models and exploring new ways of working.

Our Theory of Change

Following a review of our strategy during 2022, we developed a new Theory of Change for Glaucoma UK. The framework sets out the change we want to make in society for those living with glaucoma, expressed as our 'sustained impact goals':

1 **Increased awareness and earlier diagnosis of glaucoma among those who are most at risk.**

2 **More people are able to live well and maintain sight through equitable and timely access to effective clinical care and pastoral support.**

In order to bring about these lasting changes, it is vital that we understand the current barriers to success. These include:

Lack of knowledge and awareness of glaucoma

Delays in diagnosis

A reluctance for some individuals without symptoms to attend an eye examination

Treatment delays caused by lack of NHS capacity

Reluctance or inability of some individuals to adhere to their eye drop treatment regime

(which can feel more debilitating than the disease itself in some cases)

Lack of engagement with eye care services among those in the highest risk groups

The lack of a cure for glaucoma

Insufficient investment in glaucoma research.

To tackle these challenges, we have grouped our work into four priority areas, each with a series of outcomes that will drive us towards our sustained impact goals:

Priority 1: Raising awareness

- **Disseminating clear, accessible, impactful messaging about the risk to individuals.**
- **Ensuring professionals are aware of Glaucoma UK's role in supporting glaucoma care.**

Desired outcomes of this work include:

» More people understand why they may be at risk of glaucoma and that it could impact their vision, even without symptoms.
» More people who are at highest risk of glaucoma seek an eye examination.
» More professionals are aware of Glaucoma UK and refer people to us for advice and support.

Priority 2: Providing support

- **Giving accessible and effective advice and information to individuals and their carers.**
- **Offering practical and emotional support to help individuals to adhere to their treatment regime.**
- **Creating and promoting an active and mutually supportive glaucoma community.**

Desired outcomes of this work include:

» More people understand their condition and feel able to adhere to their treatment regime.
» More people at increased risk of sight loss are able to access support from Glaucoma UK when and how they need it.
» People feel more confident and positive about their condition by being part of a supportive glaucoma community.

Priority 3: Supporting research and development

- **Providing funding for high-quality research into glaucoma prevention, diagnosis, treatment and cure.**
- **Liaising with corporate bodies to improve glaucoma treatments and patient outcomes.**

Desired outcomes of this work include:

» Research we fund and support is more widely disseminated to inform and improve glaucoma care.
» More of our research projects demonstrably transform glaucoma prevention, diagnosis and treatment.
» We achieve more leverage from our research support and sector relationships.

Priority 4: Influencing policy and professional practice

- **Advocating for the patient perspective in the design, development and delivery of glaucoma care pathways.**
- **Providing relevant and credible information and support for medical professionals.**

Desired outcomes of this work include:

» More people at increased risk of glaucoma have equitable access to eye care services.
» Those making decisions on policy and commissioning take greater account of glaucoma patient perspectives.
» More people at increased risk receive timely access to eye care services.
» More professionals feel better informed and equipped to support people to live well with glaucoma.

Theory of Change

Problems:

Sight loss from glaucoma is irreversible. People who present late for diagnosis, those who experience treatment delays and those who don't adhere to their treatment regime are at risk of losing sight.

People from higher risk groups (those of black minority ethnic origin and those experiencing socioeconomic deprivation) engage less frequently with services. Eye research in the UK is underfunded compared to other areas of medicine.

Vision: An end to preventable sight loss from glaucoma

Activities

Raising awareness:
- **Disseminating clear, accessible, impactful messaging about the risk to individuals.**
- **Ensuring professionals are aware of Glaucoma UK's role in supporting glaucoma care.**

Providing support:
- Giving accessible and effective advice and information to individuals and carers.
- Offering practical and emotional support to help individuals to adhere to their treatment regime.
- Creating and promoting an active and mutually supportive glaucoma community.

Supporting research and development:
- Providing funding for high quality research into glaucoma prevention, diagnosis, treatment and cure.
- Liaising with corporate bodies to improve glaucoma treatments and patient outcomes.

Influencing policy and professional practice:
- Advocating for the patient perspective in the design, development and delivery of glaucoma care pathways.
- Providing relevant and credible information and support for medical professionals.

Outcomes

More people understand why they may be at risk of glaucoma and that it could impact their vision, even without symptoms.

More people understand their condition and feel able to adhere to their treatment regime.

Research we fund and support is more widely disseminated to inform and improve glaucoma care.

More people at increased risk of glaucoma have equitable access to eye care services.

More people who are at highest risk of glaucoma seek a diagnostic eye examination.

More professionals are aware of Glaucoma UK and refer people to us for advice and support.

More people at increased risk of sight loss are able to access support from Glaucoma UK when and how they need it.

People feel more confident and positive about their condition by being part of a supportive glaucoma community.

More of our research projects demonstrably transform glaucoma prevention, diagnosis and treatment.

We achieve more leverage from our research support and sector relationships

More policy and commissioning takes account of glaucoma patient perspectives.

More people at increased risk receive timely access to eye care services.

More professionals feel better informed and equipped to support people to live well with glaucoma.

Sustained impact goals

Increased awareness and earlier diagnosis of glaucoma among those who are most at risk.

More people are able to live well and maintain sight through equitable and timely access to effective clinical care and pastoral support.

Assumptions and external factors: External collaborations and membership of sector groups (VI Partnership, CERT Group, CCEHC, etc) will continue. Any governmental changes to national eye health strategy will not solve current challenges in the next 3 years.

Beneficiaries: People who have been diagnosed with glaucoma and their carers. People who are living with undiagnosed glaucoma. People who are most at risk of glaucoma but who are not engaging with services. Glaucoma professionals (primary and secondary care practitioners). Researchers.

Strategic report:

What we achieved in 2022-23

Priority 1:
Raising awareness

The first – and most vital - step in achieving our charitable mission is to raise awareness about glaucoma and the risk to individuals.

Our principal objective is to encourage people to have their eyes examined every two years, unless advised otherwise by their healthcare professional.

We also want to ensure that people living with glaucoma know about our work and seek our help via the many services we provide. That includes eye care professionals, who have an essential role to play in signposting their patients to ourcharity, so that we can provide the pastoral support that simply cannot happen in the time-strapped clinic environment.

How did we do?

Utilising digital opportunities

Digital platforms are vital for reaching large numbers of people in a fast and cost-effective way and we are pleased to report that our overall reach continues to grow across all our channels.

Social media has been a particular area of success this year, due largely to a relatively modest investment in advertising, but also a gradual refinement of our content strategy. **On Facebook, for example, the number of people reached during the year was 966,016, which is up 900% on the previous year**. This upward trend in engagement is also mirrored on Twitter, recently rebranded to 'X', which has seen an **improvement in the engagement rate from 1% to 5%** over the last two years, despite no advertising expenditure on the platform.

One of the key shifts that has driven this improved engagement is to make posts more people-focused. We've made better use of our case studies and used more frequent posts that encourage users to comment with their own glaucoma stories and perspectives. As more people comment on and share our posts, this in turn extends our reach, raising the digital profile of the charity and boosting awareness of the disease.

The launch of Glaucoma UK's Instagram profile in February 2023, along with a continuing campaign to target high-risk audiences across all our social

Over **1,000** Instagram followers

900% increase in Facebook reach

265% increase in website users

media channels, has been successful in increasing levels of engagement. The account has **over 1,000 followers** at the time of writing.

Following work on the Theory of Change, new approaches have been trialled in reaching underrepresented and high-risk audiences. In December 2022, we ran three Facebook Advert campaigns to raise awareness about glaucoma and how Glaucoma UK can help, one of which targeted expatriates of a selection of African and Caribbean countries now living in the UK and aged over 40. The ads were very successful, **reaching a total of 30,500 people and achieving over 1,300 comments and 'likes'**. A similar strategy has been used to reach people of an East Asian background. We've also run adverts to increase awareness of free eye examinations among the over-60s.

Alongside this success on social media, website traffic has also continued to grow during the year. **Website users were up 265% at more than 234,000, with over 111,000 coming from organic search and over 21,000 coming from paid search**, where we have paid to have our site shown at the top of the list of search results. This demonstrates the success of our ongoing search engine optimisation strategy and the utilisation of our Google Ad Grant, which enables approved charities to spend up to $10,000 per month on Google search marketing for an entire year.

Media coverage

We have enjoyed a wide spread of media coverage during the year, with highlights including London Live TV, Optician Magazine, Optometry Today, Eye News and The Telegraph. Glaucoma UK was also named in coverage relating to the Specsavers 'State of the UK's Eye Health' report across all four regions of the UK.

An advertorial in a campaign titled 'New Year Fresh Start' was distributed with The Guardian print newspaper (437,500 average readership) in January 2023, featuring information about glaucoma, risk factors and the importance of attending regular eye examinations.

This year, we devised a new concept for our print advertisements using the game "Spot the Difference" to help highlight that glaucoma can be symptomless in its early stages. We used this concept for multiple adverts during the year including a campaign featured in the Evening Standard 'Best of British: The King's Coronation' which was showcased to **over 690,000 readers**. We also placed the advert in the June issue of the Saga magazine, the UK's best-selling over-50s monthly subscription magazine, as well as in 'The Good Life' - a newspaper section distributed with The Telegraph with a **readership of nearly 700,000**. Broadcast coverage on ITV Meridian news, which focused on the efforts of one of our challenge fundraisers, helped to raise awareness of both the charity and glaucoma in general to an estimated audience of **1.7m viewers**.

Awareness-raising campaigns

Harnessing the added potential of national and international campaigns continues to play a key role in our annual awareness raising work. Our World Glaucoma Week campaign in March 2023 highlighted risk factors of glaucoma and featured a new case study, Choon Young Tan - a young male with East Asian heritage and a family history of glaucoma. Interviews with Choon and consultant ophthalmologist Nishani Amerasinghe achieved **coverage across 125 radio stations**.

Media coverage including
London Live TV, Optician Magazine, Optometry Today, Eye News and The Telegraph

Our main annual campaign - Glaucoma Awareness Week – took place in June. By asking members and supporters to complete the sentence "My glaucoma..." we enabled individuals to share what glaucoma means to them and also gained some extremely helpful insights in the process.

It was encouraging to receive **98 responses including statements, illustrations and photographs** and we were delighted to share a selection of the responses in the summer edition of our July edition of Insight members' magazine.

Campaign activities for the week included press releases to trade and consumer publications, a radio day covering **126 stations, a podcast featuring case studies, TV coverage, targeted social media adverts and more than 150 digital advertising billboards in major cities and towns across the UK**. We also provided an interview to the radio series 'Word on Health', which is broadcast by a network of over **90 independent local radio stations** across the UK.

Glaucoma Awareness Week 2023







Our 2023 Ramadan campaign, in partnership with the British Islamic Medical Association (BIMA) and the Muslim Council for Britain, ran throughout April. The campaign featured a radio day during which a Glaucoma UK trustee and BIMA representative gave interviews which achieved 127 instances of coverage across stations with a collective listenership of over 43 million people.

Social media advertising targeting geographic areas with the largest Muslim communities reached a total of 227,000 people and achieved 7,000 landing page views for the Glaucoma UK website page, with dedicated information about glaucoma and fasting.

127 instances
of radio coverage for our 2023 Ramadan campaign

Annual glaucoma and brand awareness survey

Insights from the annual glaucoma and brand awareness survey, conducted following Glaucoma Awareness Week, are essential in helping us to continuously refine our communication strategies. The survey, which targets a nationally representative sample of UK adults, is now in its third year, enabling the identification of emerging trends. A significant finding from the research is the gradual increase in the proportion of UK adults who have undergone an eye examination within the past two years. This trend has been particularly pronounced among the 55-64 age group, highlighting a growing awareness of eye health within this demographic and the return of confidence following the pandemic. However, challenges persist in engaging males and those employed full-time, who continue to demonstrate lower rates of take-up.

Encouragingly, glaucoma is the eye condition that is most likely to spring to mind when respondents are asked about eye health, with spontaneous awareness figures rising from 36% in 2021 to 40% in 2023. Additionally, prompted awareness of glaucoma has also risen, now encompassing an impressive 88% of UK adults.

The connection between eye examination history and glaucoma awareness remains a noteworthy finding, with those who have undergone an eye examination in the past two years proving to be more informed about glaucoma.

The 2023 survey revealed an evolving landscape of awareness channels. **Radio news and features, print news and magazines, along with increased visibility through healthcare institutions such as hospitals, GPs, and optometric practices, have all contributed to fostering awareness of Glaucoma UK during the year.**

Priority 2:
Providing support

Supporting people with glaucoma and their loved ones is a core strand of our work. Glaucoma treatment can be complex and challenging, with some individuals finding the treatment worse than the early effects of the disease itself.

Understanding glaucoma and its allied conditions and making choices about the many different treatment options can be overwhelming. With clinic appointments generally infrequent and brief, it is hard for individuals to have the time and space they need to ask questions and fully digest the replies.

At Glaucoma UK, we want to empower people by offering the right help and advice, delivered in the right way, at the right time. We want to be at the heart of a vibrant, supportive glaucoma community, where people can share their experiences – openly and confidently - with others facing the same challenges and choices. To that end **our various services provided over 700,000 instances of support, information and guidance during the year.**

642 hours
of practical advice and emotional support offered by our helpline

How did we do?

Providing a helpline service

Once again, the Glaucoma UK helpline was an essential feature of our offer to individuals. Enquiries increased by a further 17% on the previous year, with support provided for 2,752 people. Once again, the most popular discussion topic was the impact of glaucoma on driving and DVLA notifications. Problems with eye drop dispensing and side effects was the second most common query, followed by questions relating to surgical treatments.

We continued to field calls relating to appointments, with callers telling us that they had less time at appointments with consultants and clinic staff, and that they felt pressured, unsure or unable to ask the many questions they had on receiving a new diagnosis or seeing a change in their eye health.

> **I have lost my glaucoma consultant of 25 years through retirement. He knew me very well and more importantly the history of my eye problems.**
> He has not been replaced and I am now seen by a member of the glaucoma team. Apparently, glaucoma patients are now placed in a pool and not assigned to a particular consultant. As someone with a complicated ophthalmic history and 5 bulging files at the eye hospital I find this system does not work well for me."

With an average call duration of 14 minutes, our helpline service supported stretched NHS services by offering 642 hours of practical advice and emotional support outside the clinic environment. With access to an experienced Clinical Advisory Panel of 21 ophthalmology and optometry specialists, our helpline advisors are well-placed to respond to queries on a wide range of topics and can offer very welcome continuity for repeat callers.

Supporting users of the HealthUnlocked forum

HealthUnlocked (www.healthunlocked.com/glaucoma-uk) is an online glaucoma community, where individuals can seek advice and guidance from others living with glaucoma. Our helpline advisors oversee the forum, offering additional information and signposting users to Glaucoma UK's other services as appropriate. With peer-to-peer support playing such an important role in developing wellbeing and confidence, we are thrilled that **the HealthUnlocked community grew by a further 70% to 1,990 members** during the year.

While some participants prefer to listen and absorb, **active membership increased to 728 - up by 54% on the previous year - and a total of 5,257 connections were made between forum users.**

Hosting digital glaucoma support groups

Originally developed to provide support during the COVID 19 pandemic, our digital glaucoma support groups ran monthly throughout the year. Topics included the future of glaucoma treatments; primary open angle glaucoma; home testing and monitoring; glaucoma and eye drops; surgery and laser treatment; mental health and congenital glaucoma. Perhaps unsurprisingly, the most popular session was glaucoma and driving, in line with statistics from our helpline service. Each webinar is led by a specialist guest speaker and there is an interactive question and answer session at the end of each presentation.

"I have found all the topics so far were really interesting; my wife as a non-sufferer has also got a lot of understanding about the condition."

99%
of participants would recommend our digital glaucoma support groups to others

8,965
total YouTube views of our DGSG videos

As a result of staff changes and some Development Manager vacancies during the year, the number of digital support groups delivered was reduced from 19 to 13 and attendee numbers were therefore down from 717 to 404. However, sessions are also available to view online after the event and there were 8,965 total YouTube views of our DGSG videos during the year, representing 1,185 viewing hours. Satisfaction levels among participants remained extremely high, with 99% confirming that they would recommend our digital glaucoma support groups to others.

Offering face-to-face support

We know from previous consultation that bringing people together, facilitating relationships and creating a sense of 'togetherness' is a highly valued feature of our community-based support. We were therefore pleased that, despite staff changes and departures, we welcomed 840 individuals and professionals to our face-to-face support and training activities – a 60% increase on the previous year.

Recognising the importance of identifying and engaging those populations most at risk of glaucoma sight loss, we continued to broaden the scope of our face-to-face support. We established a new pilot scheme offering grants of up to £250 to start new glaucoma support groups or to develop existing ones, particularly among our target communities.

While a review of the vacant regional Development Manager roles is undertaken, four fixed-term Training and Engagement Officers have been recruited, with the responsibility for establishing a network of support groups led by professional volunteers, engaging with underserved audiences and delivering first-line training to health care professionals. The new posts, which are based in Northern England, Scotland, Wales and Northern Ireland will help to ensure – along with our Development Manager for Southern England - that we maintain levels of support while we review our structure and develop a sustainable plan for further growth throughout the UK.

Providing written information

Booklets and Guides

Having access to clear, relevant information is a vital part of our work to ensure that members feel more positive and confident about managing their glaucoma. A total of 108,635 information guides were ordered during the year, with a further 981 downloaded from our website, highlighting the ongoing demand for this type of support.

The appointment of a new Health Information Manager in January allowed us to embark upon an

ambitious schedule of reviewing, refreshing and producing new information over the next year and beyond, in response to needs raised by people living with glaucoma. The first priority was the launch of a new version of our booklet 'Driving and Glaucoma'. Questions such as 'Can I drive?' and 'Will I lose my licence?' are top concerns for many people with glaucoma, so the booklet explains when and how to contact the DVLA (or DVA in Northern Ireland), and how to make an appeal. The new booklet is more accessible and relevant to more people, with information covering arrangements across the whole of the UK.

We are so grateful to the panel of volunteer readers and medical reviewers who check that the information we produce is accessible and appropriate before publication. A Readers' Panel focus group was held in November which provided feedback that will be invaluable to us as we look to welcome more reviewers in the coming year.

A key priority for 2023-24 is the achievement of the Patient Information Forum's PIF TICK accreditation, which shows that an organisation's health information production process has been independently assessed.

Magazines and Newsletters

Our quarterly membership magazine is full of useful information for people with glaucoma and their loved ones, including the latest news from Glaucoma UK, updates from our supporters, new developments in research, interviews with glaucoma experts, information about our support services and advice for living well with glaucoma. Members receive the printed magazine delivered to their homes, but anyone can download digital back copies from our website or listen to audio editions. We produced the magazine quarterly throughout 2022-23, **reaching a total of 15,847 recipients.**

The subscriber list to our monthly email newsletter, Focus, has continued to grow, now standing at 2,324; an increase of 85% on the previous year. Focus is an essential means of keeping our audience informed and engaged throughout the year, offering content for those who prefer to receive information digitally and in a more timely way.

"Another interesting edition of Insight. I learn so much from the articles."

"When I asked the glaucoma consultant [for a copy of my visual field report] ...he wouldn't do it because he didn't have time and there was no point because, as a lay person, I wouldn't be able to understand it! I was not satisfied with this and went back to the field nurse who was actually able to do a printout on a different machine. When I got home, I looked out the excellent article by Helen Doe in the Autumn 2021 edition of Insight titled 'A field of information' and was able to interpret the results and compare them with previous fields."

Volunteering

The support of volunteers is of enormous importance to our work and we benefited from the efforts of 174 individuals during the year who provided case study material, gave us clinical advice or served on our Readers' Panel.

We were delighted by the continued growth of our 'buddy scheme', which connects anyone awaiting SLT (Selective Laser Trabeculoplasty) or eye surgery with an experienced volunteer, for reassuring peer support. A total of 73 buddy pairings were facilitated during the year and feedback has been overwhelmingly positive, with people feeling more prepared pre-and-post-surgery and confident about any aftercare too.

We have also received requests for wider opportunities for peer support about life with glaucoma and will be exploring ways to do this over the coming year, including rolling out buddy coffee mornings to create an even greater sense of community.

73
buddy pairings facilitated this year

174
individuals volunteered as case studies

"I recently had trabeculectomy surgery and have also had SLT laser. I think the buddy scheme is really great and it's been so helpful to me having someone to talk to as I was very anxious."

Priority 3:

Supporting research and development

As the only UK charity solely funding research into glaucoma, our work to support the most promising studies, led by the most talented researchers, is a vital aspect of our mission.

In addition to our annual awards for ophthalmologists, health and social care professionals and members of the UK and Éire Glaucoma Society (UKEGS), we also offer an 'Open Call' programme to attract novel research into new methods of diagnosis, care and treatment.

By helping to fund the Professor of Ophthalmology at University College London and working with partners including the Royal College of Ophthalmologists and the charity 'Fight for Sight', we aim to deliver an ambitious research programme that will have a real impact for the people we serve - now and in the future.

In 2022-23, we awarded £408,660 in new research grants - our highest ever annual figure. This was thanks to an increase in the number of high-quality, fundable applications received during the year and an encouraging return to pre-pandemic levels of confidence and activity.

How did we do?

Grants awarded

Our grants are awarded in open competition by an awards panel chaired by a Glaucoma UK trustee. Other panel members are drawn from our Clinical Advisory Panel and at least one lay member. All awards are subject to a peer review process.
We awarded the following grants during the year:

The Royal College of Ophthalmologists Research Award

This £100,000 research award, which is funded by Glaucoma UK and administered by the RCOphth, has previously funded a range of topics from prospective stem cell treatments to the use of big data in risk stratification. In 2023, the award went to Dr Giovanni Montesano of Moorfields Eye Hospital NHS Foundation Trust for his project 'Mapping clinical trial outcomes to individuals for personalised glaucoma care'. Glaucoma UK Chair, Professor Anthony King, was one of 6 co-applicants for this award but will not be a direct recipient of grant funding.

Patient characteristics are known to affect the course of glaucoma, but their relationship to treatment response is still poorly understood. In this project, Dr Montesano will work to develop a framework for the analysis of individual patient data against the background knowledge

£408,660
awarded in new research grants

from randomised clinical trials and real-world data to better predict an individual's response to treatment.

UK & Éire Glaucoma Society (UKEGS) Research Award

The £50,000 UKEGS award, joint funded by Glaucoma UK and proceeds from the UKEGS annual conference, went to Professor James Morgan of Cardiff University for his study entitled, 'Targeted microglial inhibition for the protection of retinal ganglion cells in glaucoma'.

We know that glaucoma involves the selective loss of retinal ganglion cells which connect your eyes to your brain and there is compelling evidence that changes in the optic nerve are a contributory factor to that damage. But when glaucoma starts, one of the first things that happens is the retinal ganglion cells lose their connections to the outer retina, causing visual problems even before many retinal ganglion cells are lost. Recent studies suggest that microglial cells (which protect the neurons in the brain by performing clean-up operations) might be involved in causing this early problem. Professor Morgan's project will explore whether the inhibition or depletion of microglial cells can help protect retinal ganglion cells in glaucoma.

Open Call Research Award

Due to the quality of applications, a total of three projects were awarded the £50,000 Open Call Research Award during the year 2022-23:

- Dr Ruth Hogg, of Queen's University, Belfast, for her study, 'Ten year follow up on the NICOLA study (progression of glaucoma)'. The Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA) was a study of a representative cohort of older adults living in Northern Ireland which explored the social, behavioural, economic and biological factors of ageing and how these factors change as people age. In her study, Dr Hogg will seek to determine how many people developed glaucoma during the follow-up, how glaucoma progressed in those previously diagnosed and to explore how genetic background, social context, demographics and lifestyle choices might modify progression of the disease.
- Professor Augusto Azuara-Blanco for a study entitled, 'Effect of an Oral, Peripherally-restricted Synthetic Cannabinoid, ART27.13, on Intraocular Pressure: A Pilot Randomised Cross-Over Study'. The goal of this study is to assess the safety, tolerability and effect on intraocular pressure (IOP) of an oral synthetic cannabinoid (a group of man-made chemicals that are designed to mimic the effects of cannabis).
- Dr Paul Artes, University of Plymouth, for his project, 'Visual fields in glaucoma – investigating the potential of "abundant testing" with virtual reality perimetry.' The purpose of the research is to investigate if, and how, regular home testing with a virtual reality device might reduce the variability of visual field results.

Small Grants Award

The annual small grant award, in partnership with Fight for Sight, was granted to three projects this year:

- Dr Julie Albon (Cardiff University) 'Spatial transcriptomic profiling to detect cell-specific mechanosensitive mechanisms within human optic nerve heads – a pilot study' (£7,500)
- Dr Ameenat Solebo (University College London) 'ARGO-1: Study of Anterior Segment Imaging-based Risk Stratification of Childhood Secondary Glaucoma' (£7,500)
- Dr Ester Reina-Torres (Imperial College London) 'Novel Cell Therapy Approach to Reduce IOP in Glaucoma Via Nitric Oxide Production' (£7,500).

UK National Eye and Hearing Study

The Board of Trustees were pleased to approve £10,000 from Glaucoma UK's Research Designated Fund to support Phase 1 of the UK National Eye Health and Hearing Study (UKNEHS).

Unlike many countries, the UK has no data on the underlying burden of eye disease/vision impairment within the population and minimal current data on hearing loss. This lack of information on need and associated inequalities in our community remains a serious impediment to the planning of services to meet growing demand. The UKNEHS is a collaborative, nationwide project developed by Anglia Ruskin University (in cooperation with the Royal College of Ophthalmologists, College of Optometrists, Vision UK and Thomas Pocklington Trust) to tackle this issue. The full research will consist of a population-based study of 25,000 people aged 50 years and over, from representative communities across the UK. The Phase 1 element will test the methodology on a cohort of 1,000 participants.

Changes to existing projects
The awards panel (excluding the panel Chair, Winnie Nolan, who is a co-investigator) approved additional funding of £24,760 for the 2019 RCOphth Award project led by Dr Victor Hu of the London School of Hygiene and Tropical Medicine, 'Detecting glaucoma using a combination of low-cost, portable and easy to perform tests'. The 2-year project was originally awarded £99,960 and the extra funds will cover unexpected additional costs to get approval from the Tanzanian Medicines and Medical Devices Authority, where one of the testing sites was based, as well as extended contracts for key personnel and a final trip to collect data.

Glaucoma UK Chair of Ophthalmology

In partnership with University College London and the Moorfields Biomedical Research Centre, we were pleased to provide continued support towards the salary of the Glaucoma UK Chair of Ophthalmology for Glaucoma and Allied Studies – Professor David (Ted) Garway-Heath – with an award of £73,389 during the year. A global leader in ophthalmology research, it was little surprise that Professor Garway-Heath was inducted into the 2023 Ophthalmologist Magazine Power List Hall of Fame in July. His achievements for the year include:

- Eight new scientific publications – including 'Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma' and 'Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study'.
- Over 19,000 citations of his works.
- 24 national and international lectures for a range of oganisations including Royal College of Ophthalmologists, European Glaucoma Society, Oxford Ophthalmological Congress, College of Ophthalmologists of Sri Lanka, American Glaucoma Society, Italian Glaucoma Society, Greek Glaucoma Society and Danish Glaucoma Society.
- Provision of strategic input and guidance for the European Glaucoma Society (EGS) in his capacity as member of the Executive Committee and immediate Past President.
- Initiation of the EGS patient advocacy project, the aims of which are to engage patients in the works of the EGS and to determine how the organisation can support patients across Europe and beyond.
- Service as EGS Ambassador to the American Glaucoma Society, with the aim of strengthening the links and collaborations between the two societies in relation to the education and training of ophthalmologists.
- Leadership of the 'Innovation Hub' Workstream for ORIEL: the new Moorfields and Institute of Ophthalmology, for which he co-authored the 'Creative Strategy' which formed the core of the architects' brief.

Professor Garway-Heath's research activities for the year included work as Chief Investigator on the following ongoing projects:

- 'The association between mitochondrial function and glaucoma–identifying susceptible patients'.
- 'Identifying the genetic basis for heritable normal tension glaucoma, with a focus on mitochondrial function'.
- 'Evaluation of Potential Endpoints for Ophthalmology Clinical Trials Assessing Neuroprotection'.

A further project, 'NicotinAMide in Glaucoma (NAMinG): A randomised, placebo-controlled, multi-centre, Phase III trial' - to test the effectiveness of vitamin B3 as a treatment for glaucoma - was due to commence during the year but was delayed pending a request from the Healthcare products Regulatory Agency (MHRA) for additional documentation from the manufacturer. The project will now start in November 2023, with patients recruited from ten centres across the UK.

Priority 4:
Influencing policy and practice

With the ongoing move to community-based glaucoma care, we feel we have an important role to play in providing information, advice and support to health care professionals.

We believe that all those involved in delivering glaucoma care should have up-to-date information and access to effective professional networks for sharing best practice. Through the work of our Professional Engagement Leads we seek to make connections that can help to promote, protect and safeguard the interests of people living with - or at risk of - glaucoma.

Through our administration and support for the United Kingdom and Éire Glaucoma Society (UKEGS) – which became part of Glaucoma UK in 2019 – we also want to bring together scientists and clinicians in a vibrant, aspirational scientific community.

With continuing treatment delays and stark variations in provision across the UK, we recognise our role in working to influence policy and representing the voice of glaucoma patients with those who design, commission and deliver glaucoma services.

281 people took our free professional training course

How did we do?

Engaging with Professionals

Professional engagement activity over the past year has focused on pulling together our various strands of work. We launched new eye drop support boxes (formerly known as compliance boxes) in summer 2022. Now eye care professionals such as Eye Care Liaison Officers (ECLOs) can ensure that someone gets the help they need, whether that's simply information about glaucoma, information about when to put in the eye drops, or a new dispensing aid. **We distributed 170 boxes over the course of the year and are pleased that demand is growing steadily.**

> **"I think this course is one of the most informative courses I have attended. I am a former nurse and have worked with clients with eye conditions for the last 11 years and yet there was still so much I learned."**

To accompany the boxes, we are rolling out our training courses for eye care professionals. This places our eye drop support boxes in context, helping professionals understand glaucoma, the challenges associated with using eye drops, and how dispensing aids can help. Upon completion of the training, attendees receive the box to ensure that the training is converted into practical support for people with glaucoma.

We delivered training to 281 individuals over the course of the year; these people were mostly ECLOs but also staff from sight loss charities, rehabilitation workers and those involved in domiciliary care.

Feedback from the training is very positive, with 100% of those completing the feedback survey saying they would recommend it.

100% of respondents said they would recommend our course

We also encourage anyone who receives a box or completes the training to join Glaucoma UK as a professional member. We want to turn the boxes and the training from a single point of interaction into the start of an ongoing relationship, where we can provide regular updates on changes in glaucoma care, new eye drops, and the services offered by Glaucoma UK. We want to ensure that eye care professionals come to Glaucoma UK for help in maintaining their knowledge and skill sets.

Over the course of the year, over 250 new professional members have joined Glaucoma UK as a result of our training and support boxes.

The UK and Éire Glaucoma Society (UKEGS)

The other major strand of work for our professional engagement team is supporting the UK and Eire Glaucoma Society (UKEGS), the professional wing of Glaucoma UK. Despite the difficulties posed by the original postponement and the threat of last-minute Covid disruption, the UKEGS conference in October 2022 was a success, with far greater emphasis than in previous years on the role of Glaucoma UK and the importance of the patient voice. A total of 260 delegates and speakers attended over the 2 days, comprising consultant ophthalmologists, optometrists, glaucoma fellows, specialist doctors and academics.

As well as running the annual conference and supporting a research grant worth £50,000 each year, we are developing and deepening the relationship between UKEGS and Glaucoma UK. We are looking to define more clearly what it means to be a member of UKEGS beyond attending the conference, and how this links to professional membership of Glaucoma UK. We are widening the membership of UKEGS to ensure those working in both primary and secondary care maintain excellent knowledge of glaucoma, supporting clinical decision making and ensuring that people get the best possible care, wherever they are seen. We are also working to improve the financial sustainability of the conference and reduce its environmental footprint.

260
delegates and speakers attended the 2022 UKEGS Conference

In developing our professional membership offer, we are keen to build more effective networks between glaucoma professionals and support more sharing of best practice. We hope to pilot a training course for staff in optometric practices and pharmacies, as well as rolling out the eye drop support boxes more widely. We are also aware that the professional sections of our website need revamping and hope to develop and broaden the content in due course.

We are grateful to the many professionals who volunteer for Glaucoma UK, whether that's formally as a trustee or member of our Clinical Advisory Panel, or informally by assisting our helpline advisors with challenging queries or reviewing our information booklets. We are looking to develop our professional volunteering structures so we can work together more effectively, making sure we have access to the best possible advice and support from glaucoma specialists to deliver our services.

Awards for Excellence

Our 'Awards for Excellence' scheme provides a welcome opportunity to focus on the best examples of professional practice, with patients nominating those who have provided them with exceptional glaucoma care and support. The 2023 winner – Dr. Sancy Low, Ophthalmic Surgeon, St. Thomas' Hospital, London - was nominated for her compassionate approach and keenness to understand the individual personal circumstances of her patients. Dr Low received her award at the Glaucoma UK AGM in March.

Representing the glaucoma community Glaucoma UK represents the glaucoma community on a range of national bodies, including the Clinical Council for Eye Health Commissioning, the Industry Vision Group, the Ophthalmology National Steering Group and the UK Optical Alliance.

We also continue to be active members of the VI Charity Sector Partnership, a group of 8 sight sector organisations who originally came together during the pandemic to represent the interests of those living with an eye condition. Members of the Partnership comprise RNIB, Guide Dogs, Glaucoma UK, Macular Society, Thomas Pocklington Trust, Retina UK, Blind Veterans UK and Visionary UK. A number of joint initiatives were undertaken during the year, most notably a communications project to raise awareness of the particular challenges of the cost-of-living crisis for individuals with visual impairment. Other achievements included the development of a sight loss pathway to ensure patient information and advice needs are recognised and met throughout the diagnosis and treatment process and the development of an 'Insight Hub', featuring amalgamated data and insights from across the sight loss sector.

In the coming year, Glaucoma UK will be playing an active part in discussions about the new strategic direction for the VI Charity Sector Partnership in the post-pandemic era.

In February, Glaucoma UK supported the submission of a proposal to the Government's Health and Social Care Committee regarding specific issues the Committee should explore as part of its Prevention Inquiry. The proposal covered the need to encourage the take-up of eye examinations and the threat of sight loss due to treatment delays. There will be a valuable opportunity to work with the Committee's Inquiry if the proposal is accepted.

Glaucoma UK also supported a joint call to the Government for the installation of tactile warning surfaces on every train station platform across Wales, Scotland and England to assist those with visual impairment. The call was a success, with the Department for Transport providing Network Rail with £75m to complete this vital work by 2025.

Fundraising review

Fundraising review

With almost 85% of our total income coming from voluntary gifts and donations, we owe so much to the many individuals, companies, trusts, foundations and public bodies who support our charity. Between them, our donors and supporters raised £1,484,646 to help fund our work during the year.

Legacy gifts

Once again, the majority of this income (£1,213,969) came from those who had kindly remembered Glaucoma UK in their will. Legacy donations are extremely valuable to us, not only for the essential financial support they provide, but as a most welcome indicator of the difference we have made to those lives. They also allow us to commit to the more ambitious, longer-term plans that we must put in place if we are to succeed in putting an end to preventable glaucoma sight-loss. We extend our sincere gratitude to all those who remembered us with such a valuable final gift.

Other income

Other sources of voluntary income during 2022-23 included membership subscriptions, one-off gifts, responses to direct appeals, regular giving, in memoriam donations, corporate support, challenge events and a weekly lottery. Income from these areas totalled £270,677, which was a pleasing increase of over 40% on the previous year (2022: £180,435). This was thanks in large part to the exceptional performance of our challenge fundraisers, who raised over £80,000 with their exhausting combination of thousands of steps, sky dives, half-marathons, full marathons and bike rides.

Ms Nishani Amerasinghe, Glaucoma Service Lead and Consultant Ophthalmic Surgeon at the University Hospital Southampton NHS Foundation Trust, showed true dedication to raising awareness of the disease and much-needed funds for the charity during 2023.

Her quest took her to the Swiss Alps, where she took on the formidable "Everest in the Alps" challenge, skiing the equivalent of Mount Everest's height (8,848 metres) over four gruelling days. The challenge involved tackling unforgiving terrain and ascending heights ranging from 2,000 to 2,500 metres for up to 11 hours a day. Nishani raised just over £20,000 for Glaucoma UK, thanks to the 220 individuals who donated and corporate sponsorship from ELIOS Vision, Santen, Glaukos, i-STAR Medical and Théa Pharma UK.

Professor Keith Barton, Consultant Ophthalmic Surgeon at Moorfields Eye Hospital and former Chair of Glaucoma UK, completed his 10th fundraising challenge in aid of the charity by cycling from London to Paris in under 24 hours. Undeterred by a treacherous thunderstorm as he cycled to the finish line, he raised just under £57,000. This brings Keith's fundraising total to a staggering £138,000 for Glaucoma UK over the last 10 years.

Fundraising appeal

Our Glaucoma Awareness Week fundraising appeal was our most successful to date, securing £23,729 from 287 donors (an increase of over 200% on the previous year). We were grateful to Choon Young Tan for providing a case study for the appeal and for sharing his experience of being diagnosed with glaucoma in his early 30s. Choon's reflections on his own condition, and that of his grandmother who lost most of her sight from the disease, were invaluable in helping to not only raise funds, but also in raising awareness of the vital role of early diagnosis.

"My grandma had glaucoma, but we weren't aware that the condition was hereditary. If she'd known, she'd have urged me and all our family to have our eyes checked regularly"

Organisations who helped us

We would like to take this opportunity to thank the following organisations for their support during the year:

The Dandy Charitable Trust

Wyseliot Rose Charitable Trust

The Emily Weircroft Charitable Trust

Harry and Gertrude Landy Charitable Trust

Santen UK

ELIOS Vision

Glaukos

i-STAR Medical

Théa Pharma UK

Medicom Healthcare

Specsavers

Fundraising Controls

Securing and maintaining the trust of our donors and the public is vital to the success of our fundraising activity. We therefore have controls in place to ensure our fundraising is transparent, ethical and compliant with current regulations. We have the benefit of a designated Fundraising Trustee Advocate on our Board of Trustees, to ensure oversight at the highest level. In addition, our Finance and Governance Committee monitors fundraising performance, control and regulation through quarterly reviews.

Glaucoma UK is registered with the Fundraising Regulator and follows the Code of Fundraising Practice. We comply with the key principles embodied in the Codes and are committed to the Fundraising Promise. Our website carries our complaints policy for the public and explains clearly how an individual may complain. We received no complaints from August 2022 - July 2023. We are also registered with the Fundraising Preference Service so that individuals can opt out from receiving fundraising communications, should they wish. We received no such requests during the year.

To ensure that all reasonable steps are taken to protect vulnerable adults, Glaucoma UK complies with the Institute of Fundraising guidance relating to the needs of people in vulnerable circumstances and our activities are governed by an Ethical Fundraising Policy and Supporter Promise.

Glaucoma UK monitors any third parties working with us to help raise funds, ensuring that they adhere to the Code of Fundraising Practice and are operating to the highest possible standards of respect for the personal data and wishes of our supporters and prospective supporters. We worked with one third party – Bequeathed Limited - in the delivery of a free wills service, but did not work with any external professional fundraising agencies during the year.

Our Lottery activities are managed under our Gambling Commission licence which ensures we can meet our legal obligations and provide the necessary protections for our players.

Looking forward

Looking forward

As we approach the charity's 50th Anniversary year in 2024, we have the perfect opportunity to ensure we are well-placed to face our next half-century. Our new Theory of Change framework sets out the sustained impact goals we will be pursuing and the outputs we will need to achieve them.

A key priority for the next 12 months will be to invest further in our team to increase our capacity for delivering services across the UK. Additional posts will be introduced for our helpline and outreach services. We will also be continuing our work to raise awareness among those communities who are most at risk of glaucoma sight loss and encouraging greater uptake of our services by individuals in those groups.

A new Head of Research will join the team in early 2024, in order to take forward a new strategy for developing our awards portfolio and investing our £3.9m Designated Research Fund in more ambitious and transformational projects.

Another key area of focus will be to secure greater advantage from our strategic partnerships including corporate organisations, pharmaceutical companies and other sight sector charities.

Our finances

Financial review

With the economic turbulence of the last few years still having an impact, the pursuit of voluntary income remains challenging, although it was encouraging to see donations from individuals return to pre-Covid levels during the year.

Legacy income, however, was the lowest of the last 6 years. This resulted in a reduction in total income year-on-year, against a 19% growth in expenditure as we continue to expand the charity in pursuit of our charitable goals.

We ended the year with a net income of £20,655, but unrealised losses on our investments of £124,368 led to a reduction of £111,423 in our total funds (2023: £8,047,747 versus 2022: £8,159,170).

Incoming resources

Total incoming resources for the year ending 31 July 2023 were £1,773,879, a decrease of £67,944 on the previous year (2022: £1,841,823). This was mainly due to a £276,984 reduction in legacy income. Representing 69% of our total income, we monitor legacy receipts very closely and it was evident during the year that nationwide delays in the statutory processing of grants of probate were affecting income, as the system continues to readjust after the pandemic. In addition, we currently have a number of more complicated bequests in our pipeline and we are increasingly seeing an extension in the time between being notified of a gift and receiving the funds. This trend is reflected in the debtor future, which has increased by £335,433 on the previous year (2023: £1,450,507 versus 2022: £1,115,075). The recruitment of a new Legacy and Supporter Relationship Officer in November 2022 has increased our resource for addressing these issues and has also freed up time for the Head of Fundraising to more proactively pursue other income streams and work towards reducing the heavy reliance on legacy gifts.

Our Professional Engagement income, which relates to the UK and Éire Glaucoma Society (UKEGS) conference, totalled £87,975 against the previous year in which no funds were received. This was due to the rescheduling of the 2021 conference

to October 2022 due to Covid delays and the deferral of all associated income.

Resources expended

Total expenditure in the year was £1,753,224 (2022: £1,479,106). The principal area of growth was staff costs (up by 25% to £835,770), as we work to position ourselves to deliver the strategic outputs from our new 'Theory of Change' framework. During the year, we welcomed a new Legacy and Supporter Relationship Officer to the team and our first dedicated Training and Engagement Officer for Northern Ireland. We also invested in the new post of Health Information Manager to oversee all our written advice and guidance and to further improve the accessibility of the information we provide. A salary benchmarking review and the introduction of a new employee salary scale led to an improvement in pay rates for most roles to bring them more in line with equivalents in the sector. With recruitment proving so expensive and increasingly uncertain following the changes in work patterns and attitudes during the last few years, the investment in existing expertise and experience will be a key element in successfully delivering our strategic plans. Total staff numbers at the year-end were 26 (18.53 full-time equivalent) compared to 23 (17.30 full-time equivalent) at the end of 2022.

Expenditure on research grants increased for a second year to £408,660 (2022: £364,945), due to a pleasing increase in the number of fundable applications and the ability to award two additional small grants of £7,500 in partnership with Fight for Sight and a further two additional Open Call grants of £50,000. The timing of our Open Call and RCOph awards at the end of the financial year in July and the slight time lag for recipients to submit their first invoices resulted in an increase in creditors year on year (2023: £647,532 versus 2022: £251,404). The creditor figure also includes deferred income relating to the UKEGS conference, which will take place in November 2024, but for which delegate fees and exhibitor sponsorships were received during the previous financial year.

The other significant area of growth was additional expenditure of £104,426 in the areas of awareness raising, public relations and social media (2023: £122,313 versus 2022: £17,887). From a very modest average spend of just £34,000 per annum over the previous 5 years, the increased investment reflected the vital importance of this strand of our strategic activity. In particular, we are seeking to exploit the benefits of paid-for social media advertising in reaching new audiences and those most at risk of glaucoma sight loss. We will continue to expand this aspect of our work in the coming year.

Restricted Funds

Of total funds (£8,047,747) at the year end, the sum of £1,518,802 was restricted. The majority (£1,437,760) represents the Chair Fund, which will support the Chair of Ophthalmology for Glaucoma and Allied Studies until his eight-year term comes to an end in 2026. Of the remainder, £47,802 is restricted to the delivery of the UK and Éire Glaucoma Society (UKEGS) conference, and the rest is allocated to a range of specific small projects at the request of the donors.

Reserves policy

The policy of the trustees is to maintain at least the minimum of cash reserves and working capital sufficient to meet known development plans, as well as the day-to-day needs of the charity. Funds are also held in reserve to provide secure, sustainable support for our beneficiaries and to ensure we can commit to ambitious long-term plans to end glaucoma sight loss.

The Trustees recognise the risk to income posed by the reliance on legacy gifts and factors outside the organisation's control, such as ongoing economic uncertainty and investment volatility. Having considered these factors, the Board of Trustees agreed to maintain cash reserves of 12 months' operating costs during the year.

Unrestricted reserves at the year-end amounted to £6,528,975 (2022: £6,564,793). Of the total, £3,900,000 was designated to delivery of a new research strategy, which will be taken forward by a new Head of Research from January 2024. A further £460,000 remains designated for equipment replacement and infrastructure development, which will include improvements to the Head Office building and the subsidy of new posts to strengthen our staffing infrastructure as we work to grow additional income. In accordance with the preference (but not instruction) of a legacy donor, £5,062 was designated by the Board of Trustees to outreach work in the West Yorkshire area.

General funds totalled £2,140,977 (2022: £2,081,887) against a Reserves Policy requirement of £1,918,887 at the year end. The surplus will support the delivery of the new Theory of Change framework and the expansion of our services in the period 2023 – 2026.

Going concern

In assessing the charity's status as a going concern, the trustees have considered a range of information in relation to the financial year ahead, including the current status of the UK economy, the charity's cash resources and known liabilities.

Following the development of a 3-year financial plan in support of the Theory of Change process, the trustees consider the charity to have adequate resources to continue operating an effective service for at least 12 months and to meet its obligations as they fall due. The financial statements have therefore been prepared on a going concern basis.

Investment policy and performance

The charity's assets are invested in the Rathbone Core Investment Fund for Charities, with management delegated to Rathbone Investment Management Ltd. A total return approach is adopted for the portfolio and withdrawals can be comprised of physical income and/or capital gain.

Our Investment Policy is:

- To maximise total return subject to a medium level of risk.
- To ensure that the charity's assets are invested widely and diversified by asset class and by security.
- To avoid direct investment in any companies manufacturing tobacco or tobacco products.
- To avoid investment in any companies that derive more than 10% of their revenues from the manufacture of alcoholic beverages, armaments, gambling, high interest rate lending or pornography.

Responsibility for monitoring the performance of the investment portfolio is delegated to the Finance and Governance Committee and performance benchmarks are reviewed with the fund managers on an annual basis.

The total value of our investment portfolio at the year-end was £6,860,720, a reduction of £192,054 on the previous year. A total of £167,503 in dividends was reinvested into the portfolio and a drawdown of £225,476 was made in December 2022, to support cashflow during a period of legacy income delays. This resulted in realised losses of £7,710 during the year, with unrealised losses totaling £124,368. The portfolio underperformed against the composite index benchmark, returning 0.2% versus the benchmark of 1.4%. The trustees are aware of the ongoing uncertainty relating to inflation and the potential for a recession and this has been taken into account in a review of the Investment Policy for the year 2023-24. Despite the extreme conditions of the last 3 years, the investment managers remain confident that our target total return of inflation plus 3% can be achieved over the longer term.

Governance and leadership

Trustees, advisors and staff

The trustees (who are also directors under company law) are:

Professor Anthony King	Chair
Mr Stephen Epstein	Vice Chair (Chair, Finance & Governance Committee)
Mr Prabhakar Sundaresan	Hon Treasurer (Finance & Governance Committee)
Miss Winifred Nolan	Chair, Clinical Advisory Panel
Dr Susan Blakeney	(Finance & Governance Committee)
Mrs Teresa Borsuk	(Finance & Governance Committee)
Dr Roxanne Crosby-Nwaobi	
Mr Julian Exeter	
Dr Cecilia Fenerty	
Mrs Yolanda Laybourne	(Finance & Governance Committee)
Professor Roshini Saunders	
Mr Raymond Spendiff	(Finance & Governance Committee)
Mr Christopher Hunton	(co-opted)

Chief Executive and Company Secretary	Joanne Creighton
Company Number	1293286
Charity Number	274681
OSCR Number	SC041550
Registered office & operational address	Woodcote House, 15 Highpoint Business Village, Henwood, Ashford, Kent, TN24 8DH www.glaucoma.uk
Bankers	Barclays Bank plc, 1 Churchill Place, London, E14 5HP CAF Bank Ltd, 25 Kings Hill Avenue, Kings Hill, Kent, ME19 4JQ HSBC Bank plc, Camberwell Green, 23 Denmark Hill, London, SE5 8RP
Auditors	Xeinadin Audit Limited, 12 Conqueror Court, Sittingbourne ME10 5BH
Investment Managers	Rathbone Investment Management Ltd, 8 Finsbury Circus, London, EC2M 7AZ

Structure and management

Glaucoma UK is the operating name of the International Glaucoma Association Ltd, which was incorporated on 15 July 1976 and registered as a charity on 20 December 1977. As Glaucoma UK is both a charity and a company limited by guarantee, all board members are directors for the purposes of company law and trustees for the purposes of charity law.

The objects of the charity are defined by its Articles of Association (last updated in 2015), which also set out trustees' powers and the permitted activities of the charity.

Following a review of the Articles of Association in 2021, consultation was undertaken with voting members about changing the constitution from that of a membership charity to an association model. Although the majority view was in favour of the change, the response rate was very low and there were strong views against. After further debate and consultation with those against the changes, the Board of Trustees announced the decision to maintain the membership model at the Annual General Meeting in March 2023. The Articles of Association will instead be updated during the coming year to modernise the language, improve readability and ensure they remain relevant as the charity celebrates its 50th anniversary in 2024.

The Board and committees

The Board comprises a maximum of 15 trustees, of whom up to 12 are elected by the members and a further three may be co-opted.

The current Board comprises people living with glaucoma, those with close family connections with the condition and others with backgrounds in ophthalmology, nursing, optometry, finance and business. Trustees retire after serving a three-year term but are eligible for re-election to a maximum of nine years' service. Those serving prior to the 2023 AGM are entitled to serve for a maximum of twelve years. Board meetings take place 4 times a year on either a face-to-face, virtual or hybrid basis.

There is one sub-committee: the Finance and Governance Committee, which has delegated responsibility to oversee finance, investments, risk management and policy. Consisting of six trustees, the committee meets quarterly in advance of each Board meeting and on an ad-hoc basis, should the need arise.

The charity also has a Clinical Advisory Panel (CAP) to advise on clinical matters. The chair of the CAP oversees the award of research grants.

Trustee recruitment and training

When appointing new Board members, trustees have regard to any skills or knowledge gaps and seek candidates to meet those needs. Due consideration is also given to diversity and the need to ensure that the Board appropriately represents the communities served by the charity. New trustees are sought using existing networks, advertising or professional recruitment agencies, as required. Candidates are interviewed by a sub-committee of trustees, followed by a meeting with the Chair and an invitation to meet the full Board at a Board meeting.

A Trustee Handbook sets out trustee roles and responsibilities. A personalised induction is provided for all new trustees, including a charity overview and briefings on finance, fundraising, support, services and communication. Direction is also provided on the Charity Commission Guidance, 'The Essential Trustee' and trustees are required to undertake 'Understanding Governance' training within 6 months of joining the Board. Ongoing training is provided as required, including attendance on external courses or participation in internal workshops and briefings.

Operating responsibility

Day-to-day responsibility for delivering services and achieving strategic and financial aims within organisational policies and the law is delegated to the Chief Executive, supported by the Senior Management Team.

Statement of public benefit

Glaucoma UK exists to raise awareness of the risks of glaucoma, support people to live well with the condition and fund research into the causes, prevention and treatment of the disease.

When reviewing the charity's objectives and planning future activities, the trustees refer to Charity Commission guidance on public benefit and can confirm that all Glaucoma UK's activities are undertaken to further our charitable purposes for public benefit, in accordance with Section 17 of the Charities Act 2011.



Risk management and internal control

Overall responsibility for the charity's risk management lies with the Board of Trustees, with formal assessment and review delegated to the Finance and Governance Committee. A risk register is submitted by the Chief Executive on a quarterly basis which identifies current and new risks, rates each in terms of likelihood and probability and identifies appropriate controls and mitigations.

The trustees have assessed the major risks to which Glaucoma UK is exposed as follows:

Lack of income diversity and heavy reliance on legacy gifts
With legacy gifts representing 69% of our total income in the year 2022-23, the need to diversify funding sources remains a key priority for the charity. In mitigation, the following measures are in place:

- Income position monitored via quarterly management accounts.
- Cash flow forecasts and detailed reports on the legacy gift pipeline.
- Reserves holding and investment portfolio with diversified risk to cover medium and longer-term income shortfalls.
- Staff capacity increased in the fundraising department in October 2022 to create additional resource for income diversification.
- New Theory of Change framework and outcome reporting mechanisms in place to better demonstrate the charity's impact and secure higher levels of corporate sponsorship, major donor funding and charitable trust support.

Investment failure

All investments are at risk of sustained and long-term fall in value of funds held in stock markets. The Board of Trustees seeks to offset risks to its investment holdings in the following ways:

- Investments held in a professionally managed portfolio.
- Access to live online investment reports.
- Quarterly reporting to Finance and Governance Committee and annual meeting with investment managers.
- Investment Policy reviewed annually.
- Minimum of three months' operating costs held in cash account.

Compromised IT systems and cyber security failure

In response to increasing levels of cybercrime in the UK and a tightly regulated data protection environment, the following mitigations are in place:

- Retained professional support for staff training and regular system security monitoring.
- Cyber Essentials Plus accreditation achieved in June 2023.
- Personalised cyber training programme in place for all staff, with access to up to 96 modules depending on user needs.
- 'reCAPTCHA' technology installed on the Glaucoma UK website shop to prevent automated transactions
- Daily offsite backup and office-hours support contract in place.
- Appropriate policies in place (Information Governance, ICT, Data Protection) and subject to annual review.
- Cyber insurance in place, with support for post-incident management.

Remuneration policy

The trustees consider the Board of Trustees and the Chief Executive as comprising the key management personnel, in charge of directing, controlling and operating the charity on a day-to-day basis.

All trustees give of their time freely and no trustee remuneration was paid in the year. Trustees are required to disclose all relevant interests and withdraw from decisions where a conflict of interest arises.

The pay of the charity's Chief Executive is reviewed annually by the Board Chair and Finance and Governance Committee. The Chief Executive reviews all other staff salaries annually and makes recommendations to the Board as part of the annual budget setting process.

When setting salaries, trustees are guided by a remuneration policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public and private sector pay increase estimates), affordability, sustainability, and appropriateness. Glaucoma UK aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2023 these ratios were 3.4:1 and 2.3:1 respectively.

Statement of trustee responsibilities

The trustees are responsible for preparing the Trustees' Annual Report including the strategic report and financial statements in accordance with applicable law and United Kingdom accounting standards (UK generally accepted accounting practice).

Company law requires the trustees to prepare financial statements which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees' Annual Report is approved by order of the Board of Trustees, and the Strategic Report (included therein) is approved by the Board of Trustees in their capacity as directors, in their meeting on 30 November 2023, and signed on its behalf by



Professor Anthony King
Chair

Independent Auditors' Report

Independent auditors' report

We have audited the financial statements of The International Glaucoma Association Limited for the year ended 31 July 2023 on pages 88 to 109. The financial reporting framework that has been applied in their preparation is applicable law and FRS 102 (effective January 2015), as well as the Statement of Recommended Practice for Charities (effective January 2015).

This report is made solely to The International Glaucoma Association's members and Board of Trustees, as a body, in accordance with Section 144 of the Charities Act 2011, and regulations made under Section 154 of that Act, as well as Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Council of Management those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditors

As explained more fully in the Trustees' Responsibilities set out on page 37, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditors under Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 and report in accordance with regulations made under those Acts.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees' Annual Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies, we consider the implications for our report.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities. The extent to which our procedures can detect irregularities, including fraud, is detailed below:

- Gaining a full and extensive knowledge of the entity, environment and the regulatory framework to which it must abide by.
- Evaluating and assessing the extent to which the entity's internal systems are adhering to these as well as gaining a full and comprehensive understanding of the entity's activities and effectiveness of its control environment (including those in place to identify and prevent fraud).

We achieved this by carrying out the following:

- Enquiry of the detailed communication with management and those charged with governance.
- Reviewing internal systems and controls.
- Reviewing financial statement disclosures and compliance with applicable laws and regulations.

Opinion on financial statements

In auditing the financial statements, we have concluded that the trustees/directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the entity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees/directors with respect to going concern are described in the relevant sections of this report.

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 July 2023 and of its incoming resources and application of resources, including its result, for the year then ended;
- have been properly prepared in accordance with the Financial Reporting Standards 102 (effective January 2015);
- have been prepared in accordance with the requirements of the Companies Act 2006, and Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- the information given in the Report of the Board of Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Nicholas Hume
For and on behalf of Xeinadin Audit Limited,
Registered Auditors
12 Conqueror Court,
Sittingbourne ME10 5BH
Eligible to act as an auditor in terms of Section 1212 of the Companies Act

Financial statements

for the year ended 31 July 2023

Glaucoma UK (the operating name of the International Glaucoma Association Limited). Charity No. 274681, in Scotland No. SC041550. Company No. 1293286

Statement of financial activities

incorporating an income and expenditure account

For the year ended 31 July 2023

	Note	Restricted £	Unrestricted £	2023 Total £	2022 Total £
Income					
Donations, Legacies and Subscriptions	2	38,016	1,446,630	**1,484,646**	1,671,388
Investment income	3	38,024	143,714	**181,738**	144,749
Charitable activities					
Professional Engagement	4	87,975	-	**87,975**	-
Christmas cards and glaucoma aids	4	-	6,858	**6,858**	4,654
Other income	4	-	2,178	**2,178**	6,561
Grants	4 & 5	10,484	-	**10,484**	14,471
Total income		**174,499**	**1,599,380**	**1,773,879**	**1,841,823**
Expenditure on:					
Raising funds					
Finance and support		11	22,603	**22,614**	19,516
Cost of generating funds		-	198,825	**198,825**	122,819
		11	221,428	**221,439**	142,335
Expenditure on charitable activities					
Glaucoma research		137,507	316,428	**453,935**	431,240
Patient information and support		3,317	690,928	**694,245**	676,492
Professional information and support		72,578	187,204	**259,782**	159,655
Campaigning and advocacy		5,932	113,848	**119,780**	63,241
Cost of glaucoma aids and equipment		823	3,220	**4,043**	6,142
Total expenditure	6	**220,168**	**1,533,056**	**1,753,224**	**1,479,106**
Realised losses on investment assets	12	-	(7,710)	**(7,710)**	-
Net Income		(45,669)	58,614	**12,945**	362,717
Unrealised losses on investment assets	12	(29,906)	(94,462)	**(124,368)**	(495,605)
Net incoming resources before transfers	7	(75,575)	(35,848)	**(111,423)**	(132,888)
Gross transfer between funds		-	-	**-**	-
Net movement in funds		(75,575)	(35,848)	**(111,423)**	(132,888)
Reconciliation of funds					
Total funds brought forward		1,594,377	6,564,793	**8,159,170**	8,292,061
Total funds carried forward		**1,518,802**	**6,528,945**	**8,047,747**	**8,159,171**

All of the results above are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 18 to the financial statements.

Balance sheet

As at 31 July 2023

Charity No. **274681**
Scotland No. **SC041550**
Company No. **1293286**

	Note	2023 £	2022 £
Fixed assets			
Tangible fixed assets	11	**3,210**	16,141
Investments	12	**6,860,720**	7,052,774
Total fixed assets		**6,863,930**	7,068,915
Current assets			
Stock	13	**3,656**	3,768
Debtors	14, 21	**1,450,507**	1,115,075
Cash at bank and in hand		**631,742**	438,360
		2,085,905	1,557,202
Liabilities			
Creditors: amounts due within one year	15, 20, 21	**647,532**	251,404
Net current assets		**1,438,373**	1,305,798
Total assets less current liabilities		**8,302,303**	8,374,713
Creditors: amounts due after more than one year	16, 21	**254,556**	215,543
Net assets	17	**8,047,747**	8,159,171
Funds	18		
Restricted funds		**1,518,802**	1,594,377
Unrestricted funds			
Designated funds		**4,387,968**	4,482,906
General funds		**2,140,977**	2,081,888
Total funds		**8,047,747**	8,159,171

Approved by the board of trustees of the International Glaucoma Association Limited and signed on its behalf by Mr Raymond Spendiff, Trustee.

R. Spendiff

Statement of cash flow

For the year ended 31 July 2023

Cashflows from operating activities:	**2023**	2022
Net cash provided by (used in) operating activities	**(48,332)**	(450,839)
Cashflows from investing activities		
Dividends and interest from investments	**181,738**	144,749
Purchase of property, plant and equipment	**-**	(9,442)
Proceeds from sale of investments	**225,476**	-
Purchase of investments	**(167,503)**	(492,201)
Net cash provided by (used in) investing activities	**239,711**	(356,894)
Change in cash and cash equivalents in the reporting period	**191,379**	(807,733)
Cash and cash equivalents at the beginning of the reporting period	**441,094**	1,248,827
Cash and cash equivalents at the end of the reporting period	**632,473**	441,094
Increase/Decrease in cash balances	**191,379**	(807,733)

Reconciliation of net movement in funds to net cash flow from operating activities

Net movements in funds for the reporting period (as per the statement of financial activities)	**(111,423)**	(132,888)
Adjustments for:		
Depreciation	**12,931**	9,188
Dividends & interest from investments	**(181,738)**	(144,749)
Loss/(Profit) on sale of investments	**132,078**	495,605
(Increase)/Decrease in stocks	**111**	542
(Increase)/Decrease in debtors	**(335,432)**	(806,842)
Increase/(Decrease) in creditors	**435,141**	128,305
Net cash provided by (used in) operating activities	**(48,332)**	**(450,839)**
Analysis of cash and cash equivalents		
Cash in hand	**631,742**	**438,360**
Investments Capital account	**731**	**2,734**
	632,473	**441,094**

Notes to the financial statements

For the year ended 31 July 2023

1. Accounting policies

a) The financial statements have been prepared under the historical cost convention, as modified by the revaluation of fixed asset investments, and in accordance with applicable accounting standards and the Companies Act 2006. They follow the recommendations in the Statement of Recommended Practice, Accounting and Reporting by Charities. The accounting standards policies have been prepared under Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice) and SORP 2019. The Trustees confirm that the charitable company is a public benefit entity. The accounts are prepared in sterling pound and rounded to the nearest £1. The charity is a company limited by guarantee from 627 voting members incorporated on 15 July 1976 and registered as a charity on 20 December 1977. The objects of the charity are defined by its Articles of Association updated in March 2012. The International Glaucoma Association (IGA) is constituted both as a charity and as a company limited by guarantee and as such the members of its council are directors for the purposes of company law and trustees of the charity for the purposes of charity law. The powers of the council and the permitted activities of the association are described in its governing document, which is the Articles of Association. The International Glaucoma Association registered office is Woodcote House, 15 Highpoint Business Village, Henwood, Ashford, Kent, TN24 8DH.
In assessing the charity's status as a going concern, the trustees have considered a range of information in relation to the financial year ahead, including the recovery from the pandemic, the impact of the war in Ukraine on the UK economy, the charity's cash resources and known liabilities. Although the macro-economic situation is volatile and deemed to pose some risk to fundraised income, corporate support and rising staff costs, the trustees consider the charity to have adequate resources to continue operating an effective service for at least 12 months ahead and to meet its obligations as they fall due. The financial statements have therefore been prepared on a going concern basis.

b) Voluntary income received by way of subscriptions, donations and gifts are included in full in the statement of financial activities when receivable.

c) Income from legacies is accounted for on a receivable basis, recognised when entitlement to the income has been established and it is probable that Glaucoma UK will receive the amounts ascertained. This treatment is within SORP 2019 and Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). Sales income represents sale of goods excluding VAT where appropriate. Investment income is accounted for on an accruals basis.

d) Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

e) Unrestricted funds are donations and other incoming resources received or generated for general charitable purposes.

f) Designated funds are unrestricted funds earmarked by the Board of trustees for particular purposes. Within these funds is money awarded as grants, funding a range of research projects to develop more effective methods of glaucoma diagnosis and treatment.

g) Costs of generating funds relates to the costs incurred in fundraising activities.

h) Critical accounting judgements are used within these accounts as follows:

Residual legacy income debtors are valued

1. Accounting policies (continued)

at 85% of the expected value of the legacy when certain criteria are met and receipt is probable. Residual legacies that are over the material amount set by Glaucoma UK at £300,000 are recorded in the accounts at 100% once criteria is met and receipt is probable.

The support and governance costs are re-apportioned by staff time as explained in note (i). The staff costs attributed to each activity are reviewed each year when the new budget is set.

i) Resources expended are recognised in the period in which they are incurred. Resources expended include attributable VAT which cannot be recovered.
Resources expended are allocated to a particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function which includes finance and support and governance is apportioned on the following basis which is an estimate based on staff time of the amount attributable to each activity.

Support costs

Cost of generating funds	15%
Expenditure on charitable activities	81%
Research	4%

j) Grants awarded are charged to the Statement of Financial Activities in the year in which they are awarded and are subject to receipt of progress reports.

k) Governance costs are the costs associated with the governance of the charity, including constitutional and statutory requirements and costs associated with the strategic management of the charity's activities.

l) Monetary assets and liabilities in foreign currencies are translated into sterling at the Bank of England exchange rate for that day.

m) Investments held as fixed assets are revalued at market value at the balance sheet date. The Trustees consider that market value is a reasonably accurate representation of the fair value. The gain or loss for the period is taken to the statement of financial activities.

n) The fixed assets are held at cost less depreciation and any impairment. Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures, fittings and equipment	20%
Computers	33%

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

o) Stocks are stated at the lower of cost and net realisable value. In general, cost is determined on a first in first out basis. Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation. Provision is made where necessary for obsolete, slow moving and defective stock. During the year the charity received donated items that have been stated at fair value.

p) The charity contributes to a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. Contributions payable are charged as an expense in the SOFA (Statement of financial activities) within staff costs then shared between the SOFA categories by staff time within these activities.

q) Financial instruments assets and liabilities are valued in the accounts at fair value and are subsequently carried at amortised cost shown in Note 21.

r) Debtors are stated at their net realisable value after allowing for bad and doubtful debts. The recoverability of debtors is reviewed at year end and provision is made, either general or specific, based on value, age and composition of our year end debtor balance.

2. Voluntary income

	2023 Restricted £	2022 Restricted	**2023 Unrestricted £**	2022 Unrestricted	**2023 Total £**	2022 Total £
Donations and subscriptions	**2,567**	4,239	**253,461**	174,354	**256,028**	178,593
Corporate donations	**-**	-	**14,649**	1,841	**14,649**	1,841
Legacies	**35,449**	6,926	**1,178,520**	1,484,027	**1,213,969**	1,490,953
Total	**38,016**	11,165	**1,446,630**	1,660,222	**1,484,646**	1,671,388

3. Investment income

	2023 Restricted £	2022 Restricted	**2023 Unrestricted £**	2022 Unrestricted	**2023 Total £**	2022 Total £
Interest	**-**	-	**504**	79	**504**	79
Dividends	**38,024**	33,072	**143,210**	111,598	**181,234**	144,670
Total	**38,024**	33,072	**143,714**	111,678	**181,738**	144,749

4. Incoming resources from charitable activities

	2023 Restricted £	2022 Restricted £	**2023 Unrestricted £**	2022 Unrestricted £	**2023 Total £**	2022 Total £
Professional Engagement***	**87,975**	-	**-**	-	**87,975**	-
Christmas cards and glaucoma aids	**-**	-	**6,858**	4,654	**6,858**	4,654
Other income	**-**	-	**2,178**	6,561	**2,178**	6,561
Grants received*	**10,484**	14,409	**-**	62	**10,484**	14,471
	98,459	14,409	**9,036**	11,277	**107,495**	25,686

5. Grants received*

	2023 Restricted £	2022 Restricted £	**2023 Unrestricted £**	2022 Unrestricted £	**2023 Total £**	2022 Total £
National government grant - HMRC furlough scheme	**-**	-	**-**	62	**-**	62
Professor of Ophthalmology for Glaucoma and Allied Studies at UCL	**10,484**	15,551	**-**	-	**10,484**	15,551
The National Lottery - Community Fund **	**-**	(1,142)	**-**	-	**-**	(1,142)
	10,484	14,409	**-**	62	**10,485**	14,471

** The National Lottery - Community fund has an underspend during the year 2022 which was paid back to the National Lottery

*** UKEGS (The UK and Éire Glaucoma Society) conference was held later in the year 2022 so the income was deferred

6. Total Expenditure

	Cost of generating funds	Patient information and support	Professional information and support	Campaigning and advocacy	Glaucoma research	Finance and support	Governance	2023 Total	2022 Total
	£	£	£	£	£	£	£	£	£
Staff costs (Note 8)	107,077	382,904	129,311	40,514	26,720	105,980	43,264	**835,770**	**665,097**
Research grants (Note 9)	-	-	-	-	408,660	-	-	**408,660**	**364,945**
Regional outreach & helpline	-	16,915	-	-	-	-	-	**16,915**	**17,105**
Glaucoma aids & equipment	1,778	509	1,756	-	-	-	-	**4,043**	**6,142**
Awareness events, PR, social media & volunteering	-	4,542	60,445	57,326	-	-	-	**122,313**	**17,887**
AGM, annual lectures & trustee expenses	-	3,172	-	-	-	-	7,349	**10,521**	**10,460**
Fundraising	33,762	-	-	-	-	-	-	**33,762**	**20,066**
Premises & administration	-	79,357	-	-	-	122,357	-	**201,714**	**199,967**
Finance & professional	22,614	-	-	-	4,084	88,945	3,883	**119,526**	**177,436**
Expenditure	165,231	487,399	191,512	97,840	439,464	317,282	54,496	**1,753,224**	1,479,106
Finance & support reallocated	46,553	166,470	56,219	17,614	11,618	(317,281)	18,808		
Expenses including Finance & Support	211,784	653,869	247,731	115,454	451,082	-	73,304	**1,753,224**	1,479,106
Governance reallocated	11,433	40,855	13,807	4,326	2,853	-	(73,304)		
Total Expenditure	**223,217**	**694,754**	**261,538**	**119,780**	**453,935**	**-**	**-**	**1,753,224**	1,479,106

7. Net (outgoing)/incoming resources

This is stated after charging/crediting:

	2023 £	2022 £
Depreciation charge for the year - owned assets	**12,931**	9,188
Auditors' remuneration:		
audit	**4,300**	2,270
other services	**1,348**	-
Trustees expenses	**3,143**	1,700
Investment managers fee	**18,139**	15,029

Trustees expenses represent the travel and subsistence costs of 7 trustees for 11 meeting £3,143 (2022: £1,700). Within 2023 some Trustees meetings were still held virtually.

During the accounting year unclaimed Trustees expenses totalled £1,050 (2022: £247).

Donations totalling £597 were received from Trustees (2022: £645).

No trustees received remuneration for their services during the financial year.

8. Staff costs and numbers

Staff costs were as follows:

	2023 £	2022 £
Salaries and wages	**726,053**	578,325
Social security costs	**73,727**	57,936
Pension contributions	**35,990**	28,836
	835,770	665,097

Only one member of key management personnel earned £70,000 or more in the year.

	2023 £	2022 £
£60,000 - £70,000	**0**	1
£70,000 - £80,000	**1**	1

Pension contributions in respect of the above £60,000 full-time employee totalled £3,900 (2022: £4,805). NI contributions in respect of the above £60,000-£70,000 employee totalled £9,724 (2022: £12,640)

The calculated unspent staff holiday entitlement at year end was £14,430, (2022: £12,647).

The charity contributes to a Royal London defined contribution pension scheme for employees.

The Chief Executive Officer is the sole key management personnel having authority and responsibility for planning, directing and controlling the activities of Glaucoma UK.

The management remuneration policy considers the following factors:
cost of living, pay comparability, affordability, sustainability, and appropriateness. The ratio between the highest and lowest salary should be below 4.5:1 and the ratio between the highest and median (midpoint) salary below 3.5:1. As at 1 August 2023 these ratios were 3.4:1 and 2.3:1 respectively.

8. Staff costs and numbers (continued)

The average weekly number of employees (full-time equivalent) during the year was:

	2023 No.	2022 No.
Cost of generating funds	**2.46**	1.45
Patient information and support	**9.57**	9.61
Professional information and support	**2.52**	2.18
Campaigning and awareness	**1.16**	0.95
Research	**0.38**	0.30
Governance	**0.49**	0.58
Finance and support costs	**1.95**	2.23
	18.53	17.30

The actual number of staff (including part time and full time) at July 2023 was 26 (2022: 23) at year end.

9. Grants Awarded

	2023 £	2022 £
University College London's Institute of Ophthalmology - Glaucoma UK Chair Fund	**73,389**	65,523
Fight for Sight	**22,433**	1,500
Nottingham University Hospital NHS Trust*	**-**	57,301
University of Ulster	**-**	99,910
University of Edinburgh	**-**	45,271
Cardiff University	**49,293**	98,000
London School of Hygiene and Tropical Medicine	**24,760**	-
Queens University Belfast	**99,328**	-
University of Plymouth	**48,287**	-
Moorfields Eye Hospital NHS Foundation Trust	**96,082**	-
Anglia Ruskin University	**10,000**	-
Grants underspent by researchers	**(14,912)**	(2,561)
	408,660	364,945

These grants were awarded in accordance with the Glaucoma UK grants policy, and were awarded to fund research into the diagnosis and treatment of glaucoma.

The negative figure represents an underspend by researchers on grants awarded in previous years.
Conflict of Interest - Grant

* Charity Commission approval was sought and received during the year 2022 in relation to a research grant award to Nottingham University Hospitals Trust for which Glaucoma UK Chairman - Professor Anthony King - will be the lead researcher.

10. Taxation

The charity is exempt from corporation tax and income tax as all its income is charitable and applied for charitable purposes

11. Tangible fixed assets

	Computer equipment £	**Total £**
Cost		
At the start of the year	37,185	**37,185**
Additions in the year	-	**-**
Disposals in the year	-	**-**
At the end of the year	37,185	**37,185**
Depreciation		
At the start of the year	21,044	**21,044**
Charge for the year	12,931	**12,931**
Disposals in the year	-	**-**
At the end of the year	33,975	**33,975**
Net book value		
At the end of the year	**3,210**	**3,210**
At the start of the year	15,887	15,887

12. Investments

	2023 £	2022 £
Rathbones Core Investments fund for charities		
At 1st August 2022	**7,050,040**	7,053,444
Additions at historic cost	**167,503**	492,201
Disposal proceeds	**(225,476)**	-
Realised loses	**(7,710)**	-
Unrealised loses	**(124,368)**	(495,605)
Market value at the end of the year	**6,859,989**	7,050,040
Cash held as part of portfolio	**731**	2,734
Total	**6,860,720**	7,052,774

12. Investments (continued)

Investment management costs were £18,139 (£15,029 - 2022)

Glaucoma UK Ltd, Glaucoma International Ltd, Glaucoma Europe Ltd, and Glaucoma Association Ltd are dormant companies historically held by Glaucoma UK (the operating name of the International Glaucoma Association Limited) in order to protect the company identity and to give future flexibility in terms of the charity name. International Glaucoma Association hold 100% of all the dormant companies.

Glaucoma UK Limited number 04323894 total shareholder funds £1. Glaucoma Europe Limited number 04591043 total shareholders funds £1. Glaucoma International Limited number 04323990 total shareholders funds £1. Glaucoma Association Ltd number 05316092 shareholders funds £1.

13. Stock

	2023 £	2022 £
Goods for resale	**3,656**	3,768

14. Debtors

	2023 £	2022 £
Trade debtors	**18,956**	**38,823**
Legacy debtors	**1,315,702**	**1,084,911**
Prepayments and accrued income	**115,849**	**20,807**
VAT debtor	**-**	**3,597**
Doubtful debt provision	**-**	**(33,062)**
	1,450,507	**1,115,075**

15. Creditors: amounts due within one year

	2023 £	2022 £
Trade creditors	**65,276**	43,173
Obligations under grant agreements	**282,884**	123,857
Funds held as agent	**32,205**	24,514
Accruals & Deferred income	**264,469**	59,690
Vat & National Insurance liability	**2,698**	171
	647,532	251,404

Funds held as agent represent those held for UKPGS, for which Glaucoma UK provides administration and infrastructure support as shown in note 20.

16. Creditors: amounts due after one year

	2023 £	2022 £
Obligations under grant agreements	**254,556**	215,543

17. Analysis of net assets between funds

	Restricted funds £	Designated funds £	General funds £	**Total funds £**
Tangible fixed assets	-	-	3,210	**3,210**
Investments	1,518,802	4,387,968	953,950	**6,860,720**
Net current assets	-	-	1,438,373	**1,438,373**
Creditors: amounts falling due after more than one year	-	-	(254,556)	**(254,556)**
Net assets at the end of the year	**1,518,802**	**4,387,968**	**2,140,977**	**8,047,747**

18. Movements in funds

	At the start of the year £	Incoming resources £	Outgoing resources £	Other gains and losses £	Transfers £	**At the end of the year £**
Restricted funds:						
Chair fund	1,494,729	49,709	(76,772)	(29,906)	-	**1,437,760**
North East fund	13,076	-	(3,261)	-	-	**9,815**
Research fund	8,929	36,815	(45,744)	-	-	**-**
Folkestone Fund	3,733	-	-	-	-	**3,733**
Children and Young people's Support fund	8,784	-	-	-	-	**8,784**
London fund	7,577	-	(5,990)	-	-	**1,587**
Scottish Optom fund	9,321	-	-	-	-	**9,321**
UK & Éire Glaucoma Society	48,228	87,975	(88,401)	-	-	**47,802**
Total restricted funds	**1,594,377**	**174,499**	**(220,168)**	**(29,906)**	**-**	**1,518,802**
Unrestricted funds:						
Designated funds:						
Income Endowment	22,906	-	-	-	-	**22,906**
Equipment Replacement and Infrastructure Fund	460,000	-	-	-	-	**460,000**
Research investment fund	4,000,000	-	(100,000)	-	-	**3,900,000**
West Yorkshire Support fund	-	5,062	-	-	-	**5,602**
Total designated funds	4,482,906	5,062	(100,000)	-	-	**4,387,968**
General funds	2,081,887	1,594,318	(1,433,056)	(102,172)	-	**2,140,977**
Total unrestricted funds	**6,564,793**	**1,599,380**	**(1,533,056)**	**(102,172)**	**-**	**6,528,945**
Total funds	**8,159,170**	**1,773,879**	**(1,753,224)**	**(132,078)**	**-**	**8,047,747**

18. Movements in Funds (continued)

Purposes of restricted funds

The Chair fund is used to fund the post of Professor of Ophthalmology for Glaucoma and Allied Studies at University College London.

The North East fund was established following receipt of a legacy and is restricted to supporting our work in the North East of England.

The Research fund represents donations, charitable trust and legacies income received specifically to fund glaucoma research. The fund was drawn on throughout the year as detailed on Note 9.

The Folkestone fund comprises legacy income restricted to work in Folkestone.

The Children and Young People's Support fund comprises income donated for services for young people affected by glaucoma and their families and carers. It aims to help us better understand their particular support needs and deliver appropriate services in response.

The London fund is restricted to the London area, and has been used mainly for awareness raising and support work with BAME communities at greatest risk of glaucoma sight loss.

The Scottish Optom training fund is charitable trust income earmarked for eye drop adherence training for optometrists across Scotland. Following delays due to Covid-19 and changes to the professional training landscape in the intevening period, we have now developed new training courses for optometrists and other staff in optical practices. We are hoping to get this accredited by the GOC and roll out the training over the next two years.

The UKEGS fund comprises money for the work of the United Kingdom and Éire Society (UKEGS), a national scientific society that operates under the aegis of Glaucoma UK.

The designated income endowment fund represents the donation of shares which form the basis of a stock market portfolio, which will eventually provide for the running costs of the association.

The designated Equipment Replacement and Infrastructure fund is held to cover the cost of equipment replacement, infrastructure development, premises costs and dilapidations.

The designated Research Investment fund aims to produce a reliable income stream specifically to fund the charity's research priorities in the years ahead.

The West Yorkshire Support fund was set up by the trustees from a legacy our charity received which the legator expressed interest in the funds being used towards any general activities we have in the West Yorkshire area. This aligned with Glaucoma UK setting a new project this year for funds to be awarded for establishing or developing Glaucoma support groups in areas of greatest need or with greatest potential for impact.

19. Operating lease commitments

The charity had annual commitments at the year end under operating leases expiring as follows:

	Property	
	2023	2022
	£	£
Within one year	**34,000**	**34,000**
Within 1 - 2 Years	**-**	**34,000**

The total future minimum lease payment is £34,000

20. Related parties

Included in Note 15 are funds due to related parties held for the UK Paediatric Glaucoma Society (UKPGS) of which we provide administration and infrastructure support. One Glaucoma UK Trustee is also a UKPGS trustee during the financial year.

Financial Statement of UKPGS	**2023**	2022
	£	£
Income	**26,385**	12,030
Expenditure	**(18,694)**	(10,093)
Closing balance	**7,691**	1,937
Balance brought forward	**24,514**	22,578
Total funds held	**32,205**	24,514

Included in Note 9 Grants awarded is a Related party transaction being grant awarded to Nottingham University Hospitals Trust for which Glaucoma UK Chairman Professor Anthony King will be the lead researcher. The balance outstanding to this grant is £57,301 which is the full grant awarded.

21. Financial Instruments

Financial Debt instruments measure at amortised cost	**2023**	2022
	£	£
Trade debtors	**18,956**	38,823
Legacy debtors	**1,315,702**	1,084,911
Prepayments and accrued income	**115,849**	20,807
VAT debtor	**-**	3,597
Doubtful debt provision	**-**	(33,062)
	1,450,507	1,115,075

Financial instruments measured at amortised cost		
Trade creditors	**65,276**	43,173
Obligations under grant agreements	**537,440**	339,400
Funds held as agent	**32,205**	24,514
Accruals & Deferred income	**264,469**	59,690
Vat & National Insurance liability	**2,698**	171
	902,088	466,947

Glaucoma UK
Woodcote House
15 Highpoint Business Village
Henwood
Ashford
Kent TN24 8DH

Phone: 01233 64 81 64
Email: info@glaucoma.uk
Website: glaucoma.uk

Glaucoma UK is the operating name of the International Glaucoma Association Limited.
Charity registered in England and Wales No. 274681 and Scotland No. SC041550

Company Registered in England & Wales no. 1293286

INTERNATIONAL GLAUCOMA ASSOCIATION LIMITED

England & Wales - Charity number 274681

Accounts

The International Glaucoma Association operating as **Glaucoma UK**

Report and Financial Statements

for the year ending 31 July 2022

Glaucoma UK

2021/22

Contents

	Page
Welcome from the Chair	**2**
Our Vision and Objectives	**3**
How Our Support Counted in 2021/22	**6**
Strategic Report - Performance and Achievement	**7**
Campaigning and Raising Awareness	7
Providing Advice and Support	12
Funding Research	18
Fundraising Review	**20**
Looking Forward	**22**
Our Finances	**23**
Financial Review	23
Reserves Policy	24
Going Concern	25
Investment Policy	26
Governance and Leadership	**27**
Trustees, Advisors and Staff	27
Structure and Management	28
The Board and Committees	28
Statement of Public Benefit	29
Related Parties and Connected Charities	29
Risk Management and Internal Control	30
Remuneration Policy	31
Statement of Trustee Responsibilities	32
Independent Auditor's Report	**33**
Financial Statements	**36**

Welcome from the Chair

Professor Anthony King, Consultant Ophthalmologist and Glaucoma UK Chair

“It is a pleasure and a privilege to have taken over as Chair at Glaucoma UK at such an exciting time. Having invested in additional staff capacity for community work, professional engagement and data insight, we are in a great position to understand where our work makes the most difference… and do more of it.”

As I seek to help guide the charity, I am very conscious that I am building upon the excellent work of my predecessor, Professor Philip Bloom, who was a Trustee for seven years and went on to lead the organisation as Chair for a further five. His energy and commitment were integral to the charity’s development during that time and his extensive professional knowledge and expertise proved invaluable.

Similarly, we also said goodbye to our Chief Executive Officer (CEO), Karen Osborn, in January 2022. During her five years with Glaucoma UK, Karen worked tirelessly to improve processes and ensure the charity was in the best possible shape to expand its reach and help more people. I extend my thanks to Philip, to Karen and also to Claire Cardy, who served us with enormous energy and commitment as interim CEO between January and April 2022. I look forward to working with our new CEO, Joanne Creighton, as we seek to play our parts in taking the organisation forward.

Having been a trustee of Glaucoma UK for five years, I am well aware of the extraordinary, mutually supportive community that surrounds the charity. And the members of that community are absolutely at the heart of this report. We simply could not do what we do without the generosity of our donors, the loyalty of our membership, the dedication of our staff and volunteers, the tireless efforts of those who fundraise for us and the knowledge and commitment of our Board and Clinical Advisory Panel. I thank them – one and all – for all they do, year after year, to make this a charity of which we can all feel very proud.

Our Vision and Objectives

What is glaucoma?

Glaucoma is a complicated group of eye diseases that damage the optic nerve. Left untreated, glaucoma will lead to irreversible sight loss and even blindness.

Most people experience no symptoms in the early stages and most glaucoma is picked up during a routine eye examination.

Over 700,000 people in the UK are affected by glaucoma and it is estimated that almost half of those are unaware they are living with the disease. This is because almost a third of the adult population is failing to have an eye test every two years as recommended, despite research telling us that sight is the sense people most fear to lose. Getting that message across is crucial, as early detection and appropriate treatment will enable most people with glaucoma to retain useful sight for life.

What can Glaucoma UK do to help?

Glaucoma UK is a membership charity with over 4,000 members, including those living with glaucoma and the professionals who support them. Although members benefit from our quarterly 'Insight' magazine, support is provided free of charge to anyone who needs it and you do not need to be a member to access our services.

People with, or at risk from, glaucoma and related conditions are at the heart of our activities and we aim to represent their views at national level and tailor our services to their support and information needs. Services we provide include a helpline, information guides and leaflets, online webinars, face-to-face support groups and events, as well as professional support for those working in glaucoma treatment and care.

What are the challenges we face?

Research from the Royal College of Ophthalmologists has shown that the number of people with glaucoma is increasing due to the ageing population. One in 10 people aged 75 or over are affected by glaucoma and the total number of people living with glaucoma in the UK is expected to increase by nearly a third between 2020 and 2035. And with ophthalmology services experiencing the greatest post-COVID backlog of any NHS specialty, the pressures on glaucoma detection, treatment and monitoring have never been greater.

There is a particular need to help raise awareness among those groups who are at highest risk of developing the disease, including people with a family history of glaucoma and people of African-Caribbean origin. Work is also required to tackle the impact of health inequalities in glaucoma care, especially the increased prevalence of undetected cases in areas of social deprivation.

Our vision

At Glaucoma UK, our vision is an end to preventable glaucoma sight loss.

Our strategic objectives

In working towards our vision, three areas of strategic focus underpin our work:

1. Campaigning and awareness

We want everyone in the UK who is living with glaucoma to receive swift and appropriate treatment. Our principal objective is to encourage people to have their eyes tested every two years, unless advised otherwise by their healthcare professional.

We want the voice of people living with glaucoma to be heard by those who provide treatment, design care pathways and commission services.

2. Providing advice and support

We want those living with glaucoma to have the support they need to live well. Lifelong glaucoma treatment can be complex and challenging, with some individuals finding the treatment worse than the disease itself. Many do not fully understand glaucoma, which means that making choices and effectively managing their treatment can be difficult. At Glaucoma UK, we want to address this information gap with the right help and advice, delivered in the right way, at the right time.

We want all those involved in delivering glaucoma care to have up-to-date information and access to effective professional networks for sharing best practice. Through our administration and support for the United Kingdom and Éire Glaucoma Society (UKEGS) – which became part of Glaucoma UK in 2019 – we want to bring together scientists and clinicians in a vibrant, aspirational scientific community. Through the work of our Professional Engagement Leads we play a key role in making connections that can help to promote, protect and safeguard the interests of people living with - or at risk of - glaucoma.

3. Funding research

We want to understand what causes glaucoma, how it can be prevented, what are the most effective treatments and – ultimately – how it could be cured. High quality research is needed to end glaucoma sight loss, so we are committed to funding studies that will help to test new medical and surgical models and explore new ways of working. By funding the Professor of Ophthalmology at University College London and working with partners including the Royal College of Ophthalmologists and the charity 'Fight for Sight', we aim to deliver a research programme that will have a real impact for the people we serve - now and in the future.



How our support counted in 2021/22

This year we have provided **329,527** instances of support.

Our highlights included:



90,819 ▲30%
Booklets provided (82% of these were for the NHS)

5,737 ▲25%
HealthUnlocked posts and responses

717 ▲18%
Digital glaucoma support group attendees*

67 ▲22%
Buddy pairings

189,710 ▲33%
Views of our website support pages

2,352 ▲42%
Helpline enquiries

▲X% means increase on previous year
Data covers 01.08.2021 – 31.07.2022

* Comparative data for face-to-face glaucoma support groups is unavailable due to COVID-19's impact on this service.

Strategic Report 2021/22 – Performance and Achievement

Campaigning and Raising Awareness

Our main priority for the year was to continue to develop and deliver our data-driven communication strategy to ensure that our key messages achieved maximum impact and value for money.

Using data insights

With the help of our new Data Insight Lead, we have developed a new analytics dashboard which brings together information from a range of sources and provides important live data. Alongside being used for impact reporting, the dashboard enables us to identify and respond quickly to unusual patterns of activity on our digital platforms such as bot activity which could be harmful or distort our reporting.

We also invested in a new software tool that gives us visual insights into how people are navigating and using our website. This information has allowed our communications team to identify opportunities for optimisation and prioritise development on the site to improve the user experience and accessibility.

For example, we identified that some people were having trouble moving through the website because the call-to-action buttons were too small and difficult to click for some users. The communications team addressed this by significantly increasing the clickable area to make the user experience more intuitive and improve accessibility.

Search visibility

A key focus for our communications team this year has been to improve the search visibility of the charity's website.

Visibility is directly related to search engine rankings. The higher our website ranks on a search engine result page for relevant keywords; the more likely people will see it and click through to our website.

The communications team have undertaken a range of tasks this year with the aim to increase the number of people visiting the Glaucoma UK website from both organic search and paid search.

In 2021, our Digital Communications Officer applied to the Google Ad grant scheme and was successful in securing $10,000 of free advertising a month. Google Ads enable organisations to serve adverts to people who are searching for keywords. For example, if someone searches for 'driving and glaucoma', we can serve them an ad to appear at the top of the search results meaning they are more likely to click on it and visit our website. In the previous year, only 656 sessions on our website came from paid searches. Following our successful application for the Google Ad Grant, 10,122 sessions came from paid search results. Of those, over 7,500 were new users who had not visited the site before.

The team also undertook activities, such as reviewing user experiences on our website and making improvements, creating new high-quality content, and encouraging incoming links, with the aim of improving organic search results.

During the year, we improved our rankings for six of the 10 keywords related to glaucoma which we monitor and track. These improvements saw our organic search results increase by approximately 39%.

Membership and supporter newsletters

Our community of over 4,000 members is at the very heart of our charity and is crucial to our success.

Members support our work in all sorts of ways, from taking part in surveys, focus groups and consultations, to sharing their personal experiences and supporting our fundraising efforts. The insights we receive from our members keep us connected to the reality of living with glaucoma and help to ensure that our efforts are always focused on the things that matter most.

Insight magazine, our quarterly membership publication, continues to be a popular and useful resource for our membership. Featuring a range of content including in-depth discussions about glaucoma treatments, the latest research, upcoming events and other relevant news, members often get in touch to share their thoughts after each edition. Here are a few highlights from the feedback we received this year:

> **"Enjoyed reading latest Insight, very interesting, and some complicated issues clearly explained. Excellent!"**

> **"Another really excellent edition of the magazine. Well done to you and the team! I read it from cover to cover – it was my bedtime reading. That in itself is amazing, as generally, with other books, etc – no matter how much I want to stay awake, I fall asleep! […] I really appreciate the "balance" of the information – some very personal, some quite medical and technical, but all very accessible. That really is an achievement."**

Last year we launched Focus - a new digital support newsletter. The number of subscribers to this newsletter has grown to over 1,300. With its mix of news, information and practical advice, Focus is a key tool in our mission to convey our message as cost-effectively as possible to the widest possible audience.

Social media

We have maintained a social media presence across Facebook, Twitter and LinkedIn with regular organic content designed to raise awareness of the disease, provide information to live well with glaucoma and advertise the support we can provide. We have also made a conscious effort to feature more stories from the people we support and those who support us with fundraising efforts.

Glaucoma Awareness Week

Glaucoma Awareness Week is an annual awareness-raising opportunity coordinated by Glaucoma UK where we encourage people across the UK to talk about glaucoma and find out more about the disease.

Our 2022 campaign encouraged people to put their sight in the spotlight. With the number of people living with glaucoma in the UK expected to increase by nearly a third between 2020 and 2035, we developed a campaign which urged people to get their eyes tested.

We created and made public a range of resources for people to use both online and in person to help us spread this message to new audiences including two limited edition printed poster designs, a suite of social media imagery, Zoom/Teams backdrops, and a template press release which people could use to promote their own Glaucoma Awareness Week activities.

Alongside our organic content, we launched a small set of Facebook Adverts with the aim of increasing awareness beyond our existing audience about the need to have regular eye tests. We also used adverts to encourage sign ups to our communications channels such as our e-newsletter, Focus.

Our Glaucoma Awareness Week social media adverts reached 52,304 people with a spend of just £240. On average, posts during the campaign week were shared 10 times more than posts in the previous months.

We also worked also with partner organisations to maximise the reach of our social content during the week, including staging Twitter takeovers on their accounts to help us reach new audiences.

A key feature of our campaign was our nationwide radio day which achieved 21 hours of airtime across stations with a collective audience of over 42.5 million listeners. Our interviews featured our Chief Executive and our Head of Support Services talking about the disease, the importance of having regular eye tests and the support available for people living with glaucoma. The average interview lasted over nine minutes which is testament to the skill of our media representatives and interest in the campaign messages.

A successful PR campaign also secured significant coverage in national and regional publications, including The Optician, Eye News, Optometry Today, Oldham Evening Chronicle, Sunderland Echo and Essex Magazine.

Media activity

In addition to our Glaucoma Awareness Week campaign about the importance of eye tests and rising cases of glaucoma in the UK, we secured media coverage for a range of PR initiatives throughout the year, including the launch of our new 'Easy read: putting in your eye drops' guide, information about the hereditary nature of the disease and the winner of our Excellence in Glaucoma Care Awards.

We also provided comment for third-party press activity throughout the year, including the campaign by the Driver and Vehicle Licencing Agency (DVLA) to make motorists aware they must be able to read a number plate from 20 metres away and several awareness campaigns by Specsavers.

We placed adverts in numerous publications, including the East Kent Hospitals magazine, Vista magazine, The Times, a supplement in The Guardian newspaper, Health and Wellbeing magazine and New Scientist magazine.

We were also involved in the Ashford International Jubilee Project to celebrate HM Queen Elizabeth II's 70 years of service. Our commemorative Glaucoma UK artwork was displayed as stained glass along the main walkway of Ashford International train station, one of the largest train stations in Kent, which is used by 3.6 million passengers each year.

Brand awareness

Results of our second annual brand awareness survey showed that awareness levels had increased during the year, with 10% of the survey sample being aware of Glaucoma UK and its work. The survey also provided the following helpful insights:

- Increasing numbers of people are aware of Glaucoma UK as a result of media coverage (radio / press articles).
- There is a positive correlation between general glaucoma knowledge and having an eye test in the last two years.
- There was a high level of 'spontaneous' (unprompted) awareness of glaucoma, with over half of the respondents naming it as the first eye condition they could think of.
- The most commonly held misconceptions about glaucoma are that it can be cured and that it is not possible to drive with the condition.

The survey will be conducted at the same time next year as part of our drive to capture longer-term data trends.

Sharing personal stories

Given the importance of relatability in messaging about glaucoma and its impacts, much of our awareness-raising work during the year focused on the stories of those living with the disease. We added 23 new case studies to our growing resource bank, which now contains the shared experiences of over 60 individuals. Almost half of these new case studies were added to the 'Your stories' page of our website and shared on our social media channels. Engagement levels on these posts were high, prompting others to get in touch and share their own perspectives and experiences. Case studies were also featured in Insight magazine and in Focus to help support Glaucoma UK's fundraising activities and promote our services.

Case study volunteers supported our work as speakers at digital glaucoma support groups and shared their glaucoma experiences during a virtual parliamentary roundtable event hosted by Lord Low in the early part of the year. They also supported campaign work for Glaucoma Awareness Week and National Eye Health Week. We are hugely grateful for the generosity of those who help us in this way.

Representing the glaucoma community

As part of our drive to represent the voice of people living with glaucoma to those providing treatment, designing new models of care and commissioning services, we played an active role in a number of sector collaborations during the year.

These included the VI (Visual Impairment) Sector Partnership, the National Institute for Health and Care Excellence (NICE) committee for glaucoma guidance and NHS Scotland and the Scottish Government's launch of www.eyes.scot.

We also helped our beneficiaries to engage with a range of patient consultations, including the development of a National Low Vision Service for Scotland, new NICE guidance on ab interno canaloplasty, and the National Institute of Health Research (NIHR) priorities for glaucoma research in the period 2022-27.

Providing Advice and Support

The investment in additional capacity for our Development Managers and a Professional Engagement Lead job-share role offered an exciting opportunity for our Support Services team to reflect on existing provision and explore new areas for growth and innovation. In addition to essential groundwork for future strategic development, the team achieved an increase in patient contact throughout the year, with more - and better - opportunities to provide information and advice to those who needed it.

Helpline

Our glaucoma helpline, which operates every weekday, remains a cornerstone of our provision. Enquiries increased by 42% on the previous year, with support provided to 2,352 individuals. The most common discussion topic was the impact of glaucoma on driving and DVLA notifications, followed by the various surgery options and questions relating to the use and side effects of eye drops.

With the ongoing pressure on healthcare systems impacting on the frequency and duration of eye health appointments, the ability to access practical advice and emotional support is invaluable to many of the individuals who contact us. We recognise the path from diagnosis to living well with glaucoma is not a linear one for most people and our helpline continues to play a key role in helping people find the answers and reassurance they need, at every stage of their diagnosis and treatment. The following feedback received during the year helps to highlight the crucial role played by our Helpline Advisers:

> **“Thanks a lot for your prompt responses... This session really soothed my mind a lot.”**

> **“I would like to thank you very much for being there when needed.”**

> **“I am sending the biggest cyber hug ever. I have tears running down my face in appreciation of your response.”**

> **“I can't begin to thank you enough for your email - it is so understandable and has taken away much of the fear and concern that I've carried around with me since seeing the optician.”**



HealthUnlocked

Our online glaucoma community on HealthUnlocked (www.healthunlocked.com/glaucoma-uk) has continued to grow during the year, with membership reaching 1,169 - a very encouraging increase of 81% on the previous year. A total of 5,737 connections were made between forum users, sharing insights, experiences and providing peer-to-peer support. The exchanges on the forum are overseen by our Helpline Advisers, who help to provide additional advice and information where it is needed. Plans to increase capacity within our Support Services team in 2023 will enable us to engage even more actively with the HealthUnlocked community, including better signposting for users to other relevant Glaucoma UK services.

Digital glaucoma support groups

Following their successful introduction during the COVID-19 pandemic, the delivery of digital glaucoma support groups continued in 2021/22. We saw a 20% increase in registrations on the previous year and over 700 attendees joining sessions on a wide range of subjects, including:

- Glaucoma-friendly yoga
- Changing glaucoma care – virtual clinics and community monitoring
- Glaucoma and genetics
- Glaucoma in focus – normal tension glaucoma
- Minimally invasive glaucoma surgeries
- All about eye drops
- Glaucoma and driving
- Who can help if I'm losing my sight to glaucoma?

In addition to these topics, we achieved our objective for the year to run more sessions involving patient speakers describing their experiences and taking questions from the audience. Feedback from participants has revealed that our digital glaucoma support groups are a valuable source of information, comfort and confidence for attendees:

> **Many, many thanks to you, Glaucoma UK for your brilliant webinar! It answered many questions for me and joined up so many previously disconnected bits of information. I feel so much happier, more confident and in control of my condition now that I will certainly be less apprehensive when I go for my appointments at the hospital."**

> **I would like to say thank you for the webinar yesterday, during this dreadful pandemic isolated and with difficulty accessing medical attention the meeting yesterday gave me confidence to use pain relief medication."**

> **I feel a lot more positive so a big thank you."**

> **As usual a most enjoyable zoom with pharmacists and reassuring information."**

> **I have been suffering from glaucoma for 10+ years and this is the most useful thing I have ever heard within this time. To hear it from someone else who can share their own experiences has been so much more beneficial than the NHS staff who have not been able to put it into words that mean much to me."**

> **Wonderful webinar, very informative and delivered very well. I have learnt so much which will allow me to support clients moving forward."**

> **That was a fact-finding fabulous zoom, I learnt so much as well."**

A staggering 99% of attendees would recommend our digital glaucoma support groups to other people affected by glaucoma, and around nine out of 10 attendees feel the sessions are informative, clear and easy to understand.

Face-to-face support

Although digital interventions remain an excellent way to expand our reach and engage with larger numbers of beneficiaries in an efficient and cost-effective way, we remain committed to providing face-to-face support to those who need it. The threat of a new wave of COVID-19 infections dogged activity for the first half of the year, but it was rewarding to re-establish our community-based glaucoma support groups and other in-person events in the spring of 2022.

Considerable work was undertaken in the year to explore new models for increasing contact with our beneficiaries and to improve the management and evaluation of our regional engagement in the future. Over 10 months, our Development Managers consulted with people living with glaucoma, key professionals and staff to help inform a review of support group delivery and feed into a new strategy for optimising the education and empowerment of people with glaucoma in a rapidly changing healthcare environment.

Findings of the consultation revealed that bringing people together, facilitating relationships and creating a sense of 'togetherness' were integral to the delivery of our community-based support. Support groups may serve multiple functions including education, emotional support and social interaction. To maximise the reach of support groups and ensure that the benefits are experienced by a larger number of people, a new framework has been developed to facilitate delivery by health care professionals, with guidance, resources, oversight and ongoing support provided by the Glaucoma UK team. The new framework will be piloted in the coming year.

In broadening the scope of our face-to-face support, we remain focused on the importance of identifying and engaging those populations most at risk of glaucoma sight loss. Work in this area during the year has highlighted the need to leverage the right community, corporate and charity partnerships to increase our reach, as well as the importance of establishing effective impact measuring tools. These priorities will continue to underpin our strategic development in this area in the coming year.

Information booklets

Our suite of information materials remains an important resource for people living with glaucoma and those providing their care. Over 90,000 information guides were ordered during the year and 6,348 booklets were downloaded from our website. A new easy read guide - 'Putting in your eye drops' - was added to the portfolio in early 2022 and has become one of our most popular resources.

Plans to re-write and relaunch our full set of publications during the year were delayed by staff capacity issues. Following a resource review, a new health information manager role is to be introduced to take the project forward in 2023.

Professional engagement

Working in partnership with professionals to improve outcomes for people with glaucoma is a key strand of our charitable mission. The support we provide takes a range of forms, including the provision of information resources, recruiting patients for clinical trials, staff participation in research steering committees and free professional membership of Glaucoma UK.

Devolved health and social care across the four nations creates not just political differences but also variations in resource and methodology. The focus of our professional engagement work is to encourage the sharing of best practice and to spotlight glaucoma in a crowded health field. A key task is to prioritise the patient perspective and identify the areas where behavioural change for those providing glaucoma care can have the greatest impact.

Following a review and scoping exercise by our new professional engagement leads, an ambitious new strategy has been developed to more effectively address the communication, training and support needs of different glaucoma professionals. This approach recognises the significant overlap between different professional groups, while also acknowledging the development priorities for individual practitioners at different stages of the glaucoma treatment process. Although specialists may have occasional involvement, generalists may have more frequent or lengthier interventions. Carers, families and social care may ultimately have the greatest influence over whether someone feels able to effectively manage their own treatment and so the new strategy reaches beyond those in clinical roles.

The scope of Glaucoma UK's training programme (which was originally just for eye care liaison officers) became broader during the year, with training now available for rehabilitation officers, optometry units, sight support staff and carers. Work to deliver a new accredited training programme for optometrists is ongoing and we are currently reviewing how best to utilise the programme funding in light of changes in glaucoma care and optometry training requirements since the inception of the project.

The development of new 'eye drop support boxes' was a major focus for 2021/22, with boxes now being dispatched to NHS and not-for-profit organisations across the UK. These boxes are a vital tool for eye care professionals to help people manage their eye drop regime and live well with glaucoma. They also provide an invaluable Glaucoma UK presence out in the community. Availability of the boxes will be expanded in the future to include sale to commercial optometrists and pharmacies.

A major focus of our professional engagement activity is our work with the UK and Éire Glaucoma Society (UKEGS), which officially merged with Glaucoma UK in 2019. UKEGS is a national scientific society which aims to bring glaucoma specialists together in order to stimulate research and protect the interests of people living with - or at risk of developing - the disease. With a current membership of approximately 500, the Society's annual conference is an important vehicle for networking and knowledge exchange. The ongoing threat of COVID-19 led to the postponement of the conference during the year, but the rescheduled event for October 2022 – focusing on 'Safety and success in glaucoma care' – attracted 260 delegates and speakers to an informative and thought-provoking two-day lecture programme.

Volunteering

We continued to recruit volunteers to our 'buddy' scheme during the year and now have a bank of 39 individuals who can be called upon to share their experiences of various clinical procedures with others who may be facing glaucoma surgery. The reassurance and emotional support provided by our buddies is invaluable in helping people to make informed choices about their glaucoma treatment and we are most grateful to them for their commitment to our charity. In preparation for growing and broadening the scope of our buddy scheme, work was undertaken during the year to review all procedures relating to volunteer risk management, training provision, data management and safeguarding. We hope to widen the scope of our buddy scheme to include recruitment of buddies with sight loss, those who are newly diagnosed and those with congenital glaucoma.

Volunteers also play a vital role in providing insight and feedback to help inform our work. We are grateful to the members of our Readers Panel and Consultation Panel who give their time to review and comment upon research proposals, NICE guidance and the content of our information booklets.

Funding Research

The delivery of an annual research programme is a key charitable objective for Glaucoma UK and is an essential part of our mission to improve the detection, care and treatment of glaucoma. Following the disruption of the pandemic, it was encouraging to see all delayed research studies being resumed during the last year.

Completed projects

The findings of a Glaucoma UK funded 2015 RCOphth Award Project to investigate the quality of life at different stages following glaucoma surgery were reported in July 2022. Led by Professor Anthony King of Nottingham University Hospital, the project measured the experiences of 154 patients following a trabeculectomy operation. The study concluded that health-related quality of life is affected negatively in the immediate post-operative period but returns to normal by the third month after surgery. Restrictions in physical and social functioning as well as physical and emotional role limitations were the factors that contributed most to the fall in health-related quality of life. There were no significant variations in quality of life for general health, mental health, pain or vitality. The study has provided important information that may be used to reassure and prepare future trabeculectomy patients.

We were also presented with the findings of the Glaucoma UK funded UKEGS Award study from 2015, exploring the application of virtual reality (VR) technologies for conducting perimetry tests. In her research, Dr Jenny Bosten of the University of Sussex, set out to demonstrate the potential advantages of VR for more frequent monitoring, ease of use in the home and increased accessibility for patients with impaired mobility. The study found that there was no substantial difference in reliability between the new test using a head mounted display and the standard clinical assessments for patients with glaucoma.

Next steps include seeking further funding to refine the test to make it more accessible for those living with dementia and to undertake trials in international settings where standard clinical equipment is unavailable.

New awards

The following new grants were awarded in the year:

- £98,000 - PhD Studentship, Dr Ben Mead, Cardiff University Hospital 'Exosomes as a therapy for glaucoma' starting October 2022.
- £45,271 - Open Call Award, Dr Andrew Tatham, Princess Alexandra Hospital, Edinburgh, 'Evaluation of a new low-cost applanation tonometer (Newton)' starting October 2022.
- £99,910 - Royal College of Ophthalmologists Award, Professor Colin Willoughby, Ulster University, 'Development of a disease modifying biologic therapy' starting April 2023.
- £57,300 - Royal College of Ophthalmologists Award, Professor Anthony King, Nottingham University Hospital, 'Translating the complications of glaucoma surgery into meaningful everyday consequences for glaucoma patients' starting November 2022.

Chair of Ophthalmology

A significant element of the charity's research strategy is the ongoing financial support of the Glaucoma UK Chair of Ophthalmology for Glaucoma and Allied Studies at UCL. Ranked in the top ten of the 'Ophthalmologist Power List 2020', Professor David (Ted) Garway-Heath is a global leader in ophthalmology research. His achievements for the year include:

- The award of a major new grant of £1.9 million by the NIHR for a clinical trial to test the effectiveness of vitamin B3 as a treatment for glaucoma, which may actually help to improve vision, rather than just prevent deterioration. The study, for which Professor Garway-Heath is chief investigator, will start in January 2023 and patients will be recruited from seven centres across the UK.
- The delivery of seven ongoing grant projects, including, "Identifying the genetic basis for heritable normal tension glaucoma, with a focus on mitochondrial function" and "The association between mitochondrial function and glaucoma – identifying susceptible patients".
- Sixteen peer-reviewed scientific publications, including British Medical Journal and Journal of the American Medical Association.
- Strategic input to the planning, structure and programme of the 15th biennial Congress of the European Glaucoma Society (EGS).
- Mentor to an NIHR lecturer at Moorfields Eye Hospital/UCL Institute of Ophthalmology as part of the NIHR Clinical Lectureship Post-Doctoral Award.
- Primary supervision of three PhD students and mentor to three research fellows from Italy, Spain and Japan.
- EGS Ambassador to the American Glaucoma Society, with the aim of strengthening the links and collaborations between the two societies in terms of the education and training of ophthalmologists.
- Delivery of 19 national and international lectures, including three keynote speeches.

Fundraising Review

Voluntary income during the year consisted of subscriptions for our membership scheme, one-off gifts, regular giving, in memoriam donations, legacies, corporate support, supporter challenge events, Christmas card sales and a weekly lottery.

Total fundraised income was £1,816,137, with legacies accounting for over 80% of the total income. Legacy gifts remain a lifeline for the charity and the work we do. We are indebted to all those, past and present, who have remembered Glaucoma UK in their will.

General donations and subscriptions fell by £12,995 on the previous year (2022: £178,593 – 2021: £191,548). Corporate donations were also down (2022: £1,841 – 2021: £27,000), reflecting the uncertainty of the wider economic climate and also the requirement to focus fundraising resource on higher than usual levels of legacy administration during the year.

In its second year of operation, our weekly lottery showed a pleasing level of growth, generating income of £16,034 (2021: £6,731) with associated costs of £7,167 (2021: £3,009) consisting of prizes and scheme fees. As part of the one-year anniversary celebration for the Glaucoma UK Lottery, we were able to share the story of a £1,000 New Year's Eve winner in Insight magazine and on social media, encouraging 39 new players to sign up.

We were delighted with the response to our Glaucoma Awareness Week appeal in June, which focused on the personal story of someone living with glaucoma and the importance of the support they received from Glaucoma UK. Over 130 individuals were moved by the appeal, making donations totalling £14,856.

We were grateful to our supporter Keith Barton, who cycled from London to Paris to raise funds for the charity. A consultant ophthalmologist and former Glaucoma UK Chair, Keith has been a career-long advocate of the charity and its work. Achieving the feat in less than 24 hours, Keith raised a remarkable £9,580.

We would also like to take this opportunity to thank the following organisations for their support during the year:

- Harry and Gertrude Landy Charitable Trust
- The Dandy Charitable Trust
- Wyseliot Rose Charitable Trust
- The Emily Weircroft Charitable Trust
- The Wyndham Charitable Trust
- Spire Little Aston Hospital
- Specsavers UK
- Thea pharmaceuticals

All fundraising was carried out by Glaucoma UK staff and no external fundraisers were used. We employed one fundraiser during the year (Head of Fundraising) who is an Institute of Fundraising member. A new Legacy and Supporter Relationship Officer joined the team in the autumn of 2022. This will increase capacity and allow the Head of Fundraising to give more time to the diversification of income to reduce the current reliance on legacy gifts.

Glaucoma UK is registered with the Fundraising Regulator and follows the Code of Fundraising Practice. We comply with the key principles embodied in the Code and are committed to the Fundraising Promise. Our website carries our complaints policy for the public and explains clearly how an individual may raise a concern. We received no complaints from August 2021 - July 2022. We are also registered with the Fundraising Preference Service so that individuals can opt out from receiving fundraising communications, should they wish. We received no such requests during the year.

At Glaucoma UK, we strive to treat all donors and the public fairly, showing sensitivity and adapting our approach, depending on supporters' needs. In line with Institute of Fundraising guidance, we ensure that all reasonable steps are taken to protect vulnerable adults and take care not to use any imagery or language that could cause distress or anxiety.

Glaucoma UK monitors any third parties working with us to help raise funds, ensuring that they adhere to the Code of Fundraising Practice and comply fully on both a legal and ethical level with the objectives of Glaucoma UK. We ensure that third parties are operating to the highest possible standards of respect for the personal data and wishes of our supporters and prospective supporters.

Fundraising activity is closely monitored using a range of financial and non-financial data, including return on investment, comparison with sector benchmarks, and against the standards set out in our Ethical Fundraising Policy and Supporter Promise. One of our Board members is a Fundraising Trustee Advocate, to ensure oversight of our fundraising activity at the highest level.

Looking Forward

The theme of last year's annual report was 'expansion' and - despite the disruptions caused by a change of leadership and the unsettled operating environment – we achieved success across a number of areas. We increased the capacity of our Support Services team, helped more people on our helpline, welcomed more people to our digital glaucoma support groups, recorded more visits to our website and helped to inform more people through wider circulation of our 'Insight' and 'Focus' publications.

We know, though, that the number of people living with glaucoma in the UK is continuing to rise and the devastating legacy of the pandemic continues to be felt within the eye care system. So, there is no room for complacency. To further maximise our impact in the most cost-effective way, our key priority for the coming year is to finalise and implement a new organisational strategy that moves us as quickly as possible to the achievement of our strategic vision – an end to preventable glaucoma sight-loss.

A new strategy map has been produced, setting out our vision, mission and strategic objectives, along with the enablers required to achieve them. This will be supported by a Theory of Change framework, to help to convert the strategic concepts into measurable work on the ground.

By supporting the identification, capture and dissemination of impact data, the Theory of Change process will help us to more readily demonstrate Glaucoma UK's value to beneficiaries, members, supporters and the wider professional community. Most importantly, it will ensure a shared understanding between all internal and external stakeholders about where and how the work of Glaucoma UK can make the greatest difference.

Our Finances

Financial Review

The financial year 2021/22 proved to be unpredictable and challenging in a number of ways. Although confidence grew during the course of the year with regards to the pandemic, activity levels continued to be constrained in the early months by the threat of a new wave of COVID-19. Just as tentative signs of social and economic recovery started to emerge in early 2022, a further period of economic turbulence began, prompted by the war in Ukraine and the UK's subsequent cost-of-living crisis. The charity ended the financial year with net income of £362,717, but investment assets were affected, resulting in a net movement of funds of -£132,888 due to unrealised investment losses of £495,605.

Incoming resources

Total incoming resources for the year were £1,841,823, representing an increase of £45,997 on the previous year (2021: £1,795,826). The impact of the wider economy was felt in some areas, particularly donations, subscriptions and corporate support, which collectively showed a £39,973 reduction on 2021 levels. Legacy income remained stable at £1,490,953 (2021: £1,412,867). We recognise that this is an uncertain and unpredictable income stream and continue to be extremely grateful for the generosity of those who remember Glaucoma UK in their wills. With no statutory funding received by the charity (with the exception of furlough scheme payments during the pandemic), such significant voluntary gifts help to give vital stability to our work. Legacies enable us to commit to the longer-term plans that are essential in achieving our ambitious vision to end preventable glaucoma sight-loss.

Income from charitable activities was £25,686, down by £40,217 on the previous year (2021: £65,903). This was mainly the result of postponing the annual UKEGS Conference until October 2022 in response to ongoing social distancing concerns in the first half of the financial year.

At £14,471, total income from grants received during the year was down by £32,923 (2021: £47,394). The Government's Job Retention Furlough Scheme came to an end in September 2021, with only £62 received during the year, compared to £19,368 during 2021. Income in the previous year was also bolstered by a National Lottery grant of £16,546. The project, which enabled us to research potential new models of digital support to help people stay connected during lockdown, was completed under budget and a repayment of £1,142 was made to the National Lottery Community Fund in 2022.

Resources expended

Total expenditure in the year rose by 41% to £1,479,106 (2021: £1,042,652). The principal area of growth was research, with a £254,512 increase in grant awards (2022: £364,945 - 2021: £110,443).

Staff costs also increased to £665,097 (2021: £582,119) following the investment in additional support services and data insights personnel. Total staff numbers at the year-end were 23 (17.3 full-time equivalent) compared to 20 (16.28 full-time equivalent) at the end of 2021. This continues a sustained period of investment in human resource, with staff numbers having grown from 12.7 full-time equivalent in 2018 – a key factor in the ongoing growth in range and quality of services we provide.

The requirement to contract an interim CEO for the period January to April 2022, along with professional support for data protection, legal advice, strategy development and senior management training, led to an increase in finance and professional fees of £101,780 on the previous year (2022: £177,436 – 2021: £75,656).

At £20,066, fundraising expenditure was down by £13,519 on 2021 levels. This reflects a reduction in fundraising events due the ongoing COVID-19 uncertainty in the early part of the year and the requirement to allocate more time and resource to legacy administration.

Glaucoma UK's restricted funds totalled £1,594,377 at the year-end. The majority of this figure (£1,494,729) represents the Chair Fund, which will support the Chair of Ophthalmology for Glaucoma and Allied Studies until his eight-year term comes to an end in 2026. Of the remainder, £48,228 is restricted to the work of UKEGS.

Reserves Policy

The policy of the trustees is to maintain at least the minimum level of cash reserves to meet the day-to-day needs of the charity, to provide secure, sustainable support for our beneficiaries and to ensure we can commit to ambitious long-term plans to end glaucoma sight loss.

The trustees recognise the risk to income posed by the reliance on legacy gifts and factors outside the organisation's control, such as pandemic and a backdrop of ongoing economic uncertainty. Having considered these factors, the Board of Trustees agreed to maintain a general reserve of 18 months' operating costs during the year. This will be reviewed during 2022/23 to ensure that the holding remains appropriate, given the emergence from COVID-19, while remaining mindful of the ongoing threat of recession and the associated risks of income and investment volatility. General funds totalled £2,081,888 (2021: £1,727,616) at the year-end, against an operating cost requirement of £2,128,664.

Designated funds totalled £6,564,794 (2021: £6,210,522), of which £4,000,000 was allocated to the delivery of a new research strategy, currently in development. An equipment and infrastructure fund of £460,000 was designated for the redevelopment of our office accommodation, to consolidate operations post COVID-19 and reduce overheads in the longer term.

Restricted funds of £1,594,377 (2021: £2,082,540) included £1,494,729 committed to funding the remaining 3-year term of the Chair of Ophthalmology for Glaucoma and Allied Studies at UCL. A total of £48,228 was restricted to the work of the UK and Eire Glaucoma Society (UKEGS), including the annual conference and research award. The remaining £51,420 represented funds donated or awarded for activity in specific areas and will be allocated as appropriate opportunities arise.

Going Concern

In assessing the charity's status as a going concern, the trustees have considered a range of information in relation to the financial year ahead, including the current status of the pandemic, the impact of the war in Ukraine on the UK economy, the charity's cash resources and known liabilities. Although the macro-economic situation is volatile and deemed to pose some risk to fundraised income, corporate support and staff costs, the trustees consider the charity to have adequate resources to continue operating an effective service for at least 12 months and to meet its obligations as they fall due. The financial statements have therefore been prepared on a going concern basis.

Investment Policy

Our Investment Policy is:

- To maximise total return subject to an agreed level of risk.
- To ensure that the charity's assets are invested widely and diversified by asset class and by security.
- To avoid direct investment in any companies manufacturing tobacco or tobacco products.
- To avoid investment in any companies that derive more than 10% of their revenues from the manufacture of alcoholic beverages, armaments, gambling, high interest rate lending or pornography.

The charity's assets are invested in the Rathbone Core Investment Fund for Charities, with management delegated to Rathbone Investment Management Ltd. The move from a mixed portfolio to a single, pooled fund in February 2021 enabled the charity to take advantage of lower management fees, ease of administration and a UK registered fund, with all income coming from the UK.

Responsibility for monitoring the performance of the investment portfolio is delegated to the Finance and Governance Committee and performance benchmarks are reviewed with the fund managers on an annual basis.

Investment assets showed a net loss of £18,376 at 31 July 2022. Although £492,201 was invested during the year, the total fund value fell by £495,605 as a result of ongoing market instability and the threat of recession. The trustees are aware that the economic uncertainty in relation to inflation and growth will continue for the foreseeable future and this has been taken into account in a review of the Investment Policy for the year 2022/23.

Governance and Leadership

Trustees, Advisors and Staff

The trustees (who are also directors under company law) are:

Professor Philip Bloom	Chair (to 11.03.22)
Professor Anthony King	Chair (from 11.03.22) Chair, Clinical Advisory Panel (to 11.03.22)
David Sanders	Hon Treasurer (to 22.06.22)
Prabhakar Sundaresan	Hon Treasurer (from 22.06.22)
Stephen Epstein	Vice Chair
Dr Winifred Nolan	Chair, Clinical Advisory Panel (from 11.03.22)
Teresa Borsuk	
Dr Roxanne Crosby-Nwaobi	
Dr Susan Blakeney	
Julian Exeter	
Yolanda Laybourne	
Ray Spendiff	
Dr Cecilia Fenerty	(from 11.03.22)
Dr Roshini Saunders	(from 11.03.22)
Christopher Hunton	(co-opted from 11.02.22)
Chief Executive and Company Secretary	Karen Osborn (to 13.01.22) Claire Cardy (from 13.01.22 to 27.04.22) Joanne Creighton (from 27.04.22)
Company Number	1293286
Charity Number	274681
OSCR Number	SC041550
Registered office & operational address	Woodcote House, 15 Highpoint Business Village, Henwood, Ashford, Kent, TN24 8DH www.glaucoma.uk
Bankers	Barclays Bank plc, 1 Churchill Place, London, E14 5HP CAF Bank Ltd, 25 Kings Hill Avenue, Kings Hill, Kent, ME19 4JQ HSBC Bank plc, Camberwell Green, 23 Denmark Hill, London, SE5 8RP
Auditors	Xeinadin Audit Limited, 1 City Road East, Manchester, M15 4PN
Investment Managers	Rathbone Investment Management Ltd, 8 Finsbury Circus, London, EC2M 7AZ

Structure and Management

Glaucoma UK is the operating name of the International Glaucoma Association Ltd, which was incorporated on 15 July 1976 and registered as a charity on 20 December 1977. As Glaucoma UK is both a charity and a company limited by guarantee, all board members are directors for the purposes of company law and trustees for the purposes of charity law.

The objects of the charity are defined by its Articles of Association (last updated in 2015), which also set out trustees' powers and the permitted activities of the charity.

Following a review of the Articles of Association in 2021, with help from Russell Cooke solicitors, it was felt that moving from a membership model to an association model may be more appropriate for the charity. All voting members were invited to give their views on the proposal, with 59% of respondents supporting the change, 36% against and 5% undecided. In September 2021, the charity communicated individually with all those who were against the change, answering their questions and responding to their comments and suggestions. Dialogue continued during the autumn, and the matter was debated at the Board of Trustees' meeting in September 2021. As the response rate to the initial consultation was very low with only 56 replies, trustees were keen to ensure that everyone involved in the charity had the opportunity to have their say. The decision was therefore taken to defer plans to put the proposals to the AGM in March 2022 to allow for further consultation and involvement of the new Chief Executive Officer. Any changes to the Articles of Association will now be presented for a vote at the AGM in March 2023.

The Board and Committees

The Board comprises a maximum of 15 trustees, of whom up to 12 are elected by the members and a further three may be co-opted. The current Board comprises people living with glaucoma, those with close family connections with the condition and others with backgrounds in ophthalmology, nursing, optometry, finance and business. Existing trustees retire after serving a three-year term but are eligible for re-election to a maximum of twelve years' service. There is one sub-committee: the Finance and Governance Committee, which has delegated responsibility to oversee finance, investments, risk management and policy. Consisting of six trustees, the committee meets quarterly in advance of each Board meeting and on an ad-hoc basis, should the need arise. The charity also has a Clinical Advisory Panel (CAP) to advise on clinical matters. The chair of the CAP oversees the award of research grants.

The Board returned to face-to-face meetings in 2022, with the option to join virtually for those unable to attend in person. This hybrid approach has been successful in reducing cost, lowering carbon footprint and ensuring that individuals can make a positive contribution, regardless of time or geographical constraints.

Trustee recruitment and training

When appointing new Board members, trustees have regard to any skills or knowledge gaps and seek candidates to meet those needs. Due consideration is also given to diversity and the need to ensure that the Board appropriately represents the communities served by the charity. New trustees are sought using existing networks, advertising or professional recruitment agencies, as required. Candidates are interviewed by a sub-committee of trustees, followed by a meeting with the Chair and an invitation to meet the full Board at a Board meeting.

A Trustee Handbook sets out trustee roles and responsibilities. A personalised induction is provided for all new trustees, including a charity overview and briefings on finance, fundraising, support, services and communication. Direction is also provided on the Charity Commission Guidance, 'The Essential Trustee'. Ongoing training is provided as required, including attendance at external courses or participation in internal workshops and briefings.

Conflict of interest

Charity Commission approval was sought and received during the year in relation to a research grant award to Nottingham University Hospitals Trust for which Glaucoma UK Chair – Professor Anthony King – will be lead researcher. The Commission were content that the conflict of interest had been managed appropriately and that the trustees had acted in accordance with Glaucoma UK's Memorandum and Articles of Association and Charity Commission guidelines when sanctioning the award.

Operating responsibility

Day to day responsibility for delivering services and achieving strategic and financial aims within organisational policies and the law is delegated to the Chief Executive Officer, supported by the Senior Management Team.

Statement of Public Benefit

Glaucoma UK exists to raise awareness of the risks of glaucoma, support people to live well with the condition and fund research into the causes, prevention and treatment of the disease. When reviewing the charity's objectives and planning future activities, the trustees refer to Charity Commission guidance on public benefit and can confirm that all Glaucoma UK's activities are undertaken to further our charitable purposes for public benefit, in accordance with Section 17 of the Charities Act 2011.

Related Parties and Connected Charities

Glaucoma UK acted as an agent for the unincorporated organisation the United Kingdom Paediatric Glaucoma Society (UKPGS) during the year, providing infrastructure and administrative support. UKPGS exists to promote the exchange of knowledge between glaucoma specialists, stimulate research, establish a scientific community and promote interest in glaucoma as an ophthalmological sub-specialty. One trustee of Glaucoma UK also sits on the trustee board of UKPGS.

Risk Management and Internal Control

Overall responsibility for the charity's risk management lies with the Board of Trustees, with formal assessment and review delegated to the Finance and Governance Committee. A risk register is submitted by the Chief Executive to the Finance and Governance Committee on a quarterly basis which identifies current and new risks, rates each in terms of likelihood and probability and identifies appropriate controls and mitigations. The trustees have assessed the major risks to which Glaucoma UK is exposed as follows:

Lack of income diversity and heavy reliance on legacy gifts

With legacy gifts representing 81% of our income in the year 2021/22, the need to diversify funding sources is a key priority for the charity. In mitigation, the following measures are in place:

- Income position monitored via quarterly management accounts.
- Cash flow forecasts and detailed reports on the legacy gift pipeline.
- Reserves holding and investment portfolio with diversified risk to cover medium and longer-term income shortfalls.
- Staff capacity increased in the Fundraising department in October 2022 to create additional resource for income diversification.
- New strategy in development to identify opportunities for greater corporate sponsorship and funding from charitable trusts and foundations in support of Glaucoma UK's work with communities at highest risk of glaucoma.

Investment failure

All investments are at risk of sustained and long-term fall in value of funds held in stock markets. The risk to Glaucoma UK's investment holdings has been mitigated in the following ways:

- Investments managed by Rathbones who monitor performance and take corrective action as required.
- Access to live online investment reports.
- Quarterly reporting to Finance and Governance Committee and annual meeting with investment managers.
- Investment Policy reviewed annually.
- Minimum of three months' operating costs held in cash account.

Compromised IT systems and cyber security failure

In response to increasing levels of cybercrime in the UK and a tightly regulated data protection environment, the following mitigations are in place:

- Retained professional support for staff training and regular system security monitoring.
- Biannual cyber security training mandatory for all staff.
- Cyber Essentials Plus principles followed in all IT management activity.
- Daily offsite backup & office-hours support contract in place.
- Appropriate policies in place (Information Governance, ICT, Data Protection) and subject to annual review.
- Cyber insurance in place, with support for post-incident management.

Remuneration Policy

The trustees consider the Board of Trustees and the Chief Executive Officer as comprising the key management personnel, in charge of directing, controlling and operating the charity on a day-to-day basis. All trustees give of their time freely and no trustee remuneration was paid in the year. Trustees are required to disclose all relevant interests and withdraw from decisions where a conflict of interest arises.

The pay of the charity's Chief Executive is reviewed annually by the Board Chair and Finance and Governance Committee. The Chief Executive reviews all other staff salaries annually and makes recommendations to the Board as part of the annual budget setting process.

When setting salaries, trustees are guided by a remuneration policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public and private sector pay increase estimates), affordability, sustainability, and appropriateness. Glaucoma UK aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2022 these ratios were 3.7:1 and 2.3:1 respectively.

Statement of Trustee Responsibilities

The trustees are responsible for preparing the Trustees' Annual Report including the strategic report and financial statements in accordance with applicable law and United Kingdom accounting standards (UK generally accepted accounting practice).

Company law requires the trustees to prepare financial statements which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees' Annual Report is approved by order of the Board of Trustees, and the Strategic Report (included therein) is approved by the Board of Trustees in their capacity as directors, in their meeting on 23 November 2022, and signed on its behalf by

Professor Anthony King (Chair)

Independent Auditors' Report

We have audited the financial statements of The International Glaucoma Association Limited for the year ended 31 July 2022 on page 36 to 52. The financial reporting framework that has been applied in their preparation is applicable law and FRS 102 (effective January 2015), as well as the Statement of Recommended Practice for Charities (effective January 2015).

This report is made solely to The International Glaucoma Association Limited's members and Board of Trustees, as a body, in accordance with Section 144 of the Charities Act 2011, and regulations made under Section 154 of that Act, as well as Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Council of Management those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditors

As explained more fully in the Trustees Responsibilities set out on page 32, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditors under Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 and report in accordance with regulations made under those Acts.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error.

This includes an assessment of whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements.

In addition, we read all the financial and non-financial information in the Trustee's Annual Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently

materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit.

If we become aware of any apparent material misstatements or inconsistencies, we consider the implications for our report.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities. The extent to which our procedures can detect irregularities, including fraud, is detailed below:

- Gaining a full and extensive knowledge of the entity, environment and the regulatory framework to which it must abide by.
- Evaluating and assessing the extent to which the entity's internal systems are adhering to these as well as gaining a full and comprehensive understanding of the entity's activities and effectiveness of its control environment (including those in place to identify and prevent fraud).

We achieved this by carrying out the following:

- Enquiry of the detailed communication with management and those charged with governance
- Reviewing internal systems and controls
- Reviewing financial statement disclosures and compliance with applicable laws and regulations.

Opinion on financial statements

In auditing the financial statements, we have concluded that the trustees/directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the entity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorized for issue.

Our responsibilities and the responsibilities of the trustees/directors with respect to going concern are described in the relevant sections of this report.

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 July 2022 and of its incoming resources and application of resources, including its result, for the year then ended;
- have been properly prepared in accordance with the Financial Reporting Standards 102 (effective January 2015)
- have been prepared in accordance with the requirements of the Companies Act 2006, and Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- the information given in the Report of the Board of Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Nicholas Hume

For and on behalf of Xeinadin Audit Limited,

Chartered Accountants and Registered Auditors

1 City Road East, Manchester, M15 4PN

Eligible to act as an auditor in terms of Section 1212 of the Companies Act

30 November 2022

The International Glaucoma Association operating as **Glaucoma UK**

Financial Statements

for the year ending 31 July 2022

Glaucoma UK

2021/22

Glaucoma UK (the operating name of the International Glaucoma Association Limited)

Statement of financial activities *(incorporating an income and expenditure account)*
For the year ended 31 July 2022

	Note	Restricted £	Unrestricted £	**2022 Total £**	2021 Total £
Income					
Donations, Legacies and Subscriptions	2	11,165	1,660,222	**1,671,388**	1,631,415
Investment income	3	33,072	111,678	**144,749**	98,507
Charitable activities					
Glaucoma aids and equipment sales	4	-	4,654	**4,654**	4,213
UKEGS (UK & EIRE Glaucoma Society)	4	-	-	**-**	9,703
Other income	4	-	6,561	**6,561**	4,594
Grants	4 & 5	14,409	62	**14,471**	47,394
Total income		**58,646**	**1,783,176**	**1,841,823**	**1,795,826**
Expenditure on:					
Raising funds					
Finance and support		-	19,516	**19,516**	18,483
Cost of generating funds		-	122,819	**122,819**	119,262
		-	142,335	**142,335**	137,745
Expenditure on charitable activities					
Glaucoma research		419,313	11,926	**431,240**	136,094
Patient information and support		3,321	673,171	**676,492**	588,085
Professional information and support		11,903	147,752	**159,655**	112,559
Campaigning and advocacy		-	63,241	**63,241**	64,062
Cost of glaucoma aids and equipment		681	5,461	**6,142**	4,107
Total expenditure	6	**435,219**	**1,043,888**	**1,479,106**	**1,042,652**
Realised gains on investment assets	12	-	-	**-**	480,631
Net Income		(376,573)	739,289	**362,717**	1,233,805
Unrealised gains on investment assets	12	(110,589)	(385,016)	**(495,605)**	524,250
Net incoming resources before transfers	7	(487,162)	354,273	**(132,888)**	1,758,055
Gross transfer between funds		-	-	**-**	-
Net movement in funds		(487,162)	354,274	**(132,888)**	1,758,055
Reconciliation of funds					
Total funds brought forward		2,081,540	6,210,521	**8,292,061**	6,534,006
Total funds carried forward		**1,594,377**	**6,564,793**	**8,159,171**	**8,292,061**

All of the results above are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 18 to the financial statements.

Glaucoma UK (the operating name of the International Glaucoma Association Limited)

Charity No 274681

Balance sheet

Scotland No SC041550

Company No. 1293286

As at 31 July 2022

	Note		2022 £	2021 £
Fixed assets				
Tangible fixed assets	11		**16,141**	15,888
Investments	12		**7,052,774**	7,071,150
Total fixed assets			**7,068,915**	7,087,038
Current assets				
Stock	13		**3,768**	4,311
Debtors	14	21	**1,115,075**	308,233
Cash at bank and in hand			**438,360**	1,231,121
			1,557,202	1,543,665
Liabilities				
Creditors: amounts due within one year	15	20, 21	**251,404**	249,242
Net current assets			**1,305,798**	1,294,423
Total assets less current liabilities			**8,374,713**	8,381,460
Creditors: amounts due after more than one year	16, 21		**215,543**	89,400
Net assets	17		**8,159,171**	8,292,061
Funds	18			
Restricted funds			**1,594,377**	2,081,540
Unrestricted funds				
Designated funds			**4,482,906**	4,482,906
General funds			**2,081,888**	1,727,616
Total funds			**8,159,171**	8,292,061

Approved and authorised for issue by the trustees of The International Glaucoma Association

Glaucoma UK (the operating name of the International Glaucoma Association)

Statement of cash flow

For the year ended July 2022

Cashflows from operating activities:	**2022**	2021
Net cash provided by (used in) operating activities	**(450,839)**	**950,872**
Cashflows from investing activities		
Dividends and interest from investments	**144,749**	98,507
Purchase of property, plant and equipment	**(9,442)**	-
Proceeds from sale of investments	**-**	917,254
Purchase of investments	**(492,201)**	(2,202,236)
Net cash provided by (used in) investing activities	**(356,894)**	**(1,186,475)**
Change in cash and cash equivalents in the reporting period	**(807,733)**	**(235,603)**
Cash and cash equivalents at the beginning of the reporting period	**1,248,827**	**1,484,430**
Cash and cash equivalents at the end of the reporting period	**441,094**	1,248,827
Increase/Decrease in cash balances	**(807,733)**	**(235,603)**

Reconciliation of net movement in funds to net cash flow from operating activities

Net movements in funds for the reporting period (as per the statement of financial activities)	**(132,888)**	1,758,055
Adjustments for:		
Depreciation	**9,188**	1,977
Dividends & interest from investments	**(144,749)**	(98,507)
Loss/(Profit) on sale of investments	**495,605**	(1,004,881)
(Increase)/Decrease in stocks	**542**	11
(Increase)/Decrease in debtors	**(806,842)**	308,813
Increase/(Decrease) in creditors	**128,305**	(14,595)
Net cash provided by (used in) operating activities	**(450,839)**	**950,872**
Analysis of cash and cash equivalents		
Cash in hand	**438,360**	**1,231,121**
Investments Capital account	**2,734**	**17,706**
	441,094	**1,248,827**

1. Accounting policies

a) The financial statements have been prepared under the historical cost convention, as modified by the revaluation of fixed asset investments, and in accordance with applicable accounting standards and the Companies Act 2006. They follow the recommendations in the Statement of Recommended Practice, Accounting and Reporting by Charities. The accounting standards policies have been prepared under Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice) and SORP 2019.The Trustees confirm that the charitable company is a public benefit entity. The accounts are prepared in sterling pound and rounded to the nearest £1.The charity is a company limited by guarantee from 543 voting members incorporated on 15 July 1976 and registered as a charity on 20 December 1977. The objects of the charity are defined by its Articles of Association updated in March 2012. The International Glaucoma Association (IGA) is constituted both as a charity and as a company limited by guarantee and as such the members of its council are directors for the purposes of company law and trustees of the charity for the purposes of charity law. The powers of the council and the permitted activities of the association are described in its governing document, which is the Articles of Association. The International Glaucoma Association registered office is Woodcote House, 15 Highpoint Business Village, Henwood, Ashford, Kent, TN24 8DH.

In assessing the charity's status as a going concern, the Trustees have considered a range of information in relation to the financial year ahead, including the current status of the pandemic, the impact of the war in Ukraine on the UK economy, the charity's cash resources and known liabilities. Although the macro-economic situation is volatile and deemed to pose some risk to fundraised income, corporate support and rising staff costs, the trustees consider the charity to have adequate resources to continue operating an effective service for at least 12 months ahead and to meet its obligations as they fall due. The financial statements have therefore been prepared on a going concern basis.

b) Voluntary income received by way of subscriptions, donations and gifts are included in full in the statement of financial activities when receivable.

c) Income from legacies is accounted for on a receivable basis, recognised when entitlement to the income has been established and it is probable that Glaucoma UK will receive the amounts ascertained. This treatment is within SORP 2019 and Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Sales income represents sale of goods excluding VAT where appropriate.

Investment income is accounted for on an accruals basis.

d) Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

e) Unrestricted funds are donations and other incoming resources received or generated for general charitable purposes.

f) Designated funds are unrestricted funds earmarked by the Board of Trustees for particular purposes. Within these funds is money awarded as grants, funding a range of research projects to develop more effective methods of glaucoma diagnosis and treatment.

g) Costs of generating funds relates to the costs incurred in fundraising activities.

h) Critical accounting judgements are used within these accounts as follows:
Residual legacy income debtors are valued at 85% of the expected value of the legacy when certain criteria are met and receipt is probable.

The support and governance costs are re-apportioned by staff time as explained in note (i). The staff costs attributed to each activity are reviewed each year when the new budget is set.

i) Resources expended are recognised in the period in which they are incurred. Resources expended include attributable VAT which cannot be recovered.
Resources expended are allocated to a particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function which includes finance and support and governance is apportioned on the following basis which is an estimate based on staff time of the amount attributable to each activity.

Support costs	
Cost of generating funds	11%
Expenditure on charitable activities	85%
Research	3%

1. Accounting policies (continued)

j) Grants awarded are charged to the Statement of Financial Activities in the year in which they are awarded and are subject to receipt of progress reports.

k) Governance costs are the costs associated with the governance of the charity, including constitutional and statutory requirements and costs associated with the strategic management of the charity's activities.

l) Monetary assets and liabilities in foreign currencies are translated into sterling at the Bank of England exchange rate for that day.

m) Investments held as fixed assets are revalued at market value at the balance sheet date. The Trustees consider that market value is a reasonably accurate representation of the fair value. The gain or loss for the period is taken to the statement of financial activities.

n) The fixed assets are held at cost less depreciation and any impairment. Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures, fittings and equipment	20%
Computers	33%

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

o) Stocks are stated at the lower of cost and net realisable value. In general, cost is determined on a first in first out basis. Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation. Provision is made where necessary for obsolete, slow moving and defective stock. During the year the charity received donated items that have been stated at fair value.

p) The charity contributes to a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. Contributions payable are charged as an expense in the SOFA (Statement of financial activities) within staff costs then shared between the SOFA categories by staff time within these activities.

q) Financial instruments assets and liabilities are valued in the accounts at fair value and are subsequently carried at amortised cost shown in Note 21.

R) Debtors are stated at their net realisable value after allowing for bad and doubtful debts. The recoverability of debtors is reviewed at year end and provision is made, either general or specific, based on value, age and composition of our year end debtor balance.

2. Voluntary income

	2022 Restricted £	2021 Restricted	**2022 Unrestricted £**	2021 Unrestricted	**2022 Total £**	2021 Total £
Donations and subscriptions	**4,239**	16,474	**174,354**	175,074	**178,593**	191,548
Corporate donations	**-**	-	**1,841**	27,000	**1,841**	27,000
Legacies	**6,926**	-	**1,484,027**	1,412,867	**1,490,953**	1,412,867
Total	**11,165**	16,474	**1,660,222**	1,614,941	**1,671,388**	1,631,415

3. Investment income

	2022 Restricted £	2021 Restricted	**2022 Unrestricted £**	2021 Unrestricted	**2022 Total £**	2021 Total £
Interest	**-**	-	**79**	338	**79**	338
Dividends from UK companies	**33,072**	19,227	**111,598**	59,011	**144,670**	78,238
Dividends from overseas companies	**-**	4,807	**-**	15,124	**-**	19,931
Total	**33,072**	24,034	**111,678**	74,473	**144,749**	98,507

4. Incoming resources from charitable activities

	2022 Restricted £	2021 Restricted £	**2022 Unrestricted £**	2021 Unrestricted £	**2022 Total £**	2021 Total £
Glaucoma aids and equipment sales	**-**	20	**4,654**	4,193	**4,654**	4,213
UKEGS (UK & EIRE Glaucoma Society)	**-**	9,703	**-**	-	**-**	9,703
Other income	**-**	435	**6,561**	4,159	**6,561**	4,594
Grants received*	14,409	28,026	62	19,368	**14,471**	47,394
	14,409	**38,184**	**11,277**	**27,719**	**25,686**	**65,903**

5. Grants received*

	2022 Restricted £	2021 Restricted £	**2022 Unrestricted £**	2021 Unrestricted £	**2022 Total £**	2021 Total £
National government grant - HMRC furlough scheme	**-**	-	**62**	19,368	**62**	19,368
Professor of Ophthalmology for Glaucoma and Allied Studies at UCL	**15,551**	11,480	**-**	-	**15,551**	11,480
UKEGS (UK & EIRE Glaucoma Society) grant	**-**	-	**-**	-	**-**	-
The National Lottery - Community Fund **	**(1,142)**	16,546	**-**		**(1,142)**	16,546
	14,409	**28,026**	**62**	**19,368**	**14,471**	**47,394**

** The National Lottery - Community fund had an underspend during the year which was paid back to the National Lottery

6. Total Expenditure

	Cost of generating funds	Patient information and support	Professional information and support	Campaigning and advocacy	Glaucoma research	Finance and support	Governance	2022 Total	2021 Total
	£	£			£	£	£	**£**	£
Staff costs (Note 8)	60,659	336,361	88,494	33,844	17,361	99,608	28,770	**665,097**	**582,119**
Research grants (Note 9)	-	-	-	-	364,945	-	-	**364,945**	**121,236**
Regional outreach & helpline	-	16,721	291	-	-	93	-	**17,105**	**16,469**
Glaucoma aids & equipment	1,332	3,694	1,116	-	-	-	-	**6,142**	**4,107**
Awareness events, PR, social media & volunteering	-	6,057	5,919	5,911	-	-	-	**17,887**	**21,569**
AGM, annual lectures & trustee expenses	-	4,536	-	-	-	-	5,924	**10,460**	**8,120**
Fundraising	20,066	-	-	-	-	-	-	**20,066**	**33,585**
Premises & administration	-	78,223	3,437	-	5	118,302	-	**199,967**	**179,791**
Finance & professional	19,516	1,177	104	-	36,881	72,138	47,620	**177,436**	**75,656**
Expenditure	101,573	446,769	99,361	39,755	419,192	290,141	82,314	**1,479,106**	1,042,652
Finance & support reallocated	31,123	172,580	45,404	17,365	8,909	(290,141)	14,760		
Expenses including Finance & Support	132,696	619,349	144,765	57,120	428,100	-	97,074	**1,479,106**	1,042,652
Governance reallocated	10,971	60,836	16,006	6,121	3,140	-	(97,074)		
Total Expenditure	**143,667**	**680,186**	**160,771**	**63,241**	**431,240**	**-**	**-**	**1,479,106**	1,042,652

7. Net (outgoing)/incoming resources

This is stated after charging/crediting:

	2022 £	2021 £
Depreciation charge for the year - owned assets	**9,188**	1,977
Auditors' remuneration:		
audit	**2,270**	3,778
other services	**-**	-
Trustees expenses	**1,700**	-
Investment managers fee	**15,029**	24,226

Trustees expenses represent the travel and subsistence costs of 7 trustees for 5 meetings £1,700 (2021:0). Within 2022 some Trustees meetings are still held virtually. All meetings were held as virtual meetings and no Trustee expenses for 2021.

During the accounting year unclaimed Trustees expenses totalled £247 (2021: £0.00).
Donations totalling £645 were received from Trustees, (2021: £450).
No Trustees received remuneration for their services during the financial year.

The investment managers fee has decreased as the funds are now held within the investment companies charity managed fund which is cheaper to administer

8. Staff costs and numbers

Staff costs were as follows:

	2022 £	2021 £
Salaries and wages	**578,325**	510,607
Social security costs	**57,936**	48,237
Pension contributions	**28,836**	23,275
	665,097	582,119

Only one member of key management personnel earned £60,000 or more in the year. A mid-year change of personnel meant that the post was held by two different individuals during the year. The employee earning £60,000 - £70,000 left in January and the position was filed in April by employee earning £70,000 - £80,000.

	2022 No.	2021 No.
£60,000 - £70,000	**1**	1
£70,000- £80,000	**1**	0

Pension contributions in respect of the above £60,000 full-time employee totalled £4,805 (2021: £3,335).
NI contributions in respect of the above £60,000-£70,000 employee totalled £12,640 (2021: £8,218)
The calculated unspent staff holiday entitlement at year end was £12,647, (2021: £10,745).

The charity contributes to a Royal London defined contribution pension scheme for employees.

The Chief Executive Officer is the sole key management personnel having authority and responsibility for planning, directing and controlling the activities of Glaucoma UK.

The management remuneration policy considers the following factors:
cost of living, pay comparability, affordability, sustainability, and appropriateness. The ratio between the highest and lowest salary should be below 4.5:1 and the ratio between the highest and median (midpoint) salary below 3.5:1. As at 1 August 2022 these ratios were 3.7:1 and 2.3:1 respectively.

8. Staff costs and numbers (continued)

The average weekly number of employees (full-time equivalent) during the year was:

	2022 No.	2021 No.
Cost of generating funds	**1.45**	1.83
Patient information and support	**9.61**	8.50
Professional information and support	**2.18**	1.67
Campaigning and awareness	**0.95**	1.00
Research	**0.30**	0.20
Governance	**0.58**	0.50
Finance and Support costs	**2.23**	2.58
	17.30	16.28

The actual number of staff (including part time and full time) in 2022 was 23 (2021: 20) at year end.

9. Grants Awarded

	2022	2021
University College London's Institute of Ophthalmology - Glaucoma UK Chair Fund	**65,523**	52,447
Fight for Sight	**1,500**	20,479
University Hospital of Wales	**-**	(60,684)
Nottingham University Hospital Trust *	**57,301**	-
University of Bradford	**-**	48,380
University College London	**-**	49,811
Ulster University	**99,910**	-
Edinburgh University	**45,271**	-
Cardiff University	**98,000**	-
Grants underspent by researchers	**(2,561)**	-
	364,945	110,433

These grants were awarded in accordance with the Glaucoma UK grants policy, and were awarded to fund research into the diagnosis and treatment of glaucoma.

The negative figure represents an underspend by researchers on grants awarded in previous years.

Conflict of Interest - Grant

* Charity Commission approval was sought and received during the year in relation to a research grant award to Nottingham University Hospitals Trust for which Glaucoma UK Chairman - Professor Anthony King - will be the lead researcher.

10. Taxation

The charity is exempt from corporation tax and income tax as all its income is charitable and is applied for charitable purposes.

11. Tangible fixed assets

	Computer equipment £	**Total £**
Cost		
At the start of the year	27,743	**27,743**
Additions in year	9,442	**9,442**
Disposals in year	-	**-**
At the end of the year	37,185	**37,185**
Depreciation		
At the start of the year	11,856	**11,856**
Charge for the year	9,188	**9,188**
Disposals in year	-	**-**
At the end of the year	21,044	**21,044**
Net book value At the end of the year	**16,141**	**16,141**
At the start of the year	15,887	15,887

12. Investments

	2022 £	2021 £
Rathbones Core Investments fund for charities		
At 1st August 2021	**7,053,444**	4,763,579
Additions at historic cost	**492,201**	2,202,238
Disposal proceeds	**-**	(917,254)
Realised gains	**-**	480,631
Unrealised gains	**(495,605)**	524,250
Market value at the end of the year	**7,050,040**	7,053,444
Cash held as part of portfolio	**2,734**	17,706
Total	**7,052,774**	7,071,150

12. Investments continued

Investment management costs were £15,028.67 (£24,226.07 - 2021)

Glaucoma UK Ltd, Glaucoma International Ltd, Glaucoma Europe Ltd, and Glaucoma Association Ltd are dormant companies historically held by Glaucoma UK (the operating name of the International Glaucoma Association Limited) in order to protect the company identity and to give future flexibility in terms of the charity name. International Glaucoma Association hold 100% of all the dormant companies.

Glaucoma UK Limited number 04323894 total shareholder funds £1. Glaucoma Europe Limited number 04591043 total shareholders funds £1. Glaucoma International Limited number 04323990 total shareholders funds £1. Glaucoma Association Ltd number 05316092 shareholders funds £1.

13. Stock

	2022	2021
	£	£
Goods for resale	**3,768**	4,311

14. Debtors

	2022	2021
	£	£
Trade debtors	**38,823**	**25,241**
Legacy debtors	**1,084,911**	**266,590**
Prepayments and accrued income	**20,807**	**16,402**
VAT debtor	**3,597**	**-**
Doubtful debt provision	**(33,062)**	**-**
	1,115,075	**308,233**

15. Creditors: amounts due within one year

	2022 £	2021 £
Trade creditors	**43,173**	124,735
Obligations under grant agreements	**123,857**	87,627
Funds held as agent	**24,514**	22,578
Accruals & Deferred income	**59,690**	13,050
National Insurance	**171**	1,253
	251,404	249,242

Funds held as agent represent those held for UKPGS, for which Glaucoma UK provides administration and infrastructure support as shown in note 20.

16. Creditors: amounts due after one year

	2022 £	2021 £
Obligations under grant agreements	**215,543**	89,400
	215,543	89,400

17. Analysis of net assets between funds

	Restricted funds £	Designated funds £	General funds £	**Total funds £**
Tangible fixed assets	-	-	16,141	**16,141**
Investments	1,594,377	4,482,906	975,491	**7,052,774**
Net current assets	-	-	1,305,798	**1,305,798**
Creditors: amounts falling due after more than one year	-	-	(215,543)	**(215,543)**
Net assets at the end of the year	**1,594,377**	**4,482,906**	**2,081,888**	**8,159,171**

18. Movements in funds

	At the start of the year £	Incoming resources £	Outgoing resources £	Other gains and losses £	Transfers £	**At the end of the year £**
Restricted funds:						
Chair fund	1,657,900	49,823	(102,404)	(110,589)	-	**1,494,729**
North East fund	15,724	-	(2,648)	-	-	**13,076**
Compliance Project fund	1,239	-	(1,238)	-	-	**-**
Research fund	315,873	9,965	(316,909)	-	-	**8,929**
Folkestone Fund	3,733	-	-	-	-	**3,733**
Children and Young people's Support fund	8,900	-	(116)	-	-	**8,784**
London fund	7,577	-	-	-	-	**7,577**
Scottish Optom fund	9,321	-	-	-	-	**9,321**
UK & Eire Glaucoma Society	60,131	-	(11,903)	-	-	**48,228**
Digital Support fund	1,142	(1,142)	-	-	-	**-**
Total restricted funds	**2,081,540**	**58,646**	**(435,219)**	**(110,589)**	**-**	**1,594,377**
Unrestricted funds:						
Designated funds:						
Income Endowment	22,906	-	-	-	-	**22,906**
Equipment Replacement and Infrastructure Fund	460,000	-	-	-	-	**460,000**
Research investment fund	4,000,000	-	-	-	-	**4,000,000**
Total designated funds	4,482,906	-	-	-	-	**4,482,906**
General funds	1,727,616	1,783,176	(1,043,888)	(385,016)	-	**2,081,888**
Total unrestricted funds	**6,210,521**	**1,783,176**	**(1,043,888)**	**(385,016)**	**-**	**6,564,793**
Total funds	**8,292,061**	**1,841,822**	**(1,479,107)**	**(495,605)**	**-**	**8,159,171**

18. Movements in Funds (continued)

Purposes of restricted funds

The Chair fund is used to fund the post of Professor of Ophthalmology for Glaucoma and Allied Studies at University College London.

The North East fund was established following receipt of a legacy and is restricted to supporting our work in the North East of England.

The Compliance Project fund was granted by pharmaceutical companies to provide demonstration and educational eye drop materials.

The Research fund represents donations and charitable trust income received specifically to fund glaucoma research. The fund was drawn on throughout the year as detailed on Note 9.

The Folkestone fund comprises legacy income restricted to work in Folkestone.

The Children and Young People's Support fund comprises income donated for services for young people affected by glaucoma and their families and carers. It aims to help us better understand their particular support needs and deliver appropriate services in response.

The London fund is restricted to the London area, and has been used mainly for awareness raising and support work with BAME communities at greatest risk of glaucoma sight loss.

The Scottish Optom training fund is charitable trust income earmarked for eye drop adherence training for optometrists across Scotland. Following delays due to Covid-19 and changes to the professional training landscape in the intevening period work is ongoing to identify the best possible use of the grant funding, while still meeting - and we hope exceeding - the funding objectives.

The UKEGS fund comprises money for the work of the United Kingdom and Eire Society (UKEGS), a national scientific society that operates under the aegis of Glaucoma UK.

The Digital support fund was received from national lottery community fund to be spent within 6 months on the Glaucoma UK Digital care and support project. The £1,142 underspend on the Digital support fund has been returned to the national lottery.

The designated income endowment fund represents the donation of shares which form the basis of a stock market portfolio, which will eventually provide for the running costs of the association.

The designated Equipment Replacement and Infrastructure fund is held to cover the cost of equipment replacement, infrastructure development, premises costs and dilapidations.

The designated Research Investment fund aims to produce a reliable income stream specifically to fund the charity's research priorities in the years ahead.

19. Operating lease commitments

The charity had annual commitments at the year end under operating leases expiring as follows:

	Property	
	2022	2021
	£	£
Within one year	**34,000**	**34,000**
Within 1 -2 Years	**34,000**	**68,000**

The total future minimum lease payment is £68,000

20. Related Parties

Included in Note 15 are funds due to related parties held for the UK Paediatric Glaucoma Society (UKPGS) of which we provide administration and infrastructure support. One Glaucoma UK Trustee is also a UKPGS trustee during the financial year.

Financial Statement of UKPGS	**2022**	2021
	£	£
Income	**12,030**	11,920
Expenditure	**(10,093)**	(14,882)
Closing balance	**1,937**	(2,962)
Balance brought forward	**22,578**	25,540
Total funds held	**24,514**	22,578

Included in Note 9 Grants awarded is a Related party transaction being grant awarded to Nottingham University Hospitals Trust for which Glaucoma UK Chairman Professor Anthony King will be the lead researcher. The balance outstanding to this grant is £57,301 which is the full grant awarded.

21. Financial Instruments

Financial Debt instruments measured at amortised cost	**2022**	2021
	£	£
Trade debtors	**38,823**	25,241
Legacy debtors	**1,084,911**	266,590
Prepayments and accrued income	**20,807**	16,402
VAT debtor	**3,597**	-
Bad debt provision	**(33,062)**	-
	1,115,075	308,233
Financial instruments measured at amortised cost		
Trade creditors	**43,173**	124,735
Obligations under grant agreements	**339,400**	177,027
Funds held as agent	**24,514**	22,578
Accruals	**59,690**	13,050
National Insurance	**171**	1,253
	466,947	338,643

22. Covid-19 pandemic and cost of living impact

The trustees report that during the financial year ended 31st July 2022, face-to-face activity levels in the early months were constrained by concerns of a further wave of Covid-19. Extensions were also granted to a number of ongoing research projects following delays caused by the pandemic. However, helpline support and online provision (including digital support groups) were largely unaffected. The war in Ukraine and the resultant impact on the UK economy was felt in a reduction in donations, subscriptions and corporate support, as well as a diminution in the value of the investment portfolio. The trustees anticipate that the operating environment will continue to be challenging throughout 2022-23, but are confident that sufficient financial reserves are in place to continue to offer all existing services and pursue planned activities for growth in the coming year.

INTERNATIONAL GLAUCOMA ASSOCIATION LIMITED

England & Wales - Charity number 274681

Accounts

The International Glaucoma Association
operating as **Glaucoma UK**

Report and Financial Statements

for the year ending 31 July 2021

Contents

	Page
Our objectives and activities	**2**
Strategic Report 2020/21 – achievements and performance	**3**
The impact of COVID-19	4
Campaigning and awareness	5
Advice and support	9
Glaucoma research	16
Future plans – 2022 and beyond	**19**
Financial review	**20**
Fundraising in lockdown	22
Investment Policy	23
Reserves Policy	24
Remuneration Policy	25
Glaucoma UK trustees, advisors and staff	**26**
Structure, governance and management	**28**
Related parties and connected charities	29
Risk management	29
Statement of trustee responsibilities	30
Independent auditors report	**32**
Financial statements	**35**

Our objectives and activities for the year ending 31 July 2021

Glaucoma is a blinding eye disease affecting over 700,000 people in the UK. If detected early and treated appropriately, most people with glaucoma will retain useful sight for life. But it is estimated that half those living with glaucoma don't know they have it, and these people risk serious sight loss or blindness as a result. At Glaucoma UK, our vision is an end to needless glaucoma sight loss. To make this a reality we focus on three key areas of work.

The most common types of glaucoma are asymptomatic: vision is lost so gradually that people often don't realise that they have the condition. A simple eye health check is usually all it takes to spot the signs of glaucoma, so one of the three key pillars of our work is campaigning to raise awareness, so that fewer people lose sight.

The chance of having glaucoma increases with age, and as our population ages, the number of people affected is growing. Hospital eye services are stretched beyond capacity, and many glaucoma patients have faced major delays in diagnosis, care and treatment. Add to this the fact that lifelong glaucoma treatment can be complex and challenging, and it's not surprising

that many people need extra support to understand the condition and to live well with glaucoma. Helping them to do this is the second pillar of our work.

The third pillar of our work is research. The tools available for glaucoma care and treatment are developing fast, but glaucoma is complex, and we still don't properly understand even what causes the disease. High quality research will be needed to end glaucoma blindness, so we are committed to funding an annual research programme that will have a real impact on the lives of people living with glaucoma, now and in the future.

Strategic Report 2020/21 – performance and achievements

In their 2017 'Way Forward' report the Royal College of Ophthalmologists predicted that between 2020 and 2035 there would be a 31% increase in the number of people living with glaucoma[1]. Our main strategic aim for the past year has been to expand our reach and scale up the provision of our support services so that we can help the fast-growing number of people with glaucoma in the UK.

Key elements of this strategy are to:

- Understand who is most at risk of glaucoma sight loss, where they are, and how best to reach them.
- Scale up our communications to reach more people – both those living with glaucoma and those at greatest risk – and help them to access our services.
- Nurture partnerships that help others to understand patients' needs, encourage them to amplify our messages and signpost people to our support.
- Continue to improve the accessibility, scale and scope of our support services.

This section reviews our achievements and performance across the three pillars of our work in light of the challenges of the pandemic.

[1] https://www.rcophth.ac.uk/wp-content/uploads/2015/10/RCOphth-The-Way-Forward-Glaucoma-300117.pdf

The impact of COVID-19

“Throughout the pandemic, so many of us in eye health services have worked hard to provide urgent care to those who have needed it. Initially, community optometry was required to severely restrict services, causing a reduction in referrals to hospital. Almost all routine testing in hospital eye services stopped and we dealt with emergency and urgent cases only. We developed risk assessments so that we could give care to those who needed it most. As restrictions began to ease, requirements for social distancing and other means of infection control meant that we all saw far fewer patients.

This has caused long delays and some patients have been waiting for more than a year for assessment or treatment. I am concerned about the huge backlog and that when people do start coming to see us – and they are still fearful of doing so – we will uncover a large amount of disease. While many will not have experienced any disadvantage from such a delay, sadly for some their condition will have progressed in a way it would not have done with earlier intervention and treatment.”

Professor Philip Bloom, Chair of Glaucoma UK, first published in the foreword of The State of the UK’s Eye Health 2021

According to Specsavers’ The State of the UK’s Eye Health 2021 report[2] , there was an estimated 4.3 million drop in the number of eye examinations delivered in 2020, 23% lower than the previous year. And between March and December 2020, referrals to ophthalmology fell by 316,000 compared to the same period in 2019, a 28% decrease.

[2] State of the UKs Eye Health 2021 | Specsavers UK

Eye health checks are particularly important in glaucoma detection, and unfortunately, the number of people referred for suspected glaucoma fell by an estimated 43,000 in the same period. Of these, around 2,600 would have been referred on for treatment. In essence, the number of people living with undiagnosed glaucoma is rising, and this makes our awareness raising work and our eye health messaging more urgent than ever.

Unfortunately, the news isn't much better for many of the people already diagnosed with glaucoma. Since the start of the pandemic, glaucoma services have been radically reconfigured in an attempt to manage both increasing prevalence and the tidal wave of the COVID-19 backlog. This is bringing real improvements for the future of some aspects of glaucoma care but inevitably, large numbers of patients have experienced worrying delays and cancellations of appointments and sometimes in treatment. Many patients report living with high levels of stress and anxiety that impact on many aspects of their daily lives. Their experiences reinforce the urgency of our strategy of broadening our reach and scaling up service provision, so that we can reach more of the people who need advice, support, and sometimes just a listening ear.

COVID-19 restrictions brought our face-to-face patient support groups, events and conferences to a halt, and also impacted much of the professional engagement work that could be carried out. But in its place, we developed new digital support services, and new ways of reaching out to people. Our staff team have been working remotely since the start of the pandemic, and although we were affected by COVID-19 illness, long COVID-19 and carer absences, we are delighted to report that the main aspects of our work have continued uninterrupted throughout the pandemic, and we continue to put the needs of people living with glaucoma at the heart of everything we do. Our staff team and trustees have continued to grow and develop the charity, and as this report shows, as the financial year ended we were excited to be recruiting new staff to help in our mission of ending preventable glaucoma sight loss.

1. Campaigning & awareness to end preventable sight loss

In summer 2020 we completed a major rebrand: adopting the operating name of Glaucoma UK and launching a new website and a new brand identity. We are delighted to say that not only are the new name and new look loved by

our members and supporters, but crucially they are helping us to extend our reach and influence whole new audiences. For example, after a challenging start, we are pleased to have achieved all the targets we set for phase one of our new website:

- ✓ **Attract a UK audience - previously only c.35% of website users were in the UK, but this has risen to 69% and climbing**
- ✓ **Improve the average session duration – this has increased by over 14%**
- ✓ **Increase the number of pages users visit on the site before leaving – this has risen by over 31%**
- ✓ **Reduced bounce rate – down 20% and falling**

We also exceeded targets for increasing our social media reach, as shown in this snapshot of one quarter's mid-year activity:

- ✓ **Facebook impressions up 215%**
- ✓ **Facebook engaged users up 292%**
- ✓ **Twitter profile visits up 402%**
- ✓ **LinkedIn impressions up 5,080%**
- ✓ **YouTube watch time up 89%**



A key part of our communications strategy is to extend our reach with bespoke materials aimed at the particular needs of different audiences, so we

were pleased to launch a new digital supporter newsletter, Focus, in July 2020. By the end of the 20/21 financial year, 697 supporters had signed up to hear about our activities and how they can get involved. Of these, 118 were already members of the charity, but the remaining 579 are an entirely new audience, and we are delighted to report a retention rate of almost 98% which is a testament to the quality of the content produced by our communications team.

Our national Glaucoma Awareness Week in June 2021 fell at a time when many families were separated by the pandemic, so we felt that the theme of family had real significance. People are up to ten times more likely to develop glaucoma if they have a close blood relative who has the disease – with the risk level depending on the closeness of the relationship - so we focused our awareness campaign on this, and the importance of family support for patients. A vibrant new range of materials supported the week, much of it targeted at those at greatest risk of glaucoma sight loss such as people of African Caribbean and South Asian heritage and those from older age groups.

Awareness week activity also included a nationwide radio day that gained over 21 hours of air time and a reach of around 21 million listeners, plus a successful press PR campaign which secured significant coverage in national and regional publications.

During the year we continued to trial paid-for advertising, including on social media. For example, a modest £460 Facebook spend during Glaucoma Awareness Week produced some heartening results:

- ✓ **People reached – 114,405 (2,363% increase on the whole previous month)**
- ✓ **Post engagements – 14,920**
- ✓ **Video views – 27,672**
- ✓ **Engagement rate – 11.90% (global average 0.27%)**

We also commissioned a short radio advert for the first time last year. This targeted a demographic aged 55+ with an eye health check message and signposting listeners to our website. It ran in four areas of the UK for two weeks around Glaucoma Awareness Week, and again the results were very positive, with increases in website sessions from IP addresses in all of the areas we targeted:

- ✓ **Northern Ireland – up 90%**
- ✓ **Glasgow – up 61%**
- ✓ **Leeds – up 154%**
- ✓ **Liverpool – up 48%**

Continuing to build our data-driven communication strategy is a key aim for the charity in the next year, and we plan to increase our testing and use of these methods into 2022 and beyond.

Another exciting achievement for 2020/21 was the successful launch of a Glaucoma UK podcast, initially showcasing our work and raising awareness of glaucoma and good eye health care. Content was distributed on all major podcast platforms including Spotify and iTunes. These were well received, so new case study episodes were recorded for Glaucoma Awareness Week, and we used excerpts to produce new videos for use on social media. Repurposing our campaign materials for different media has proved both effective and cost-efficient, and we will continue to build this bank of high quality accessible campaign materials in the coming year.

A final element of our awareness raising work was to plan a benchmark UK-wide survey of understanding and awareness of glaucoma, eye health and Glaucoma UK itself. The survey – of 1,000 people representative of the UK adult population in terms of gender, age, region, socio-economic background etc - was carried out in the first week of August 2021, the very start of the new financial year, and revealed some very useful data that will form the basis

of campaigning key performance indictors in the year ahead. Improving one key statistic – that only 9% of the sample were aware of Glaucoma UK – will be a priority for us!

Finally, given the challenges of communicating remotely during lockdown, we also worked to improve our internal communications, launching a new monthly trustee briefing and surveying the staff team as part of a review of internal communications. The next stage of this work will be to develop a formal internal communications strategy in 2022.

2. Advice & support to help people live well with glaucoma

We run a range of support services for people living with glaucoma, with the aim of helping them understand their condition, engage with their eye care and their treatment, live well with the disease and retain useful sight for life:

Patient information

We produce a family of 16 free booklets on all aspects of glaucoma. The publications are authored by leaders in the fields of ophthalmology and optometry and are reviewed by a patient panel before publication.

We usually distribute upwards of 80,000 publications each year, and the highest demand comes from hospital eye clinics and other healthcare providers. Demand slowed when the pandemic hit, but orders are slowly returning to pre-pandemic levels.

A major accessibility review of all our publications began in 2020 with the aim of aligning the content with the average UK reading age. The project was hampered by staff absences during the pandemic, but this major task is now

almost complete, and we will relaunch our full set of publications in spring 2022. Other aims for information services are to launch and disseminate a new accessible eye drop infographic card for UK-wide distribution, and to complete work on a short eye drop video for dissemination among partner organisations, eye clinic waiting rooms and online.

As mentioned earlier, our new website is also a key source of help and advice for patients, and since its launch, the range of content has been expanded. We have seen an encouraging increase in site visits and the number of materials downloaded each week.



Online glaucoma community

In 2020 we launched a new online forum on Health Unlocked: https://healthunlocked.com/glaucoma-uk



The forum has proved incredibly successful and has been a vitally important source of support for hundreds of people during lockdown. It's not appropriate to share posts from this online community in this report, but we can share the statistics: membership has grown from 289 to 676 during the year, and new content has grown by more than 1,000% in that time.

Membership services

Glaucoma UK is a membership charity with around 4,300 members, comprising both people living with glaucoma and the professionals who support them. Professionals comprise 24% of our membership, and our other members are people living with glaucoma, their family and supporters. Of these, 16% opted for voting membership and 60% opted for non-voting membership. Our membership retention rate for 2020/21 was 93.5%, up very slightly from the previous year, but membership isn't required to access our support services: these are freely available to everyone who needs our help.

Our members receive a quarterly magazine, and we are particularly pleased with the reception of the revamped and rebranded 'Insight' magazine since it launched in summer 2020. Members' comments clearly demonstrate that it is having a positive impact on their eye health:

> **"May I say how much I am enjoying the editions of Insight these days. I have been receiving the magazine for many years and I do feel it has improved tremendously in terms of relevance to current events, detailed research topics, useful information e.g. demystifying the jargon etc. Please pass on my grateful thanks to the team."**

> **"Love the new designs and magazine!"**

“Not being a scientist, I find these articles you are now publishing from ordinary members ... especially interesting and helpful.”

“Thank you for another excellent edition of Insight - it has really become a very interesting publication … I particularly liked Joanna’s piece on the terminology glaucoma patients are sometimes presented with - it answered some of those questions one is too afraid to ask!”

Helpline

Our telephone helpline provides advice, information and support to anyone living with glaucoma. It operates every weekday and is staffed by two full-time advisors, supported by locum optometrists.

The COVID-19 lockdown caused an immediate drop in helpline calls because surgery and laser treatment – the most common call topics reasons for calling – were halted overnight. Call volume has returned to pre-COVID-19 levels, but with this has come a steep growth in the number of callers experiencing high levels of emotional distress and anxiety, and from people terribly worried about delays in their care and treatment.

Support for professionals

Glaucoma UK supports professionals by providing them with free patient information resources and, as mentioned above, free membership of the charity. We also help by recruiting glaucoma patients for their clinical trials, and our staff and members act as patient representatives for focus groups and research steering committees.

Working in partnership with professionals is a key way for us to amplify our messages and increase service uptake, and to this end, we have been developing free training courses for professionals. A new accredited training programme for optometrists that was due to be piloted in early 2020 was again delayed by COVID-19, but we plan to go ahead with the pilot in 2022. We also took the opportunity during lockdown to develop plans for a new online eye drop training programme for pharmacists which we hope to pilot in the year ahead.

Glaucoma UK also supports the two UK specialist ophthalmological glaucoma societies: the UK and Eire Glaucoma Society (UKEGS) and the UK Paediatric Glaucoma Society (UKPGS). Both groups exist to promote the exchange of knowledge between glaucoma specialists, stimulate research, establish a scientific community, and promote interest in glaucoma as an ophthalmological sub-specialty. Glaucoma UK provides infrastructure and administrative support to both societies, and historically we have acted as an agent for both. As agent for the UKPGS, our role remains one of financial administration, but the unincorporated association UKEGS merged into Glaucoma UK in 2019/20 and the funds previously held as an agent are now incorporated into our main accounts but are restricted to UKEGS work (see notes 4 and 18). The Glaucoma UK team organise the annual UKEGS conference, and we are pleased to report that the first ever virtual UKEGS conference was held successfully in November 2020.

The charity has not had any staff dedicated solely to our work with professionals, but given the importance of expanding our professional partnerships, at the end of 2020/21 it was agreed to invest in a new post of Professional Engagement Lead. We are pleased to report that two part-time colleagues have been recruited to job share this exciting new role, and they joined the charity in October 2021. Plans for the year ahead include developing a more formal professional membership strategy and developing new insights and links with pharmacy and ophthalmic nursing.

Regional work

Healthcare and health policy differs widely across the UK, so we employ a small team of regional Development Managers (DMs) whose role is to bring an understanding of regional needs and services into the charity and roll out services that meet local needs.

A particular aim in recent years has been to increase our level of contact with our beneficiaries, so it was frustrating that the face-to-face element of their role - networking, organising support groups and patient events, influencing local providers and supporting local professionals – could not be carried out during the last year. However, our DMs have been instrumental in developing a new programme of digital support groups that launched in September 2020 and has gone from strength to strength. We ran 22 online groups between September 2020 and June 2021, attended by over 450

individuals living with glaucoma and some carers. The topics ranged from information for newly diagnosed people and the various types of glaucoma and treatments, through driving, diet and lifestyle to 'How does glaucoma 'look' and what's Kate Moss got to do with it?'. Many people attended several groups and 97% said they would recommend the groups to others.

Comments included:

> **"What an excellent session this evening, packed with information and very positive. Glaucoma UK has really helped me in many ways to cope with my diagnosis, I really value being a member."**

> **"This webinar really was fantastic, (as was the last one I attended) and are helping me on my slow and difficult journey towards coming to terms with my diagnosis and accepting my sight loss. Thank you"**

> **"Excellent presentation. I feel less anxious and very reassured that with continuous care, I will not lose my eyesight"**

> **"I find the digital support very comforting & inclusive. Thank you"**

> **"I really enjoyed the session, especially the first slide about your hospital experience, this was exactly what happened to me! Still have questions but know who I can ask now!!"**

During lockdown, our DMs undertook some project work for the charity which was outside their usual regional work. This worked so well that in summer 2021 when some of the team retired or moved on, we took the opportunity to revise the DM role to permanently include project development work. We also expanded the team, replacing some part-time DM roles with full-time roles. Our new DM colleagues joined the team in October 2021, and we are really looking forward to seeing our service provision expand in scale and scope as a result, including working in Northern Ireland for the first time.

Knowing exactly where to deploy regional resources for the greatest impact has long

been a challenge, so a key aim for 20/21 was to commission a data tool that would help us to do just that. We received the data tool from Wilmington Healthcare in summer 2021, and we are grateful to The Hospital Saturday Fund for supporting this work. In the year ahead, we will work to identify those populations most at risk of glaucoma sight loss, using demographic and socioeconomic data combined with eye health data, availability of diagnostic services, workforce data and more. We'll then be able to test to what extent deploying resources in key areas is effective in reaching new audiences and engaging with those at highest risk.

As outlined elsewhere in this report, during the year we have become increasingly concerned about the emotional wellbeing of people whose care and treatment was interrupted by COVID-19. People using our services have reported high levels of distress and anxiety, and we were keen to see whether our digital support services could be expanded during lockdown to meet these emotional and mental health needs. We are very grateful to the Coronavirus Community Support Fund for a grant that allowed us to test three new support group models: a group via Zoom for people who are newly diagnosed, a group via Zoom for people with sight loss, and a group via telephone for people with advanced sight loss.

We discovered that it was incredibly resource intensive to run these sessions, as participants needed to be matched closely to ensure they were at roughly the same stage in their glaucoma journey, and many needed support to use technology that was new to them. So, while there were definite benefits for participants, the groups sadly weren't viable as a way of meeting large-scale needs. However, we did gain numerous insights into the services we offer as a result of the pilot and our future plans now include:

- ✓ **More proactive support on Health Unlocked: devise a development plan for the forum to provide more support and better signposting to our other services.**
- ✓ **Include more patient stories in our existing services: new leaflets and booklets will include case studies, and we will grow the use of patient stories on our website.**
- ✓ **Run more digital support groups involving patient speakers describing their experiences of living with glaucoma and taking questions from the audience.**

Volunteering and the buddy service

In recent years we have been lucky to have had the support of regional

volunteers who helped with activities like awareness raising in local hospital eye clinics and giving talks about glaucoma to local groups. For obvious reasons this face-to-face activity has been on hold throughout the year, but in other areas volunteering has continued. One example is our buddy scheme, which matches people facing laser or surgical treatments with volunteer buddies who have experienced the procedures themselves. Buddies provide reassurance and emotional support and improve patients' ability to play an active and informed role in their treatment choices. Buddies often play a key role in giving someone the confidence to agree to sight saving surgery or laser treatment, and given this impact, we are keen to expand the service in the year ahead.

Volunteers have also been active on our Readers Panel and Consultation Panel throughout the pandemic. Panel members act as a sounding board for us and the professionals we work with, feeding back on research proposals, NICE guidance, the content of our patient information leaflets and much more.

We would like to thank all those who have given their time, skills, kindness and compassion so generously during a testing 12 months: our services are so much stronger for your input, and we are very grateful for your help.

3. Glaucoma research

Glaucoma UK funds an annual research programme that supports studies into the causes, detection, care and treatment of glaucoma.

COVID-19 continues to have a profound impact on medical research. At the start of the pandemic, academic institutions were closed, laboratories were repurposed and researchers were redeployed to front line healthcare. Glaucoma clinicians have been working long hours to tackle huge backlogs, and this reduces their availability not just to complete their own research, but also to act as peer reviewers and award panel members, and to mentor the next generation of glaucoma researchers. Studies involving patients also ground to a halt when appointments were cancelled, and patients were no longer able to attend eye clinics.

Many of the research studies that we were funding at the start of COVID-19 were temporarily paused, and the start of others was postponed, but we are

pleased to report that none of our funded projects have yet been permanently deferred. Although our total research expenditure increased by £14,909 in 2020/21, it is still much lower than planned at £136,094. One grant awarded to the University Hospital of Wales in 2019/20 had to be reversed in 2021 (see note 9) as a result of administrative delays, but we are hopeful that the research team will be able to take up the award again in the coming year.

On a more positive note, five new grants were awarded during the year:

- £49,811 was awarded to Dr Christin Henein from University College London for a study into real-world evidence on resource utilisation and adverse events following minimally invasive glaucoma surgery.

- £48,380 was awarded to Dr Jonathan Denniss from the University of Bradford for his study 'Melanopsin-Based Intrinsically Photosensitive Retinal Ganglion Cell Function: A Novel Objective Test for Glaucoma'.

- Three £15,000 small grants, funded jointly with the charity Fight for Sight:
    - Dr Andrew Want, Cardiff University: Investigating the Effects of Brain-Derived Neurotrophic Factor (BDNF) on Retinal Ganglion Cell Degeneration/Recovery.
    - Professor Maryse Bailly, University College London: Investigating doxycycline-loaded biodegradable microparticles as a means to prevent inflammation-mediated scarring in the eye.
    - Professor Christopher Owen, St Georges University of London: Using English primary care data to examine the vascular aetiology of glaucoma.

We had hoped to add a new £100,000 PhD grant to our awards during 2020/21, but unfortunately the panel was delayed by illness. However, the grant was finally agreed in August 2021 and has been awarded to Dr Ben Mead of Cardiff University who will shortly recruit a PhD student to research the role of exosomes in preventing retinal ganglion cell death.

Our commitment to glaucoma research is also delivered through our support for the Glaucoma UK Chair of Ophthalmology for Glaucoma and Allied Studies at UCL Professor David (Ted) Garway-Heath. By supporting this post, the charity both increases its profile and advances the wider cause of research and learning in the field of glaucoma. As ever, the trustees are delighted with another extremely successful year, during

which Professor Garway-Heath was again among the global leaders in ophthalmology, being ranked in the top ten in the *Ophthalmologist* Power List 2020. He was also bestowed honorary membership of the Belgian Glaucoma Society for his contribution to education and research in glaucoma, and the trustees send their sincere congratulations to him on these fantastic achievements.

Professor Garway-Heath secured significant new research funding during the year, most notably as chief investigator and co-applicant on a £1.8 million study funded by the MRC Biomedical Catalyst: Developmental Pathway Funding Scheme, into 'Novel area-modulation perimetry for identifying changes in visual field sensitivity in glaucoma'.

Despite the pandemic, Professor Garway-Heath continued to lecture globally, giving 15 virtual national and international lectures between May 2020 and May 2021, among which were three keynote lectures to:

- The 125th Annual Meeting of the Japanese Ophthalmological Society, Osaka, Japan, April 2021.
- The Italian Glaucoma Society, Parma, Italy, December 2020.
- The UK and Eire Glaucoma Society, UK, November 2020.

Professor Garway-Heath authored a large number of peer-reviewed scientific publications during the year, and notably was co-editor/author of the fifth edition of the *European Glaucoma Society Terminology and Guidelines for Glaucoma.* British Journal of Ophthalmology 2021 Jun;105 (Suppl 1):1-169.

Professor Garway-Heath is committed to supporting the next generation of glaucoma specialists, and during the year he has been mentor to an NIHR lecturer at Moorfields Eye Hospital/UCL Institute of Ophthalmology. He was also primary supervisor to four PhD students from the UK, Greece and Mexico, and to four research fellows from Italy, Spain and South Korea.

As President of the European Glaucoma Society (EGS), Professor Garway-Heath provided strategic input to the planning, structure and programme of the 14th biennial Congress of the EGS which marked the 40th anniversary of the EGS. A great deal of time and effort was required to put the Congress online owing to the pandemic, but it was a highly successful event with around 2,000 delegates worldwide. He also provided strategic and

educational input to the annual EGS Residents' Course.

Finally, Professor Garway-Heath continued to support the major project to move Moorfields Eye Hospital and the Institute of Ophthalmology. As Lead for the Whole Building Design Workstream by Moorfields and the Institute, Professor Garway-Heath has worked extensively with professionals across departments from both institutions to produce the Creative Strategy Brief. The project has now progressed to an advanced stage: planning permission has been granted by Camden Council's planning committee and the City Road site has been put on the market. Exciting times ahead!

Future plans: 2022 and a bright future ahead

In recent years, Glaucoma UK has focused on consolidation: on improving our 'back room' administrative and financial systems and processes, our data management and information gathering, and our policies. At the same time, we've improved our recruitment systems, and we've invested in the skills, capacity and resilience of our staff team. This has paid off, and we're now in an excellent position to really scale up our services and reach more of the people who need our help.

The key theme throughout this report is expansion. There are more people living with glaucoma in the UK than ever before, and their number is rising. There is a growing wave of people experiencing delayed treatment and cancelled appointments, and they will need help and support while services catch up. And there are increasing numbers of people who – because of the pandemic – haven't been diagnosed when they normally would have been. This is why we are investing in new staff posts this year. We've reviewed and expanded our regional capacity, added new professional engagement colleagues to our team, and we are also investing in a new full-time Data and Insight Lead. This role will help us become a data driven organisation and make the most effective use of our resources by targeting them where they are needed most.

We will also spend time in the coming year planning for our future workspace

needs. Our team have enjoyed working remotely and the majority favour a permanent move to a hybrid model that blends office-based and home working. We will look at reconfiguring our office space as part of the trial, and if successful we may plan to downsize in the coming years.

Financial review

Despite the widespread impact of COVID-19, we are pleased to report that the charity ended the year in very sound financial shape. Overall income increased by £77,936 to £1,795,826. This was mainly driven by an increase in legacy income which rose by £185,867 to £1.41 million – almost 79% of total income. Given the impact of the pandemic on many areas of fundraising, this income stream is more vital than ever to the charity, and we would like to express our sincere thanks to all those who remembered us in their wills: without their kindness and generosity, much of our work would simply not be possible.

Income from donations and subscriptions increased by just over £17,000 to £191,548, and again we would like to thank our supporters for their loyalty and generosity. Corporate support fell by £36,578 to £27,000 last year. This reflects both the high level of support from our corporate partners when the pandemic first hit in 2019/20, but also – we suspect – the financial impact of the pandemic on commercial companies. Given this challenging environment, we are especially grateful to all our corporate partners for their help.

Investment income fell by just over £25,000 during the year; further details are given in the Investments section, below.

Income from charitable activities also fell last year, from £72,654 in 2019/20 to £18,510. The main reason for this drop was an unusually high level of income transferred from UKEGS to Glaucoma UK when it merged into the main charity in 2019/20 (see page 9/10). Last year income fell back to normal levels, with £9,703 received in sponsorship fees for a virtual conference run in November 2020. Income related to the sale of eye drop aids and equipment was the lowest for many years at £4,213, reflecting the fact that staff were

unable to dispatch the aids while working from home; for this reason, spending on aids also fell. Income from other charitable activities remained.

During the year, we were grateful to receive a grant of £16,546 from the Coronavirus Community Support Fund, distributed by The National Lottery Community Fund, which helped us research new models of digital support during lockdown (see page 14). Other grant income included £11,480 from the NIHR Moorfields Biomedical Research Centre as part of their ongoing support for the Chair of Ophthalmology for Glaucoma and Allied Studies, and £19,368 from the Government Coronavirus Job Retention (furlough) Scheme, which helped us to offset staff costs when some of our team were unable to work.

Overall expenditure was £1,042,652 – a fall of £48,340 on the previous year. Within this are three areas to note. Firstly, a research grant of £60,684 awarded to University Hospital of Wales was reversed in 2020/21 (see page 16) due to delays caused by COVID-19. Spending was also down in fundraising, where a drop of £17,319 on the previous year was due to a staffing gap while we recruited a new fundraising manager, and to a change in cost allocation. Finally, patient information and support – always our highest area of expenditure - fell by £47,111, due partly to our inability to deliver any face-to-face support work during the year. It was also partly caused by reduced printing and postage costs for patient information booklets. The reasons for this are complex, including reduced demand from eye clinics, reduced supply as we run down stocks prior to relaunching more accessible materials, and - happily - higher levels of digital downloading of patient materials from our new website.

There was one main area where spending increased, and while we are pleased to report that research spending increased by £14,909 to £136,094, this is still much lower than we would have liked, for the reasons outlined under ‘research’ on page 16.

At year end, restricted funds totaled £2,081,540. As ever, the largest of these is the Chair Fund which holds funds to meet the cost of the Chair of Ophthalmology for Glaucoma and Allied Studies for the remaining five years of Professor Garway-Heath’s eight-year term, and the Research Fund, which comprises donations and legacy income where the donor has asked that their gift is used for research. Our plans to use other restricted funds for service delivery and development were frustrated by the pandemic, but we hope to be

able to launch these projects in the coming year.

Fundraising in lockdown

Prior to the pandemic, our fundraising strategy centred on diversifying funding streams to reduce reliance on legacy income. The strategy was broad-based: it aimed to build engagement across a host of fundraising activities, develop new resources to support this activity, and pro-actively engage new supporters. While this remains our longer-term strategy, the pandemic made much of this work impractical, so in the interim, we have focused on trialling legacy giving options such as free will writing schemes and membership of national legacy awareness programmes. We have also improved our data and analytics and our ability to engage with new supporters, and have added new improved ways of giving on our website. These strategies have proved effective, and we are delighted that donations and subscriptions rose by £17,011 last year to £191,548. Within this total, individual donations rose by a staggering £25,001 to £60,739, and gifts given in memory rose by £5,359 to £12,756. One new activity – a weekly lottery - raised new income of c. £6,700 with associated costs of c. £3,000 charged by the commercial entity running the scheme.

Individual and community fundraising was again hit hard by lockdown. In the year ahead we hope that some new community and challenge activity may be possible, and we very much look forward to working with existing and new supporters to launch some exciting new activities. But for now, we would simply like to thank all those magnificent individuals who cycled, ran, shaved, walked and climbed for us during lockdown, raising a wonderful total of £13,769. Thank you so much – we know how hard you worked for us!

Income from charitable trusts and foundations totalled £6,931 which funded the Glaucoma UK Chair of Ophthalmology for Glaucoma and Allied Studies at UCL Professor Garway-Heath, core services and much of our exciting new development work during the last year. We are most grateful to The Emily Weircroft Charitable Trust, The Dandy Charitable
Trust, The Ellis Foundation, The Hospital Saturday Fund Charitable Trust, The Wyndham Charitable Trust, The Grand Charity of Freemasons and Blindcare for their kind support.

We are registered with the Fundraising Regulator and comply with all the relevant standards set out in the Code of Fundraising Practice. We are pleased to report that once again no complaints were received about our fundraising activities during the year. Our Fundraising Manager is a member of the Institute of Fundraising and ensures high standards in all our income generating activities. The charity also has an Ethical Fundraising and Partnerships Policy which is reviewed at least every two years, and a Supporter Promise which is clearly displayed on our website's fundraising and supporter pages. Both these documents set out how staff and volunteers will act to safeguard the interests of the general public and supporters who may be vulnerable. Fundraising activity is closely monitored using a range of financial and ROI data where available, comparison with sector benchmarks, and against the standards set out in the Ethical Fundraising Policy and Supporter Promise. A Fundraising Trustee Advocate is also in place to ensure good trustee oversight of fundraising.

All fundraising was carried out by Glaucoma UK staff and no external fundraisers were used during the year. Our Fundraising Manager moved on in February after 6 years with us, and the role was vacant for 3 months while we recruited her replacement. During this period little new activity was possible, and overall we are pleased with our fundraising performance during what has been a challenging year.

Investment policy

Management of the charity's assets is delegated to Rathbone Investment Management Ltd, and their performance is reviewed regularly against annually agreed benchmarks. In the financial year 2021/22, the trustees' investment goal is to maximise total return subject to a medium risk profile.

In previous years this has been achieved using a mixed managed portfolio, but following lengthy consideration, in February 2021 trustees moved the charity's assets into a single fund: the Rathbone Core

Investment Fund for Charities. The fund's stated objective is “to achieve long term capital growth and a level of income while employing a total return approach ... Client suitability: investors should be medium risk charities, seeking to achieve long-term returns generated from a mixture of capital growth and income, with lower levels of volatility than equity markets.”

The change was made to take advantage of sound performance in recent years, lower management fees and ease of administration. The ethical framework of the Core Investment Fund meets - and indeed exceeds - the charity’s minimum ethical investment criteria, which is avoiding direct investment in companies predominantly involved in the production of tobacco, because of its adverse effects on eye health. The trustees also considered environmental factors when making the change.

Reserves policy

In line with Charity Commission guidance, the trustees consider it prudent to hold reserves to enable the charity to deliver planned services and meet growing needs, fund research commitments, manage unforeseen risks or issues, and take advantage of unexpected opportunities.

A key challenge in the coming years will be to scale up services to meet the needs of the growing number of people living with glaucoma. Additional effort will also be needed to support those whose diagnosis and treatment have been delayed by COVID-19. Added to this, the trustees recognise that the economic impact of the pandemic and other geopolitical factors may adversely affect all aspects of charitable giving and investment values and yield for some time to come. The charity also remains heavily dependent on legacy giving, the income from which is inherently uncertain. To mitigate the risk associated with all these factors, the reserve requirements have been increased, and the Board now feels it prudent to hold operating costs of 18 months (£1.65 million), funds designated for additional service development from 2022/23, and a research investment fund of £4 million that will generate vital income to support future glaucoma research trials.

At the end of 2020/21 the total reserve requirements were £6,212,000, and actual reserves held totalled £6,210,522 of which £4.482,906 was designated and £1,727,616 held in general funds.

As mentioned above, the charity also held £2,081,540 in restricted funds.

Remuneration policy

The trustees consider the Board of Trustees and the Chief Executive as comprising the key management personnel of the charity in charge of directing and controlling the charity and running and operating the charity on a day to day basis. All trustees give of their time freely and no trustee remuneration was paid in the year. Trustees are required to disclose all relevant interests and withdraw from decisions where a conflict of interest arises.

The pay of the charity's Chief Executive is reviewed annually by the Chair of the Board of Trustees and Treasurer. The Chief Executive reviews all other staff salaries annually and makes recommendations to the Board as part of the annual budget setting process. When setting salaries, trustees are guided by a remuneration policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public and private sector pay increase estimates), affordability, sustainability, and appropriateness. Glaucoma UK aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2021 these ratios were 3.4:1 and 2.2:1 respectively.

Glaucoma UK Trustees, advisors and senior staff

Trustees
The trustees (who are also directors under company law) are:

Prof. Philip Bloom	Chair
David Sanders	Hon Treasurer
Stephen Epstein	Vice Chair

Dr Susan Blakeney
Prof. Anthony King
Ray Spendiff
Dr Winifred Nolan (from 24.2.21)
Nicholas Strouthidis (to 25.11.20)
Prof. Pete Shah (from 25.11.20 to 24.2.21)

Julian Exeter
Yolanda Laybourne
Dr Roxanne Crosby-Nwaobi
Teresa Borsuk (from 16.9.20)
Christine Wall (to 11.5.21)

Chief Executive and Company Secretary	Karen Osborn
Company Number	1293286
Charity Number	274681
OSCR Number	C041550
Registered office and operational address	Woodcote House 15 Highpoint Business Village Henwood, Ashford Kent TN24 8DH www.glaucoma.uk
Bankers	Barclays Bank plc 1 Churchill Place London E14 5HP CAF Bank Ltd 25 Kings Hill Avenue Kings Hill Kent ME19 4JQ

	HSBC Bank plc Camberwell Green 23 Denmark Hill London SE5 8RP
Auditors	Calcutt Matthews Chartered Accountants 19 North Street Ashford Kent TN24 8LF
Investment Managers	Rathbone Investment Management Ltd 8 Finsbury Circus London EC2M 7AZ

Structure, governance and management

Glaucoma UK is the operating name of the International Glaucoma Association Ltd, a charitable company limited by guarantee incorporated on 15 July 1976 and registered as a charity on 20 December 1977. As Glaucoma UK is both a charity and a company limited by guarantee, all board members are directors for the purposes of company law and trustees for the purposes of charity law. The objects of the charity are defined by its Articles of Association (last updated in 2015), which also set out trustees' powers and the permitted activities of the charity.

When reviewing the charity's objectives and planning future activities, the trustees refer to Charity Commission guidance on public benefit and can confirm that all Glaucoma UK's activities are undertaken to further our charitable purposes for public benefit.

The Board comprises a maximum of 15 trustees, of whom up to 12 are elected by the members and a further three may be co-opted by the Board. There is one sub-committee: a Finance and Governance Committee that oversees finance, investments, risk management and policy. The charity also has a Clinical Advisory Panel to advise on clinical matters, whose chair oversees research grantmaking.

A Trustee Handbook sets out trustee roles and responsibilities. An induction process is in place, and ongoing training is provided. In 2020/21 this included mandatory training in equality and diversity, and unconscious bias.

The trustees are committed to reflecting on their own performance and skill set, and during 2021 they completed a governance review with input from NCVO. The review included trustee self-assessments, a review of trustee and officer role descriptions, revision of the trustee recruitment policy, and updating committee terms of reference. One to one peer appraisals are planned for winter 2021.

The Board also reviewed the Articles of Association during the year, with help from Russell Cooke solicitors. A recent review revealed a mismatch between the level of legal accountability and responsibility of current trustees, and the authority held by a broadly unaccountable membership. It was felt that moving the charity from a membership model to an association model would help to resolve the mismatch, and the Board put this suggestion to the membership in summer 2021 and began a consultation period. The majority of members supported the proposal, but given the

complexity of the issues and the range of views aired, the Board decided to extend the period of consultation to autumn 2022 to allow for detailed discussions.

The current Board comprises people living with glaucoma, and others with backgrounds in ophthalmology, nursing, optometry, finance and business. Existing trustees retire after serving a three-year term but are eligible for re-election to a maximumof 12 years' service.

Trustee meetings have been held virtually throughout the pandemic, and a virtual AGM was held on 12 March 2021. These virtual meetings have been extremely successful: attendance has been excellent, travel costs have been eliminated, and the change has helped us to reduce our carbon footprint in line with the aspirations of our environmental policy.

Day to day responsibility for service delivery and for ensuring that charitable, strategic and financial aims are met is delegated to the Chief Executive, supported by the Senior Management Team. During the year there were on average 18 colleagues on the wider staff team.

Related parties and connected charities

There was one related party during 2020/21: Glaucoma UK acted as an agent for the unincorporated organisation the United Kingdom Paediatric Glaucoma Society (UKPGS). Details of our work with them is described on page 13.

Risk management

Risks are formally assessed and reviewed every six months by the Finance & Governance Committee and reported to the Board. A risk register captures the likelihood of an occurrence and the potential severity of its impact, and details the controls that are in place to manage this.

In 2020/21 the two main risk areas remained unchanged from the two previous years:

- **Data security risk**
  In response to increasing levels of cybercrime in the UK, and to an increasingly regulated data protection environment, the charity continued to invest in its systems and ICT infrastructure during the year and achieved Cyber Essentials accreditation in early 2021. Regular mandatory cyber security training is also in place for staff.

- **Dependence on unpredictable legacy income**
  Our fundraising strategy has been heavily impacted by COVID-19, and plans to expand our portfolio of fundraising activity to reduce reliance on legacy income have in large part been postponed. Income diversification

remains a long-term goal but, in the meantime, risk is managed by cash flow monitoring and holding adequate reserves to cover any medium and longer-term shortfall.

Statement of trustee responsibilities

The trustees are responsible for preparing the trustees' report including the strategic reportand financial statements in accordance with applicable law and United Kingdom accounting standards (UK generally accepted accounting practice).

Company law requires the trustees to prepare financial statements which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP (Statement of Recommended Practice);
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriateto presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and

- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware ofthat information.

This Trustees' Report is approved by order of the Board of Trustees, and the Strategic Report (included therein) is approved by the Board of Trustees in their capacity as Directors on 10 December 2021 and signed on its behalf by

Professor Philip Bloom
Chair of the Board of Trustees

Report of the Independent Auditors to the Trustees of Glaucoma UK

We have audited the financial statements of Glaucoma UK for the year ended 31 July 2021 on pages 35 to 50. The financial reporting framework that has been applied in their preparation is applicable law and FRS 102 (effective January 2015), as well as the Charities Statement of Recommended Practice (effective January 2015).

This report is made solely to Glaucoma UK's members and Board of Trustees, as a body, in accordance with Section 144 of the Charities Act 2011, and regulations made under Section 154 of that Act, as well as Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Council of Management those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditors

As explained more fully in the Trustees Responsibilities set out on page 30, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed as auditors under Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 and report in accordance with regulations made under those Acts.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the charitable company's circumstances and have been

consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies, we consider the implications for our report.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- Gaining a full and extensive knowledge of the entity, environment and the regulatory framework to which it must abide by.
- Evaluating and assessing the extent to which the entity's internal systems are adhering to these as well as Gaining a full and comprehensive understanding of the entity's current activities and effectiveness of its' control environment (including those in place to identify and prevent fraud.)

We achieved this by carrying out the following:

- Enquiry of and detailed communication with management and those charged with governance.
- Reviewing internal systems and controls.
- Reviewing financial statement disclosures and compliance with applicable laws and regulations.

Opinion on financial statements

In auditing the financial statements, we have concluded that the trustees/directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the entity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees/directors with respect to going concern are described in the relevant sections of this report.

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 July 2021 and of its incoming resources and application of resources, including itsresult, for the year then ended;

- have been properly prepared in accordance with the Financial Reporting Standards102 (effective January 2015);

- have been prepared in accordance with the requirements of the Companies Act 2006, and Section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- the information given in the Report of the Board of Trustees is inconsistent in any material respect with the financial statements; or

- the charitable company has not kept adequate accounting records; or

- the financial statements are not in agreement with the accounting records and returns; or

- we have not received all the information and explanations we require for our audit.

Nicholas Hume
For and on behalf of Calcutt Matthews
Chartered Accountants and Registered Auditors
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 200619

North Street
Ashford
Kent TN24 8LF

10 December 2021

Glaucoma UK (the operating name of the International Glaucoma Association Limited)

Statement of financial activities *(incorporating an income and expenditure account)*
For the year ended 31 July 2021

	Note	Restricted £	Unrestricted £	**2021 Total £**	2020 Total £
Income					
Donations, Legacies and Subscriptions	2	16,474	1,614,941	**1,631,415**	1,465,115
Investment income	3	24,034	74,473	**98,507**	123,621
Charitable activities					
Glaucoma aids and equipment sales	4	20	4,193	**4,213**	6,101
UKEGS (UK & EIRE Glaucoma Society)	4	9,703	-	**9,703**	62,237
Other income	4	435	4,159	**4,594**	4,317
Grants	5	28,026	19,368	**47,394**	56,499
Total income		**78,692**	**1,717,134**	**1,795,826**	**1,717,890**
Expenditure on:					
Raising funds					
Finance and support		0	18,483	**18,483**	30,295
Cost of generating funds		10,803	108,459	**119,262**	124,769
		10,803	126,942	**137,745**	155,064
Expenditure on charitable activities					
Glaucoma research		136,094	-	**136,094**	121,185
Patient information and support		30,069	558,016	**588,085**	635,196
Professional information and support		11,175	101,384	**112,559**	112,086
Campaigning and advocacy		2,987	61,075	**64,062**	62,104
Cost of glaucoma aids and equipment		-	4,107	**4,107**	5,356
Total expenditure	6	**191,128**	**851,524**	**1,042,652**	**1,090,992**
Realised gains on investment assets	12	25,023	455,608	**480,631**	88,628
Net Income		(87,413)	1,321,218	**1,233,805**	715,526
Unrealised gains on investment assets	12	289,741	234,509	**524,250**	(440,286)
Net incoming resources before transfers	7	202,328	1,555,727	**1,758,055**	275,239
Gross transfer between funds		-	-	**-**	-
Net movement in funds		202,328	1,555,727	**1,758,055**	275,239
Reconciliation of funds					
Total funds brought forward		1,879,212	4,654,794	**6,534,006**	6,258,767
Total funds carried forward		**2,081,540**	**6,210,521**	**8,292,061**	**6,534,006**

All of the results above are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 18 to the financial statements.

As at 31 July 2021

	Note		2021 £	2020 £
Fixed assets				
Tangible fixed assets	11		**15,888**	17,864
Investments	12		**7,071,150**	4,993,414
Total fixed assets			**7,087,038**	5,011,279
Current assets				
Stock	13		**4,311**	4,324
Debtors	14	22	**308,233**	617,047
Cash at bank and in hand			**1,231,121**	1,254,595
			1,543,665	1,875,966
Liabilities				
Creditors: amounts due within one year	15	20, 22	**249,242**	277,640
Net current assets			**1,294,423**	1,598,324
Total assets less current liabilities			**8,381,460**	6,609,603
Creditors: amounts due after more than one year	16		**89,400**	75,597
Net assets	17		**8,292,061**	6,534,006
Funds	18			
Restricted funds			**2,081,540**	1,879,212
Unrestricted funds				
Designated funds			**4,482,906**	2,782,906
General funds			**1,727,616**	1,871,888
Total funds			**8,292,061**	6,534,006

Approved and authorised for issue by the trustees of The International Glaucoma Association

Approved by the Board of Trustees on 10 December 2021 and signed on its behalf by Professor Philip Bloom, Chair

Philip Bloom

Glaucoma UK (the operating name of the International Glaucoma Association)

Statement of cash flow

For the year ended July 2021

Cashflows from operating activities:	**2021**	2020
Net cash provided by (used in) operating activities	**950,872**	572,895
Cashflows from investing activities		
Dividends and interest from investments	**98,507**	123,621
Purchase of property, plant and equipment	**-**	(18,400)
Proceeds from sale of investments	**917,254**	1,733,197
Purchase of investments	**(2,202,236)**	(2,342,458)
Net cash provided by (used in) investing activities	**(1,186,475)**	(504,041)
Change in cash and cash equivalents in the reporting period	**(235,603)**	68,856
Cash and cash equivalents at the beginning of the reporting period	**1,484,430**	1,415,574
Cash and cash equivalents at the end of the reporting period	**1,248,827**	1,484,430
Increase/Decrease in cash balances	**(235,603)**	**68,856**

Reconciliation of net movement in funds to net cash flow from operating activities

Net movements in funds for the reporting period (as per the statement of financial activities)	**1,758,055**	275,239
Adjustments for:		
Depreciation	**1,977**	9,157
Dividends & interest from investments	**(98,507)**	(123,621)
Loss/(Profit) on sale of investments	**(1,004,881)**	351,658
(Increase)/Decrease in stocks	**11**	3,797
(Increase)/Decrease in debtors	**308,813**	267,562
Increase/(Decrease) in creditors	**(14,595)**	(210,897)
Net cash provided by (used in) operating activities	**950,872**	**572,895**
Analysis of cash and cash equivalents		
Cash in hand	**1,231,121**	**1,254,595**
Investments Capital account	**17,706**	**229,835**
	1,248,827	**1,484,430**

1. Accounting policies

a) The financial statements have been prepared under the historical cost convention, as modified by the revaluation of fixed asset investments, and in accordance with applicable accounting standards and the Companies Act 2006. They follow the recommendations in the Statement of Recommended Practice, Accounting and Reporting by Charities. The accounting standards policies have been prepared under Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice) and SORP 2019.The Trustees confirm that the charitable company is a public benefit entity.

Going concern policy when assessing the charity's ability to continue to adopt the going concern basis of accounting, the Trustees have considered all the information available to them regarding the financial year ahead and have paid due regard to the Charities SORP committee guidance on financial reporting during the Covid-19 pandemic. They have reviewed the charity's financial position in the light of Covid-19 and any possible further lockdown's. They have considered the possible risks, liabilities, supply chains, and potential impact on staffing and service continuity. They have also reviewed the expected fall in some income streams during a continued pandemic in the light of the expected reduction in operating costs and can confirm that even under these circumstances Glaucoma UK will be able to continue operating an effective service in the year ahead and to meet its obligations as they fall due. The trustees have no plans to close the charity.

b) Voluntary income received by way of subscriptions, donations and gifts are included in full in the statement of financial activities when receivable.

c) Income from legacies is accounted for on a receivable basis, recognised when entitlement to the income has been established and it is probable that Glaucoma UK will receive the amounts ascertained. This treatment is within SORP 2019 and Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Sales income represents sale of goods excluding VAT where appropriate.

Investment income is accounted for on a accruals basis.

d) Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

e) Unrestricted funds are donations and other incoming resources received or generated for general charitable purposes.

f) Designated funds are unrestricted funds earmarked by the Board of Trustees for particular purposes. Within these funds is money awarded as grants, funding a range of research projects to develop more effective methods of glaucoma diagnosis and treatment.

g) Costs of generating funds relates to the costs incurred in fundraising activities.

h) Critical accounting judgements are used within these accounts as follows:

Residual legacy income debtors are valued at 85% of the expected value of the legacy when certain criteria are met and receipt is probable.

The support and governance costs are re-apportioned by staff time as explained in note (i). The staff costs attributed to each activity are reviewed twice a year.

i) Resources expended are recognised in the period in which they are incurred. Resources expended include attributable VAT which cannot be recovered.

Resources expended are allocated to a particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function which includes finance and support and governance is apportioned on the following basis which is an estimate based on staff time of the amount attributable to each activity.

Cost of generating funds	10%
Expenditure on charitable activities	88%
Research	2%

1. Accounting policies (continued)

j) Grants awarded are charged to the Statement of Financial Activities in the year in which they are awarded and are subject to receipt of progress reports. During this year we received two statutory grants, both are recognised in the accounts on the receivable date. The first grant came from central government as part of their Coronavirus job retention scheme which paid part of the salaries of furloughed staff (all of whom were paid at 100% of their normal salary while furloughed). The second statutory grant was received from the government national lottery award to fund our coronavirus community support to fund a digital care and support project for 6 months to deliver activities specifically aimed to support communities through the COVID-19 crisis. Neither statutory grant was subject to performance criteria. The national lottery grant is subject to sending monitoring impact reports on our communities.

k) Governance costs are the costs associated with the governance of the charity, including constitutional and statutory requirements and costs associated with the strategic management of the charity's activities.

l) Monetary assets and liabilities in foreign currencies are translated into sterling at the Bank of England exchange rate for that day.

m) Investments held as fixed assets are revalued at market value at the balance sheet date. The Trustees consider that market value is a reasonably accurate representation of the fair value. The gain or loss for the period is taken to the statement of financial activities.

n) The fixed assets are held at cost less depreciation and any impairment. Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures, fittings and equipment	20%
Computers	33%

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

o) Stocks are stated at the lower of cost and net realisable value. In general, cost is determined on a first in first out basis and includes transport and handling costs. Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation. Provision is made where necessary for obsolete, slow moving and defective stock. During the year the charity received donated items that have been stated at fair value.

p) The charity contributes to a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. Contributions payable are charged as an expense in the SOFA (Statement of financial activities) within staff costs then shared between the SOFA categories by staff time within these activities.

q) Financial instruments assets and liabilities are valued in the accounts at fair value and are subsequently carried at amortised cost shown in Note 21.

2. Voluntary income

	2021 Restricted £	2020 Restricted	**2021 Unrestricted** £	2020 Unrestricted	**2021 Total £**	2020 Total £
Donations and subscriptions	**16,474**	36,166	**175,074**	138,371	**191,548**	174,537
Corporate donations	**-**	-	**27,000**	63,578	**27,000**	63,578
Legacies	**-**	458,772	**1,412,867**	768,228	**1,412,867**	1,227,000
Total	**16,474**	494,938	**1,614,941**	970,177	**1,631,415**	1,465,115

3. Investment income

	2021 Restricted £	2020 Restricted	**2021 Unrestricted £**	2020 Unrestricted	**2021 Total £**	2020 Total £
Interest	**-**	-	**338**	4,223	**338**	4,223
Dividends from UK companies	**19,227**	26,097	**59,011**	66,282	**78,238**	92,379
Dividends from overseas companies	**4,807**	7,633	**15,124**	19,386	**19,931**	27,019
Total	**24,034**	33,730	**74,473**	89,891	**98,507**	123,621

4. Incoming resources from charitable activities

	2021 Restricted £	**2020** Restricted £	**2021 Unrestricted** £	**2020** Unrestricted £	**2021 Total £**	2020 Total £
Glaucoma aids and equipment sales	**20**	-	**4,193**	6,101	**4,213**	6,101
UKEGS (UK & EIRE Glaucoma Society)	**9,703**	62,237	**-**	-	**9,703**	62,237
Other income	**435**	-	**4,159**	4,317	**4,594**	4,317
	10,158	62,237	**8,352**	10,418	**18,510**	72,654

5. Grants received

	2021 Restricted £	**2020** Restricted £	**2021 Unrestricted** £	**2020** Unrestricted £	**2021 Total £**	2020 Total £
Local government grant - Ashford Borough Council	**-**	-	**-**	10,000	**-**	10,000
National government grant - HMRC furlough scheme	**-**	-	**19,368**	22,608	**19,368**	22,608
Professor of Ophthalmology for Glaucoma and Allied Studies at UCL	**11,480**	13,549	**-**	-	**11,480**	13,549
UKEGS (UK & EIRE Glaucoma Society)	**-**	-	**-**	10,342	**-**	10,342
The National Lottery - Community Fund	**16,546**	-	**-**	-	**16,546**	-
	28,026	13,549	**19,368**	42,950	**47,394**	56,499

6. Total Expenditure

	Cost of generating funds	Patient information and support	Professional information and support	Campaigning and advocacy	Glaucoma research	Finance and support	Governance	2021 Total	2020 Total
	£	£			£	£	£	**£**	£
Staff costs (Note 8)	45,266	293,968	62,860	30,819	10,388	110,211	28,607	**582,119**	**582,519**
Research grants (Note 9)	10,803	-	-	-	110,433	-	-	**121,236**	**95,250**
Regional outreach & helpline	-	16,201	268	-	-	-	-	**16,469**	**25,051**
Glaucoma aids & equipment	806	31	3,270	-	-	-	-	**4,107**	**5,356**
Awareness events, PR, social media & volunteering	-	1,676	6,961	12,932	-	-	-	**21,569**	**44,010**
AGM, annual lectures & trustee expenses	-	-	-	-	-	-	8,120	**8,120**	**8,963**
Fundraising	33,585	-	-	-	-	-	-	**33,585**	**26,822**
Premises and administration	-	71,896	1,355	153	-	105,847	540	**179,791**	**227,440**
Finance & professional	18,483	12,064	-	-	8,478	27,495	9,136	**75,656**	**75,581**
Expenditure	108,943	395,836	74,714	43,904	129,299	243,553	46,403	**1,042,652**	1,090,992
Finance and support reallocated	23,362	151,718	32,442	15,906	5,362	(243,553)	14,763		
Expenses including Finance & Support	132,305	547,554	107,156	59,810	134,661	-	61,166	**1,042,652**	1,090,992
Governance reallocated	6,246	40,562	8,673	4,252	1,433	-	(61,167)		
Total Expenditure	**138,551**	**588,116**	**115,829**	**64,062**	**136,094**	**-**	**-**	**1,042,652**	1,090,992

7. Net (outgoing)/incoming resources

This is stated after charging/crediting:

	2021	2020
	£	£
Depreciation charge for the year - owned assets	**1,977**	9,157
Auditors' remuneration:		
audit	**3,778**	3,750
other services	**-**	-
Trustees expenses	**-**	3,354
Investment managers fee	**24,226**	29,923

Trustees expenses represent the travel and subsistence costs of trustees for no face to face meetings in 2021, in (2020:9). All meetings were held as virtual meetings and no Trustee expenses for 2021.

During the accounting year unclaimed Trustees expenses totalled £0.00 (2020: £519).

Donations totalling £450 were received from Trustees, (2020: £428).

No Trustees received remuneration for their services during the financial year.

8. Staff costs and numbers

Staff costs were as follows:

	2021	2020
	£	£
Salaries and wages	**510,607**	512,558
Social security costs	**48,237**	47,580
Pension contributions	**23,275**	22,380
	582,119	582,518

Only one member of key management personal earns over the rate of £60,000 or more in the year as follows:

	2021	2020
	No.	No.
£60,000 - £70,000	**1**	1

Pension contributions in respect of the above full-time employee totalled £3,335 (2020: £3,335).

NI contributions in respect of the above employee totalled £8,218 (2020: £8,387)

The calculated unspent staff holiday entitlement at year end was £10,745, (2020: £11,907).

The charity contributes to a Royal London defined contribution pension scheme for employees.

The Chief Executive Officer is the sole key management personnel having authority and responsibility for planning, directing and controlling the activities of Glaucoma UK.

The management remuneration policy considers the following factors:

cost of living, pay comparability, affordability, sustainability, and appropriateness. The ratio between the highest and lowest salary should be below 4.5:1 and the ratio between the highest and median (midpoint) salary below 3.5:1

8. Staff costs and numbers (continued)

The average weekly number of employees (full-time equivalent) during the year was:

	2021 No.	2020 No.
Cost of generating funds	**1.83**	1.34
Patient information and support	**8.50**	7.77
Professional information and support	**1.67**	1.27
Campaigning and awareness	**1.00**	0.65
Research	**0.20**	0.30
Governance	**0.50**	0.35
Finance and Support costs	**2.58**	2.71
	16.28	14.39

The actual number of staff (including part time and full time) in 2021 was 20 (2020: 19)

9. Grants Awarded

	2021	2020
University College London's Institute of Ophthalmology - Glaucoma UK Chair Fund	**52,447**	23,775
Fight for Sight	**20,479**	10,307
University Hospital of Wales	**(60,684)**	60,684
Nottingham University Hospital	**-**	2,500
University of Bradford	**48,380**	-
University College London	**49,811**	-
Grants underspent by researchers	**-**	(2,017)
	110,433	95,249

These grants were awarded in accordance with the Glaucoma UK grants policy, and were awarded to fund research into the diagnosis and treatment of glaucoma.

The negative figure represents an underspend by researchers on grants awarded in previous years. Also one grant awarded to University Hospital of Wales that is not going ahead this year.

10. Taxation

The charity is exempt from corporation tax and income tax as all its income is charitable and is applied for charitable purposes.

11. Tangible fixed assets

	Fixtures, fittings and equipment £	Computer equipment £	**Total £**
Cost			
At the start of the year	210,917	27,743	**238,660**
Additions in year	-	-	**-**
Disposals in year	-	-	**-**
At the end of the year	210,917	27,743	**238,660**
Depreciation			
At the start of the year	209,636	11,160	**220,796**
Charge for the year	1,281	696	**1,977**
Disposals in year	-	-	**-**
At the end of the year	210,917	11,856	**222,773**
Net book value At the end of the year	**-**	**15,887**	**15,887**
At the start of the year	1,281	16,583	17,864

12. Investments

	2021 £	2020 £
Market value at the start of the year	**4,763,579**	4,505,976
Additions at historic cost	**2,202,238**	2,342,458
Disposal proceeds	**(917,254)**	(1,733,197)
Realised gains	**480,631**	88,628
Unrealised gains	**524,250**	(440,286)
Market value at the end of the year	**7,053,444**	4,763,579
Cash held as part of portfolio	**17,706**	229,835
Total	**7,071,150**	4,993,414
Historic cost at the end of the year	**6,546,896**	4,757,455

12. Investments continued

Investment management costs were £24,226.07 (£29,923.21 - 2020)

In February 2021 the charities mixed portfolio was transferred into a single pooled charity fund operated by Rathbones Investment management. The change was made in order to streamline administration, reduce investment management fees and maintain or increase returns. Investments are now held as units within a core fund, classified as a UK investment fund.

Glaucoma UK Ltd, Glaucoma International Ltd, Glaucoma Europe Ltd, and Glaucoma Association Ltd are dormant companies historically held by Glaucoma UK (the operating name of the International Glaucoma Association Limited) in order to protect the company identity and to give future flexibility in terms of the charity name.

Glaucoma UK Limited number 04323894 total shareholder funds £1. Glaucoma Europe Limited number 04591043 total shareholders funds £1. Glaucoma International Limited number 04323990 total shareholders funds £1. Glaucoma Association Ltd number 05316092 shareholders funds £1.

13. Stock

	2021	2020
	£	£
Goods for resale	**4,311**	4,324

14. Debtors

	2021	2020
	£	£
Trade debtors	**25,241**	14,582
Legacy debtors	**266,590**	529,185
Prepayments and accrued income	**16,402**	72,206
VAT liability	**-**	1,073
	308,233	617,047

15. Creditors: amounts due within one year

	2021 £	2020 £
Trade creditors	**124,735**	49,436
Obligations under grant agreements	**87,627**	160,668
Funds held as agent	**22,578**	25,540
Accruals	**13,050**	41,996
VAT receivable	**1,253**	-
	249,242	277,640

Funds held as agent represent those held for UKPGS, for which Glaucoma UK provides administration and infrastructure support as shown in note 20.

16. Creditors: amounts due after one year

	2021 £	2020 £
Obligations under grant agreements	**89,400**	75,597
	89,400	75,597

17. Analysis of net assets between funds

	Restricted funds £	Designated funds £	General funds £	**Total funds £**
Tangible fixed assets	-	-	15,888	**15,888**
Investments	2,081,540	4,482,906	506,704	**7,071,150**
Net current assets	-	-	1,294,423	**1,294,423**
Creditors: amounts falling due after more than one year	-	-	(89,400)	**(89,400)**
Net assets at the end of the year	**2,081,540**	**4,482,906**	**1,727,615**	**8,292,061**

18. Movements in funds

	At the start of the year £	Incoming resources £	Outgoing resources £	Other gains and losses £	Transfers £	**At the end of the year £**
Restricted funds:						
Chair fund	1,364,881	36,534	(58,279)	314,764	-	**1,657,900**
North East fund	30,987	435	(15,698)	-	-	**15,724**
Compliance Project fund	5,405	-	(4,166)	-	-	**1,239**
Research fund	388,004	15,436	(87,567)	-	-	**315,873**
Merseyside fund	657	-	(657)	-	-	**-**
Folkestone Fund	3,733	-	-	-	-	**3,733**
Children and Young people's Support fund	8,862	38	-	-	-	**8,900**
London fund	9,907	-	(2,330)	-	-	**7,577**
Scottish Optom fund	9,321	-	-	-	-	**9,321**
UK & Eire Glaucoma Society	57,455	9,703	(7,027)	-	-	**60,131**
Digital Support fund	-	16,546	(15,404)	-	-	**1,142**
Total restricted funds	**1,879,212**	**78,692**	**(191,128)**	**314,764**	**-**	**2,081,540**
Unrestricted funds:						
Designated funds:						
Income Endowment	22,906	-	-	-	-	**22,906**
Equipment Replacement and Infrastructure Fund	460,000	-	-	-	-	**460,000**
Research investment fund	2,300,000	-	-	-	1,700,000	**4,000,000**
Total designated funds	2,782,906	-	-	-	1,700,000	**4,482,906**
General funds	1,871,888	1,717,134	(851,524)	690,119	(1,700,000)	**1,727,616**
Total unrestricted funds	**4,654,794**	**1,717,134**	**(851,524)**	**690,119**	**-**	**6,210,521**
Total funds	**6,534,006**	**1,795,826**	**(1,042,652)**	**1,004,881**	**-**	**8,292,061**

18. Movements in Funds (continued)

Purposes of restricted funds

The Chair fund is used to fund the post of Professor of Ophthalmology for Glaucoma and Allied Studies at University College London.

The North East fund was established following receipt of a legacy and is restricted to supporting our work in the North East of England.

The Compliance Project fund was granted by pharmaceutical companies to provide demonstration and educational eye drop materials.

The Research fund represents donations and charitable trust income received specifically to fund glaucoma research. The fund was drawn on throughout the year as detailed on Note 9.

The Merseyside fund comprises legacy income restricted to the Merseyside area.

The Folkestone fund comprises legacy income restricted to work in Folkestone.

The Children and Young People's Support fund comprises income donated for services for young people affected by glaucoma and their families and carers. It aims to help us better understand their particular support needs and deliver appropriate services in response.

The London fund is restricted to the London area, and has been used mainly for awareness raising and support work with BAME communities at greatest risk of glaucoma sight loss.

The Scottish Optom training fund is charitable trust income earmarked for eye drop adherence training for optometrists across Scotland. The work was scheduled to start in spring 2020 but was postponed due to COVID-19. We hope to restart this workstream as soon as is feasible.

The UKEGS fund comprises income previously held by the charity as an agent for the unincorporated body the UK & EIRE Glaucoma Society (UKEGS) shown in Note 18. When UKEGS merged into the Glaucoma UK (at the time the International Glaucoma Association Limited), in December 2019 the funds were restricted to supporting the ongoing work of UKEGS.

The Digital support fund was received from national lottery community fund to be spent within 6 months on the Glaucoma UK Digital care and support project. The £1,142 underspend on the Digital support fund has been agreed that this balance will be returned to the national lottery.

The designated income endowment fund represents the donation of shares which form the basis of a stock market portfolio, which will eventually provide for the running costs of the association.

The designated Equipment Replacement and Infrastructure fund is held to cover the cost of equipment replacement, infrastructure development, premises costs and dilapidations.

The designated Research Investment fund aims to produce a reliable income stream specifically to fund the charity's research priorities in the years ahead.

19. Operating lease commitments

The charity had annual commitments at the year end under operating leases expiring as follows:

	Property	
	2021	2020
	£	£
Within one year	**34,000**	**34,000**
Within 1 -2 Years	**68,000**	**68,000**
Within 2 - 5 Years	**-**	**34,000**

The total future minimum lease payment is £102,000

20. Related Parties

Included in Note 15 are funds due to related parties held for the UK Paediatric Glaucoma Society (UKPGS).

Financial Statement of UKPGS	**2021**	2020
	£	£
Income	**11,920**	22,073
Expenditure	**(14,882)**	(18,353)
Closing balance	**(2,962)**	3,720
Balance brought forward	**25,540**	21,820
Total funds held	**22,578**	25,540

21. Financial Instruments

Financial Debt instruments measured at amortised cost	**2021**	2020
	£	£
Trade debtors	**25,241**	14,582
Legacy debtors	**266,590**	529,185
Prepayments and accrued income	**16,402**	72,206
VAT liability	**-**	1,073
	308,233	617,047

Financial instruments measured at amortised cost		
Trade creditors	**124,735**	49,436
Obligations under grant agreements	**177,027**	160,668
Funds held as agent	**22,578**	25,540
Accruals	**13,050**	41,996
VAT liability	**1,253**	-
	338,643	277,640

22. Covid-19 pandemic impact

The trustees report that during the financial year ended 31st July 2021 the pandemic delayed both the awarding of new and the progress of existing research projects. Our helpline service was able to continue without much disruption, however all patient and public events had to be postponed. Financial reserves have been built during the year 20/21 which will enable the charity to restore activities and accelerate development plans when COVID restrictions are gradually removed. The trustees expect this to happen during 2021/2022 and plans for this are in place.